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1 Abstract 
 
 
Presented here are the results concerning the early biosynthesis of the 
telomerase inhibitor griseorhodin A. 
 
The griseorhodin biosynthetic gene cluster encodes components of a type II 
polyketide synthase (PKS). The cluster consists of 33 genes, many of which 
encode oxidoreductases. The grh biosynthetic cluster was isolated from 
Streptomyces sp. JP95, a bacterium isolated from the marine tunicate 
Aplidium lenticulum collected in the Great Barrier Reef, Australia. The 
complete grh cluster is available for expression on the cosmid pMP31, 
which can be heterologously expressed in S. albus J1074.  
     
To investigate the early biosynthetic steps in grh biosynthesis, the genes 
grhA, grhB, grhC, grhE, grhT and grhQ were cloned for heterologous 
expression in the host organism S. albus. S. albus strains expressing the 
grh minimal PKS with and without the grh cyclases did not result in 
detectable amounts of polyketides or shunt products. This is in high contrast 
to other type II PKS systems. In an alternative approach, all cyclase genes 
were individually deleted withinin the grh cluster. Based on these results, 
the enzyme GrhE does not seem to play a significant role in the grh 
biosynthesis since griseorhodin A was still produced. The deletion of the 
other cyclases, GrhT and GrhQ, abolished the biosynthesis and no 
polyketides were detected. This suggests that a multienzyme complex is 
required for early polyketide assembly. To further investigate early 
griseorhodin A biosynthesis, two other griseorhodin A gene deletion 
mutants, ∆grhH-P (deletion of all post-PKS genes) and ∆grhH-Q (deletion of 
all post-PKS genes and a cyclase gene), were generated during the present 
study. The ∆grhH-P mutant contained only the proposed early griseorhodin 
genes. Heterologous expression of this construct led to the production of a 
complex mixture of compounds. It produced identical intermediates to the 
∆grhM mutant, which was generated and expressed during a previous 
study1 and for which an early oxygenation role is proposed during 
           1 Abstract       
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griseorhodin A biosynthesis. Four compounds from the ∆grhH-P mutant 
expression were isolated and analysed indicating potentially new early 
intermediates. However, insufficient material was isolated for structure 
elucidation by 2D NMR.  
 
To further investigate whether a functional protein complex is relevant at the 
early stage of griseorhodin A biosynthesis, in the second mutant ∆grhH-Q, 
the cyclase GrhQ was additionally deleted, and the expression led to 
abolishment of griseorhodin A biosynthesis. This was in agreement with the 
GrhQ inactivation study. These results indicate and further support the 
presence of a multienzyme complex during the course of griseorhodin A 
biosynthesis. To date, griseorhodin A is one of the longest aromatic 
polyketides and therefore, could require the synergistic actions of cyclases 
(GrhQ) and other stabilising enzymes such as GrhS for correct polyketide 
assembly.  
 
In order to gain deeper insights into the enzymatic activities responsible for 
griseorhodin A biosynthesis, two constructs with single gene deletions within 
the cluster, constructed in a previous study were further investigated. The 
two deleted genes, grhU and grhV encode proteins with unknown function. 
In the present study, these modified clusters were subsequently 
heterologously expressed in S. albus and analysed by high performance 
liquid chromatography (HPLC), high resolution mass spectroscopy (HRMS) 
and cryogenic or capillary NMR for the production of secondary metabolites. 
Heterologous expression of both mutants resulted in complex mixtures of 
compounds, and 21 pure compounds were isolated by various 
chromatographic methods. The structure of one of the compounds 
originating from the ∆grhV gene deletion mutant was elucidated from 500 µg 
of sample and the structure revealed the decarboxylated 13,13´- fused  
tridecaketide dimer. The structure suggests that GrhV is responsible for an 
oxidative modification in the griseorhodin A molecule. To our knowledge, the 
present study gives first insights into the oxygenase function of GrhV and its 
homologues found in other pentangular biosynthetic pathways.  
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2 Introduction 
 
 
2.1  Polyketides 
 
Polyketides are a notable class of natural products that represent a group 
of structurally and functionally highly diverse substances found in bacteria, 
fungi and plants.2 They have different biological functions in organisms, 
such as pigments, defence or communication molecules. However, in most 
cases their ecological role is not yet known.3 Many of these compounds are 
very interesting to humans due to their pharmacological properties ranging 
from antibiotics (erythromycin A, 1), anticancer drugs (doxorubicin, 2) and 
cholesterol-lowering agents (lovastatin, 3), to antiparasitics (avermectin 
B1b, 4) and immunosuppressants (rapamycin, 5).4 Representative 
examples of polyketides and their natural producers are shown in Figure 1. 
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Fig. 1: Representative examples of polyketides and their natural producers.4 
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Erythromycin A is an antibiotic that inhibits protein biosynthesis in Gram-
positive bacteria.5 Doxorubicin is used in chemotherapy against different 
cancer types such as breast cancer, childhood solid tumours and soft tissue 
sarcomas.6 Avermectin plays a role in parasitic diseases, while rapamycin 
is an immunosuppressant that inhibits T-cell distribution by specifically 
binding to intracellular receptors.4,  7      
 
First investigations on polyketides were carried out in 1883 by James 
Collie, who discovered the aromatic substance orcinol.8 Since then, the 
research interest in polyketides has been enormous. Collie assumed that 
orcinol-like natural products were derived from two-carbon “CH2-CO” 
building blocks by cyclisation of poly-β-keto intermediates which led to the 
definition “polyketon”.9 Later, this name changed to polyketide.10  
 
2.1.1 Polyketide biosynthesis 
 
Despite their structural and functional diversity, polyketides possess the 
similar biosynthetic pathways. Polyketides are synthesised by 
multifunctional enzymes called polyketide synthases (PKSs) by repeated 
rounds of carbon chain extensions and further tailoring modifications.11, 12 
PKSs are related to fatty acid synthases (FASs), but PKSs usually produce 
metabolites with more complex structural architectures.8 The variability of 
the structure is influenced by how the PKSs are programmed: choice of 
starter unit, the nature and number of the chain extender units, control of 
the β-keto group on oxidation level of the growing carbon chain, 
stereochemistry of hydroxyls and alkyl side groups and pattern of 
cyclisation of the nascent carbon chain.11  
 
Figure 2 displays the different functionalities of PKS and FAS 
mechanisms.11, 13 Polyketides consist of a long carbon chain constructed 
from small organic molecules; for example (e.g.) acetic acid 6 and malonic 
acid 7 that are first activated as coenzyme A (CoA) esters. FASs use 
acetyl-CoA 8 as a starter unit and malonyl-CoA 9 as extender units 
whereas PKSs can use different acyl-CoA substrates.14  The starter unit is 
attached to the active site of the ketosynthase (KS), while the chain 
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extender unit is loaded onto an acyl carrier protein (ACP). Both units are 
Claisen condensed by the KS resulting in a loss of carbon dioxide and 
production of a carbon chain attached to the ACP. This is then transferred 
back to the KS and further rounds of condensations take place with 
malonyl-CoA (FAS, PKS) or other extender unit (PKS), where the chain is 
extended by two carbons at each step.  
 
Depending on the PKS system, the extended carbon chain is either 
partially, fully, or not reduced. Enzymes or domains labelled ketoreductase 
(KR), dehydratase (DH) and/or enoylreductase (ER) are responsible for 
these modifications. In fatty acid (FA) synthesis, all possible reduction steps 
take place to produce a fully saturated chain.11  
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Fig. 2: General reaction scheme for FASs and PKSs.11, 13 
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2.1.2 Classification of PKS types 
 
 
PKSs are categorised into three different classes: type I, type II and type III. 
Each type possesses different types of functions; modular and iterative, 
which lead to the structural differences in polyketides.2 Type I PKSs are 
present in bacteria and fungi, type II PKSs are found only in bacteria and 
type III PKSs can be found in plants, bacteria and fungi.15 Type I and type II 
PKSs use ACPs to activate acyl-CoA substrates and to transfer the growing 
polyketide intermediates, whereas type III PKSs lack this enzymatic relay 
mechanism.2  
 
Modular type I PKSs are multifunctional enzymes that are organised into 
modules and to date, these are among the largest proteins encountered in 
nature.16 Every module possesses non-iteratively acting domains 
responsible for polyketide chain elongation.2  
 
The antibiotic erythromycin A 1 PKS (6-deoxyerythronolide B synthase -
DEBS) is the most thoroughly investigated example of modular type I 
PKSs. An illustration of this system is shown in Figure 3.4 The DEBS uses 
one propionyl-CoA as a starter unit and six (2S)-methylmalonyl-CoA as 
extender units for erythromycin A biosynthesis and comprises of one 
loading module, six chain-extension modules and a chain-terminating 
thioesterase (TE). The system is distributed on three gigantic proteins 
which are named DEBS 1, 2 and 3. The loading module contains an acyl 
transferase (AT) and an ACP domain and each chain-elongation module 
contains an AT, a KS and an ACP domain along with additional reductive 
elements such as KR, ER and DH domains. The TE catalyses the release 
of the aglycon from the PKS and tailoring enzymes form the fully active 
erythromycin A 1.17 The linear organisation of modules and their domains 
as seen in Figure 3, determine the structure of the polyketide, a feature 
known as the collinearity rule.18      
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Fig. 3: The modular PKS paradigm.4 
 
In this figure, erythromycin A (1) biosynthesis is used to illustrate the modular PKS 
reaction scheme. DEBS, 6-deoxyerythronolide B synthase; AT, acyl transferase; 
ACP, acyl carrier protein; KR, ketoreductase; DH, dehydratase; ER, enoylreductase; 
TE, thioesterase. 
 
 
Iterative type I PKSs are mainly found in fungi.19 These PKS systems exist 
as iterative-acting modules and each module is used in every elongation 
cycle.20 In fungi, type I PKSs are responsible for the biosynthesis of the 
aromatic polyketide 6-methylsalicylic acid from Penicillum patulum21, 22 and 
of lovastatin, the cholesterol lowering agent from Aspergillus terreus.8, 23 
More rare examples from bacteria include avilamycin from Streptomyces 
viridochromogenes Tu57.24 
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Type II PKSs comprise of multienzyme complexes that act iteratively in 
carbon chain elongation. The aromatic polyketide compound griseorhodin A 
that is investigated in the present study is synthesised by a type II PKS,25 
and therefore this type of PKS is highlighted in section 2.1.3.  
 
Type III PKSs, also known as chalcone/stilbene-synthase-like PKSs are 
homodimeric enzymes that function iteratively and catalyse 
decarboxylation, condensation, cyclisation and aromatisation.26 These 
PKSs act directly on the acyl-CoA due to the lack of an ACP.2 Flavolin, an 
aromatic polyketide is synthesised by a type III PKS.27  
 
2.1.3 Type II PKSs 
 
Type II PKSs are structurally analogous to bacterial FASs consisting of 
several individual enzymes.28 The investigation of polyketide assembly by 
type II PKSs has proven to be more difficult than other PKS types due to its 
multienzymatic characteristics.6 In addition to that, the poly-β-keto 
intermediates are highly unstable and tend to cyclise spontaneously.6 In the 
1980s, Hopwood and co-workers pioneered genetic studies aimed at 
understanding the biosynthesis of polyketides using the polyketide 
actinorhodin as a suitable test system due to its characteristic blue color.29 
To date, the antibiotic actinorhodin PKS (act PKS) is the most heavily 
investigated example of an iterative type II PKS. The poly-β-keto chain of 
aromatic polyketides is synthesised by a minimal set of iteratively used 
enzymes, the so-called minimal PKS, each expressed from a distinct gene.6 
The minimal PKS is comprised of two KS units, KSα and KSβ, and an ACP 
that serves as an anchor for the growing polyketide chain.30 The genes 
encoding these proteins are usually grouped together in type II PKS 
biosynthetic gene clusters. However, in the biosynthetic gene cluster of 
griseorhodin A, the investigated gene cluster in this study, the ACP gene 
grhC is located 26 kb upstream of the ketosynthase genes grhA and grhB.25 
The structure of the nascent poly-β-keto intermediates is further processed 
by a KR, cyclases (CYC) and aromatases (ARO).31 The final modifications 
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are carried out by post-PKS enzymes such as oxidoreductases, glycosyl 
transferases and methyl transferases.8    
 
2.1.3.1 Minimal PKS 
 
The minimal PKS catalyses iteratively the Claisen condensation of a starter 
acyl and a defined number of extension units; different starter units can be 
used but the extension unit is always derived from malonyl-CoA (Figure 4).6 
This is a remarkable difference to modular PKSs.32 However, there is some 
speculation regarding the transfer of the malonyl extension unit and the 
presence of a potential malonyl-CoA:APC transferase (MCAT) in the 
minimal PKS. Currently, it is assumed that endogenous MCATs are 
recruited from FA biosynthesis due to the absence of these genes in most 
type II PKS gene clusters.6, 33 More information is known concerning the 
roles of KSs encoded within the minimal PKS. The subunit KSα catalyses 
decarboxylative condensation, while the KSβ subunit is largely responsible 
for the determination of the polyketide chain length and was thus termed 
chain length factor (CFL).34   
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Fig. 4: Basic mechanisms of aromatic polyketide biosynthesis by type II PKS.6 
 
KSα, ketosynthase α; KSβ, ketosynthase β; ACP, acyl carrier protein; MCAT, 
malonyl-CoA:APC transferase. 
 
2.1.3.2 Polyketide chain length 
 
Investigations of the actinorhodin KSα-KSβ crystal structure revealed an 
alternating α-helix and β-fold heterodimeric structure.35 The polyketides are 
elongated inside an amphipathic tunnel at the heterodimer interface (Figure 
5). Here, the nascent polyketide chain is protected from spontaneous 
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intramolecular reactions due to the steric separation of reactive keto 
groups.36 A study by Tang et al. confirmed that the length of the chain is 
controlled by the interface of the KSα-KSβ heterodimer.35 In this study they 
performed structure-based mutagenesis to confirm that a small set of amino 
acid residues serve as gatekeepers of the tunnel. By reducing the size of 
these residues, two more elongation cycles were allowed in the tunnel. 
Therefore, filling the heterodimer tunnel is crucial for chain length 
elongation and by engineering the polyketide tunnel gates, novel chain 
lengths can be generated.6, 35 In addition to that, a study by Xu et al. 
indicated that the size of the starter unit acts a part in the determination of 
the polyketide chain length.37 The bigger or smaller the starter units are, the 
less or the more chain elongations are accomplished respectively. Other 
studies have shown that cyclases also play a role in determination of 
polyketide chain length and these are discussed in detail in section 2.2.1. 
ACP
KSα
O
O
O
O
O
O
O
S
O
KSβ
 
 
Fig. 5: Model for minimal PKS complex with chain elongation.6 
 
 
2.1.3.3 PKS priming 
 
Most type II PKSs utilise an acetyl as a starter unit. The biosynthesis and 
attachment of other starter units, such as propionate, (iso)butyrate, 
malonamate and benzoate have been reviewed by Moore and Hertweck.38 
Two biosynthetic pathways to starters other than of acetyl were proposed.  
Candidates responsible for alternative starter units are the FabH-like KSIII 
and an additional ACP, which have homology to proteins responsible for 
the biosynthesis and priming of short-chain fatty acids.6  
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FabH is an enzyme carrying out the condensation of acetyl and malonyl 
units in bacterial fatty acid synthesis.39 FabH homologs are found in the 
biosynthetic pathways of daunorubicin (DpsC),40 frenolicin 12 (FrnI),41 
R1128 13-16 (ZhuH),42 and benastatin A 17 (BenQ)43 and are responsible 
for the biosynthesis and attachment of short-chain fatty acids (Figure 6). 
Another KSIII (HedS) was identified in hedamycin biosynthesis, which 
belongs to the group of pluramycin antibiotics.44 Here, an iterative type I 
PKS (HedT and HedU) is used for the biosynthesis of a short-chain unit. 
The second hypothesis for alternative starter unit incorporation describes 
insertion of the malonamate and benzoate starter units by activation and 
transfer through an acyl-CoA ligase followed by AT-mediated transfer onto 
the PKS in the biosynthetic pathways of tetracycline and enterocin.38   
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Fig. 6: PKS priming involving KSIII components.6        
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2.2  Early PKS genes 
 
2.2.1 Type II PKS cyclases 
 
For the production of any polyketide, the minimal PKS is always required 
(section 2.1.3.1). The expression of the minimal PKS results in highly 
reactive poly-β-keto intermediates that can undergo spontaneous 
cyclisation reactions.6 Cyclases (CYC) are enzymes suppressing these 
spontaneous aldol reactions and hence, promote cyclisation specificity of 
polyketide intermediates.31 The cyclisation process is often supported by 
aromatases and they dehydrate cyclic alcohols to yield aromatic rings.6   
 
The regioselectivity of the first intramolecular aldol condensation must be 
fixed by aromatic PKS immediately upon/following completion of the 
polyketide chain.31  This action also dictates the structure of the final 
aglycon in that it determines where the carbon backbone “turns the corner” 
as described by Rawlings.32 The first cyclisation step and the corresponding 
cyclases are well studied, among which C7-C12 and C9-C14 cyclisations 
are the most common cyclisation patterns.32 These patterns lead to the 
formation of the most important bacterial aromatic polyketide scaffolds, 
including tetracyclines, anthracyclines, tetracenomycins, angucyclines, 
pentangular polyketides and benzoisochromanequinones.31 Other first ring 
cyclisation patterns have been observed in the presence of nonacetate 
starter units or longer polyketides.45 
 
Analyses of deduced gene products from different type II PKSs revealed 
that cyclases may occur as didomain enzymes with internally duplicated 
motifs, such as ActVII in actinorhodin biosynthesis41, 46 and that expression 
of the N- or C-termini alone resulted in loss of function. Alternatively, CYCs 
may also exist as bifunctional enzymes, e.g. TcmN containing both, a 
cyclase and an aromatase (ARO) function.47 In various cases, these CYC 
domains are fused with other functionalities, e.g. CYC/MT or CYC/KR.6  
Despite the large number of cloned CYC genes, the only biochemically 
characterised cyclases are the TcmI cyclase48 and TcmN 
cyclase/aromatase49, 50 from the tetracenomycin pathway, and the ester 
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cyclases SnoaL and AknH involved in nogalamycin and aclacinomycin 
biosynthesis.51  
 
2.2.1.1 C7-C12 first-ring cyclisation 
 
It has been shown that the minimal PKS synthesises C7-C12 first-ring 
cyclisation of polyketides such as SEK4 18 (act minimal PKS),52 SEK12 19 
(tcm minimal PKS),52 and a set of compounds such as TW93c 20 (whiE 
minimal PKS) (Figure 7).45 These compounds are all derived from 
regioselective C7-C12 aldol condensations followed by spontaneous 
cyclisation of the remaining polyketide chain. The formations of SEK4 18, 
SEK12 19 and TW93c 20 in the absence of any cyclases suggest various 
KSα-KSβ have influence on product folding and promote C7-C12 cyclisation. 
Investigations of the act KSα-KSβ crystal structure revealed that the tunnel 
(section 2.1.3.2) not only determines polyketide chain length but also 
directs where the linear intermediate folds in order to fit fully into the 
tunnel.36 Furthermore, in the act KSα-KSβ heterodimer, a water molecule is 
present in the middle of the tunnel and is proposed to act as a proton donor 
and to facilitate the C7-C12 aldol condensation.31  
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Fig. 7: Representative C7-C12 first-ring cyclisation products.31  
 
Additionally, several cyclases such as ZhuI (R1128),42 StfQ (steffimycin),53 
and MtmQ (mithramycin) have been identified that catalyse the C7-C12 
first-ring cyclisation in unreduced polyketides.54 The crystal structure of 
ZhuI resembles TcmN (C9-C14 first-ring cyclase from tetracenomycin 
biosynthesis). However, ZhuI shows a smaller substrate binding pocket 
and,50 therefore, favors cyclisation of the polyketide intermediate between 
C7 and C12 instead of at C9 and C14.55 
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2.2.1.2 C9-C14 first-ring cyclisation 
 
For unreduced aromatic decaketides or larger polyketides, the C9-C14 
cyclisation pattern is observed.31 TcmN is a well-studied example for a 
cyclase catalysing this type of cyclisation and is known to suppress the C7-
C12 cyclisation of the minimal PKSs. Co-expression of tcmN with the act, 
fre, tcm or whiE minimal PKSs led to C9-C14 cyclisation products RM77 
21,56 PK8 22,47 RM80 23,56 and TW95a 24, respectively (Figure 8).45  
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Fig. 8: Representative C9-C14 first-ring cyclisation products.31 
 
 
In tetracenomycin biosynthesis, the tcm minimal PKS produces a linear 
decaketide intermediate that is folded, cyclised and aromatised by TcmN 
via aldol condensation and dehydration reactions to form the first two 
aromatic rings (C9-C14 and C7-C14) (Figure 9).49 Hence, this enzyme 
seems to play a role in the second-ring cyclisation in longer polyketides. 
The N-terminus of the TcmN crystal structure revealed that the substrate 
binding pocket favors C9-C14 regioselectivity in the polyketide 
intermediates.50 Docking simulation studies confirmed this result; however, 
docking simulations with C7-C12 regioselectivity predicted a much weaker 
interaction with the pocket and the polyketide intermediate. Mutagenesis 
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studies of TcmN residues R69 and Y35, which are essential for the C9-C14 
regioselectivity, resulted in the loss of the C9-C14 regioselectivity and led to 
the synthesis of C7-C12 cyclised products. In comparison to the N-TcmN 
structure, the crystal structure of WhiE-OrfVI, which directs C9–C14 
cyclization of dodecaketides, indicates a larger cyclization chamber that is 
needed to harbour a longer polyketide backbone.50  
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Fig. 9: C9-C14 and C7-C14 cyclisations in tetracenomycin C  biosynthesis.50 
 
 
2.2.1.3 Additional cyclisation steps 
 
Following the initial first-ring cyclisations, the subsequent regioselective 
cyclisations lead to the folding of the polyketide intermediates either in a 
linearly fused fashion resulting in tetracyclines, anthracyclines or 
tetracenomycins or in an angularly fused fashion, producing angucyclines 
and pentangular polyketides. Both polyketide structural types possess the 
first-ring C7-C12 and C9-C14 cyclisation steps.  
 
In the biosynthesis of the linear fused oxytetracycline, OxyN directs the 
second-ring C5-C14 cyclisation. The third ring is probably cyclised 
spontaneously, and so far no enzyme has been identified for the fourth-ring 
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cyclisation.31 Another example for the linearly cyclised polyketides are the 
tetracenomycins. In the biosynthesis of tetracenomycin C 29 (Figure 10), 
the first- and the second-ring cyclisations are mediated by the well 
investigated TcmN, followed by the third-ring cyclisation C5-C18 to form 
Tcm F2 30,57 which is either enzyme-mediated or form spontaneously. The 
cyclase TcmI catalyses the fourth-ring formation at C2-C19, resulting in 
Tcm F1 31.58   
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Fig.10: Linearly cyclised polyketide scheme.31 
 
Tetracenomycin C biosynthesis scheme. TcmN directs the first- and the second 
cyclisation leading to Tcm F2 30; TcmI is responsible for the fourth-ring cyclisation 
resulting in Tcm F1 31. 
 
The angularly cyclised polyketides are usually derived from backbones that 
are dodecaketides or longer. The third ring closure at C4-C17 in 
angucyclines is a critical step in differentiating the tailoring steps of 
anthracyclines and angucyclines. In the biosynthesis of jadomycin B 32 
(Figure 11), the most well studied angucycline,  the cyclase JadI (jadomycin 
B from Streptomyces venezuelae)59 was identified and proposed to direct 
the angular cyclisation steps of C4-C17 and C2-C19 to form UWM6 33, a 
common angucycline intermediate leading to jadomycin B 32. 
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Fig. 11: Angularly cyclised polyketide scheme.31 
 
Jadomycin B biosynthesis scheme. JadD directs the first- and the second ring 
cyclisation; JadI is proposed to dictate the angular cyclisation steps of C4-C17 and 
C2-C19 leading to UWM6 29 and eventually to jadomycin B 28. 
 
The fourth-ring closure between C4 and C21 in polyketide backbones with 
more than 24 carbon atoms induces bending of the structure and, thereby 
promoting additional cyclisation such as C2-C23. This leads to the 
benzonaphthacene quinone skeleton common to many compounds in this 
family.31 Pentangular compounds such as benastatin J 34, pradimicin A 35, 
griseorhodin A 36 and fredericamycin A 37 are examples of this cyclisation 
pattern (Figure 12).31 
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Fig. 12: Representative pentangularly cyclised polyketides with more than 24 carbon 
atoms.31 
 
2.3  Post-PKS enzymes 
 
The polyketide poly-β-keto chain is usually further modified by post-PKS 
enzymes such as oxidoreductases, reductases, glycosyl transferases and 
methyl transferases, resulting in highly structural diversity. 
 
2.3.1 Oxidoreductases 
 
Oxidoreductases are enzymes comprising of oxygenases, oxidases, 
peroxidases, reductases and dehydrogenases. Among these, oxygenases 
are the most important post-PKS tailoring enzymes, because they generate 
an enormous structural diversity within polyketides due to their various 
types of functions. In general, they carry out the incorporation of oxygen 
atoms into a substrate. These enzymes are divided into monooxygenases 
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and dioxygenases, differentiated by the number of oxygen atoms that are 
incorporated.6, 60 Monooxygenases incorporate a single atom of molecular 
oxygen, whereas the other oxygen atom is reduced to water (Figure 13 A). 
Dioxygenases incorporate both atoms of molecular oxygen atoms to 
generate very reactive peroxides and dioxanes that further react to produce 
rearrangements and cleavages (Figure 13 B). The enzymes catalyse such 
reactions as hydroxylations, epoxidations, quinone formation and oxidative 
rearrangements of the Baeyer-Villiger or the Favorskii type.6 Recently, 
bifunctional oxidoreductases have been identified, e.g. TcmG 
(monooxygenase /dioxygenase),61 JadH (oxygenase/dehydratase),62 and 
LndM2 (oxygenase/reductase).63 In the following sections, oxygenases are 
described in more detail that act a part in the griseorhodin A biosynthesis.  
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Fig. 13: Generation of structural diversity by oxygenases.60 
 
Examples of immediate products of mono (A)- and dioxygenases (B), and possible 
follow-up reactions.  
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Cytochrome P-450 (CYP450) oxygenases are a diverse class of heme-
containing enzymes found ubiquitous in mammals, bacteria and plants.64 
They are potent oxidants and catalyse hydroxylation of saturated carbon-
hydrogen bonds, the epoxidation of double bonds, perform dealkylation 
reactions and oxidations of aromatics.64 For the reconstitution of the 
oxygenase activity, CYP450 additionally require the presence of a NADPH-
cytochrome-P-450 reductase and a ferredoxin-like iron-sulfur protein. 
However, these enzymes are not often clustered with the CYP450-
encoding genes.60  
 
CYP450 catalyses the following reaction: 
 
RH O2 NAD(P)H+ + + H+ ROH H2O NAD(P)+++
 
 
Fig. 14: CYP450 catalysed reaction.65 
 
RH represents any substrate of the broad substrate specificity of CYP450. 
Many of the substrates are harmful lipophilic compounds such as polycyclic 
aromatic hydrocarbons, chlorinated diphenyls and steroids that are 
hydroxylated by CYP450 for better degradation or excretion.65  
 
To date, only few CYP450 monooxygenases have been described in the 
context of bacterial aromatic polyketide biosynthesis. EncR, a CYP450 
monooxygenase from enterocin biosynthesis, catalyses the hydroxylation 
step from desmethyl-5-deoxyenterocin 47 to the final product enterocin 48, 
assisted by the translationally coupled ferredoxin-like EncQ (Figure 17).66 
Another example is a CYP450 monooxygenase DoxA from daunorubicin 
and doxorubicin biosynthetic pathways that catalyses hydroxylations on C-
13 and C-14 positions of anthracyclines.67   
 
Flavin-dependent oxygenases catalyse oxidations and hydroxylation 
reactions and are involved in dehydrogenation reactions and are also 
involved in light emissions and in one- and two-electron transfers.68-70 They 
are highly regio- and/or enantioselective and employ a purely organic 
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cofactor flavin adenine dinucleotide (FAD) 41.71 For reactivity with 
molecular oxygen the co-factor has to be in the reduced form 38. The 
biocatalysis begins with the reduction of the bound FAD 41 by NADPH to 
38 which is then oxygenated using molecular oxygen to form peroxyflavin 
39 (Figure 15).71 FAD-dependent monooxygenases are able to stabilise 
peroxyflavin to hydroperoxy species 40 and prevent peroxyflavin from 
decay as it is unstable and otherwise decays to form hydrogen peroxide 
and oxidised flavin 42. Depending on the protonation state of the 
peroxyflavin 39, either a nucleophilic 39 or electrophilic attack 40 on the 
substrate occurs. Finally, a single atom of molecular oxygen is incorporated 
into the substrate, while the other oxygen atom is reduced to water. The 
cycle ends with the dissociation of the product and the co-factor from the 
enzyme.71, 72   
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Fig. 15: General mechanism of oxygenation reactions by external flavoprotein 
monooxygenases.71 
 
R = Ribitol adenosine diphosphate. 
 
In the flavin-dependent oxygenases, the FAD cofactor is usually non-
covalently bound, but there are also oxygenases where it is covalently 
bound. For example, the vanillyl-alcohol oxidase contains FAD linked to a 
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histidine.73 It was shown that the covalent linkage enhances the oxidative 
power of the flavin cofactor. Another example for covalently bound oxidases 
is EncM in enterocin biosynthesis as shown in Figure 17. In polyketide 
biosynthesis, additional reactions that increase structural diversity include 
hydroxylations, epoxidations and Baeyer-Villiger oxidations and Favorskii 
rearrangements.38, 74-76 TcmG, a monooxygenase/dioxygenase from 
tetracenomycin biosynthesis, carries out a triple hydroxylation of 
tetracenomycin Tcm A2 to form tetracenomycin C 29.61 The Baeyer-Villiger 
monoxygenases (BVMOs) catalyse molecular oxygen reactions as 
described above. The best studied BVMO, a cyclahexanase 
monooxygenase isolated from an Acinetobacter, catalyses the  reaction of 
cyclohexanone and a “Criegee” intermediate leading to a formation of a 
lactone 45 (Figure 16).72, 76    
 
O
O-O
O
O
O
O
O
R
R-OO- +
Peroxyflavin
 38 Cyclohexanone
 43
Criegee adduct 
44
Hydroxyflavin 
41
-NAD(P)+
-H2O
Oxidised flavin 
42
+
Caprolactone 
45
 
 
 
Fig. 16: Mechanism of the BVMO cyclohexanose monooxygenase.72 
 
 
BVMOs are the most common FAD-dependent oxygenases in type II PKSs. 
In mithramycin biosynthesis, the tetracyclic intermediate premithramycin B 
is formed and further processed to a tricyclic mithramycin precursor by the 
BVMO MtmOIV, which finally results in the active mithramycin after a 
decarboxylation.77 Other BVMOs have been characterised in biosynthesis 
of urdamycin A (UrdM)78, 79 as well as JadF, JadH and JadG from 
jadomycin A biosynthesis.80  
 
To date, only one example of a Favorskii-type oxidative rearrangement is 
described, namely EncM that is involved in enterocin 52 biosynthesis 
(Figure 17).75 EncM uses 47 as a substrate to form the 11,12,13-trione 
intermediate 49. In addition, EncM acts as a dioxygenase and oxidatively 
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cleaves 48 to 49. EncM also catalyses the Favorskii-like rearrangement and 
facilitates aldol condensations and two heterocycle-forming reactions in the 
formation of desmethyl-5-deoxyenterocin 51.  
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Fig. 17: Proposed biosynthetic pathway of enterocin.75 
 
In compounds 47-50, the carbon numbering is based on linear 47 in which priority is 
given to the carboxyl carbon; the numbering of 51 and 52 is defined for enterocin 
and its derivatives. Dashed lines in structures 49 and 50 represent newly created 
bonds. 
 
Ketoreductases catalyse the stereospecific hydrogen transfer from 
NAD(P)H onto a keto group, leading to a formation of an alcohol. Most of 
the aromatic polyketides are reduced by a KR during the polyketide 
backbone assembly.32 The growing acyl chain is folded due to a transition 
from sp2 to sp3 hybridisation and reduced, respectively, at the keto group 
nine carbons (C9) from the final position of thioester carbonyl.6 This strict 
regiochemistry is independent from the polyketide chain length as well as 
from the nature of the starter unit. The extensively studied act KR reduces 
polyketide backbones of nearly all lengths.32 Another type of KR was 
observed during enterocin biosynthesis, where ketoreduction by EncD 
takes place during polyketide assembly.81 Ketoreduction can lead to the 
formation of a chiral carbon centre as was observed in doxorubicin from S. 
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peucetius. Its C-17 keto group is stereospecifically reduced by the 
aklaviketone reductase DnrH.82  
2.3.2 Transferases 
 
Transferases catalyse transfer reactions and are comprised of methyl 
transferases (MT), alkyl transferases, acyl transferases, amino 
transferases, glycosyl transferases (GT) and kinases.60 They introduce 
novel functional groups such as methyl, acetyl, sugar and phosphate 
moieties and hence, the characteristics of a molecule and even the 
biological activity are modified in this manner (Figure 18).60, 83 In the 
following, GTs and MTs, the most important transferases in the context of 
polyketide synthesis,60 are described.  
O
O
H3C
HO
HO
ONDP
OHO
HO
H3C
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GT
R - OCH3R - OH
NDP
H-bond-donor
less lipophilic
no H-bond-donor
more lipophilic
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less complex (bulky)
more complex (bulky)
OH
H-bond-donor
change of 
stereoelectronic
complexity, bulkyness 
etc.
no longer H-
bond-donor
newly positioned 
H-bond-donor
increased hydrophilicity
 
Fig. 18: Possible effects of group transferases on the biological activities.60 
 
Effects of manipulation of methyl- and glycosyltransferases, MT = 
methyltransferase, GT = glycosyltransferases, SAM = S-adenosyl-L-methionine, NDP 
= nucleoside diphosphate. In arrow-direction: recombination with a gene encoding 
additional enzyme; against arrow direction: gene inactivation experiment. 
 
GTs attach sugar moieties to the polyketide aglycons by catalysing the 
sugar transfer from an NDP-activated sugar donor to an acceptor 
molecule.84 Most of the sugars belong to the 6-deoxyhexane (6-DOH) 
family and are linked to the aglycone as saccharides of variable sugar 
2 Introduction  
25 
                                                                 
 
lengths.85 Through sugar attachment, the structural diversity of polyketides 
is increased and often modulates the biological activity of natural 
products.85, 86  
MTs use SAM as a cofactor to methylate nitrogen, carbon, sulfur and 
oxygen atoms.6 The methyl transfer occurs via an SN2 mechanism that has 
a steric impact on methylations, especially on the C-methylation in 
generating a chiral centre.6 In addition, O- (DnrK from S. peuceticus) and 
N-methylations increase the lipophilicity of a molecule and remove 
hydrogen-bond sites.60 The methylation reactions take place at the 
polyketide-derived-aglycon moiety or on sugar residues, either prior to or 
after the glycosyl transferase step.60   
 
2.4  Ongoing search for novel bioactive metabolites 
 
To date, most bioactive metabolites are found from soil microorganisms 
and about half of all of these compounds are produced by the 
actinomycetes, mainly by the genus Streptomyces.87, 88 Furthermore, 
bioactive metabolites have been isolated from marine actinomycetes as 
well, suggesting such marine bacteria organisms as a second potential 
niche for discovering novel drugs.89-91 Due to the emergence of multi-drug 
resistant microbes, it is significant to discover novel drugs for the treatment 
of microbial, fungal and parasitic infections.92 Furthermore, anti-cancer 
therapies require novel anti-tumour compounds with fewer side effects and 
improved therapeutic properties.93 In the following, several approaches in 
the discovery of novel drugs are discussed. 
 
Novel natural products can be discovered e.g. by intensive screening.94 An 
example for this is the antibiotic platensimycin, produced by S. platensis. 
The compound was identified through a systematic screening of natural 
product extracts and belongs to a previously unknown class of antibiotics.95, 
96
 
More recent methods in novel bioactive natural product discovery involve 
genome mining and metagenomic approaches. Genome mining uses 
bioinformatics to predict the presence of potential natural product 
biosynthesis genes in microbial genomes.97 In metagenomics, genetic 
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material is directly recovered from environmental samples and enables so 
access to organisms that are not (easily) cultured in laboratory.98 These 
techniques allow accession to yet, undiscovered cryptic, inactive and/or 
intractable biosynthetic gene clusters in their native hosts.99 These gene 
clusters subsequently can be identified, cloned and heterologously 
expressed efficiently in more suitable host organisms. 100 
 
A very useful method that is widely applied in drug discovery is genetic 
engineering. It can be applied to manipulate biosynthetic pathways to 
increase the chemical diversity and bioactivity of natural products.12 
Inactivation of specific biosynthetic genes lead to mutants that accumulate 
different compounds with possible improved pharmacological properties, 
e.g. increased biological activity.101 Isolation and structure elucidation of 
such compounds then allow the functional analysis of the involved 
enzymes. Oviedomycin from S. antibioticus ATCC 11891102 exhibits in vitro 
anti-tumour activity and induces apoptosis in cancer cell lines.103, 104 During 
the inactivation of oxygenase genes, two new metabolites were produced 
with improved anti-tumour activity compared to oviedomycin.104  
 
In combinatorial biosynthesis, biosynthetic pathway genes are combined 
and/or replaced to produce “unnatural” natural products in a mix-and-match 
fashion.32, 105 This method results in novel molecules never encountered in 
nature and therefore represents an important new source of chemicals for 
use in drug discovery.106, 107 David Hopwood and co-workers combined 
different antibiotic gene clusters, medermycin or granaticin, with 
actinorhodin to produce the first hybrid aromatic polyketide mederrhodin.108 
Since then, many type II PKS systems have been found and characterised, 
leading to the production of hybrid metabolites.28, 32 Combinatorial 
biosynthesis has been successfully applied in post-PKS steps such as 
oxidation, O-methylation or glycosylation.60 For example, through co-
expression of the doxorubicin genes with a sugar gene eryBIV from the 
erythromycin cluster in S. peucetius ATCC 29050, the anti-cancer agent 
derivative epirubicin, previously generated by semisynthesis, was produced 
for the first time using fermentation.109  
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While combinatorial biosynthesis has been widely used for post-PKS 
genes, there are studies revealing the potential of combinatorial 
biosynthesis for exploiting the early biosynthetic type II PKS genes such as 
minimal PKSs and cyclases. Through exchange of cyclases, the cyclisation 
patterns of polyketides can be influenced.110 Furthermore, spontaneous 
cyclisations take place through expression of only the minimal PKS in the 
absence of cyclases, as was shown by study of Shen and co-workers.111 
The expression of whiE minimal PKS in S. coelicolor resulted in a diverse 
substance library comprising more than 30 polyketides differing in chain 
lengths and cyclisation patterns (Figure 19).111 To date, this is the largest 
and the most complex substance library produced by combinatorial 
biosynthesis. However, these kinds of systems are rare and have not yet 
been investigated in this respect.   
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Fig. 19: Representative polyketide structures through the expression of the whiE 
minimal PKS.45 
 
The numbers represent the cyclisation topologies of the first rings. 
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Furthermore, the primer unit of a polyketide backbone is an attractive site 
for introducing unnatural building blocks resulting in novel structures. 
Genes encoding for KSIII-like enzymes are found in frenolicin, R1128 and 
hedamycin (section 2.1.3.3). In the biosynthesis of R1128, the zhu PKS 
uses butyryl, valeryl and 4-methyl starter units; its loading complex 
comprises of a KS (ZhuH), an AT (ZhuC), and an additional ACP (ZhuG).42 
Khosla and co-workers engineered modified aromatic polyketides by 
recombination of the R1128 loading complex with the act and tcm minimal 
PKSs (Figure 20).112 The expression of the act minimal PKS alone leads to 
the octaketide DMAC 59. Co-expression of the act minimal PKS and the act 
KR with the R1128 initation module resulted in two novel hexaketide 
structures YT46 60 and YT46b 61. The tcm minimal PKS produces octa- 
and decaketides when expressed alone. Co-expression with the R1128 
iniation module and the act KR, ARO and CYC genes leads mainly to 
octaketide-DMAC derivatives YT127 62 and YT127b 63. Incorporation of 
bigger building blocks resulted in fewer chain length elongations, whereas 
the chain length stays the same. Similar results were produced by the 
deletion of BenQ in the benastatin A gene cluster.43 The starter units were 
recruited from FA biosynthesis and incorporation of the butyryl starter unit 
led to an additional chain elongation step. 
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Fig. 20: Engineered biosynthesis of aromatic polyketides.112 
 
(A) Actinorhodin (act) minimal PKS 
(B) act minimal PKS and R1128 initation module 
(C) Tetracenomycin (tcm) minimal PKS and R1128 iniation module  
ARO, aromatase; DMAC, dihydroxymethylanthraquinone; bold bindings represent 
acetate units. 
 
In the biosynthesis of griseorhodin A, a successful combinatorial 
biosynthetic approach was carried out by complementing the griseorhodin 
A minimal PKS by co-expressing the benastatin A minimal PKS; BenA 
(KSα), BenB (KSβ), BenC (ACP) and BenQ (KSIII homolog). BenQ is 
responsible for selection of the hexanoyl starter unit in benastatin A 
biosynthesis (section 2.1.3.3). The expression resulted in the successful 
production of the novel polyketide hybrid benarhodin A 65 (Figure 21).1 
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Fig. 21: Benarhodin A.1  
 
So far, combinatorial biosynthesis has been demonstrated as a powerful 
method for generating versatile natural products.113 However, several 
technical bottlenecks in this approach still exist.114 In addition, often narrow 
substrate specificities play significant roles affecting optimal biosynthesis of 
compounds. A general lack of suitable heterologous expression systems 
limits genetic engineering of interesting metabolic pathways. Therefore, 
further investigations are necessary to overcome these challenges.             
   
2.5  Griseorhodin A 
 
Griseorhodin A was first isolated from S. griseus JA2640 extracts and its 
biological activity was described by Treibs and Eckardt in 1961.115 The 
structure was elucidated in late 1970s,116, 117 and the absolute configuration 
of griseorhodin A was determined in 2008.118  
 
Griseorhodin A is a tridecaketide and belongs to the rubromycin family 
(Figure 22).119 Most rubromycins are strong inhibitors of human telomerase 
and retroviral reverse transcriptase.120, 121 They possess an aplanar, axially 
chiral structure due to the presence of a highly unusual spiroketal moiety.122 
This pharmacophore is responsible for its inhibition, as an open spiroketal 
decreases the activity by two orders of magnitude as seen in α-
rubromycin.120  
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Fig. 22: Representative members of the rubromycin family.119 
 
During a study on bacterial symbionts of marine invertebrates, a bacterial 
strain, Streptomyces sp. JP95, was isolated from the marine tunicate 
Aplidium lenticulum and was found to produce a number of rubromycin-type 
compounds with griseorhodin A as the major compound.25 A DNA cosmid 
library was constructed, resulting in the isolation of the griseorhodin A gene 
cluster. For heterologous expression, the gene cluster was cloned into an 
E. coli-Streptomyces shuttle cosmid pMP31 and successfully expressed in 
S. lividans and S. albus.25   
 
The griseorhodin A biosynthetic cluster is 34.2 kilobases (kb) in length 
(Figure 23). The gene cluster is comprised of 33 open reading frames 
(ORF) encoding a type II minimal PKS (ACP and KSα-KSβ), cyclases 
(GrhE, GrhQ and GrhT), and enzymes involved in regulation, resistance 
and post-PKS tailoring activities (11 redox-tailoring enzymes, several FAD-
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dependent monooxygenases, one NADPH:chinone oxidoreductase, one 
CYP-450 oxygenase and two KRs).25  
grh R1    R2      D     C     E          F            G            H I        O1       O2        O3    O4         
ACPactivator gene
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TE         CYC             OXY       KR      P450        
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doxin
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grh O9         M   N           P           Q  S        A            B           T       O10   U   V
OXY                    OXY OXY Efflux                MT         OXY    
PPT-ase
PKS gene
redox post-PKS gene
other post-PKS gene
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Unknown gene functions
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OXY                                                      KSα KSβ CYC-KR KR
CYC             
CYC
 
Fig. 23: Organisation of the grh biosynthetic pathway gene cluster.25 
 
Every arrow represents the direction of the transcription of an open reading frame 
(ORF) 
 
In year 2009, griseorhodin A biosynthesis was postulated by gene knock-
outs and analysis of the corresponding intermediates (Figure 24).1 After 
formation of the poly-β-keto chain, early oxidation/cyclisation/methylation 
steps take place at the same time and/or in parallel routes on a multi-
enzyme complex. At this stage, collinone 70, is formed and three carbon-
carbon bonds are cleaved by GrhO5 in cooperation probably with GrhO1 
leading to the spiro compound lenticulone 71. A further carbon-carbon bond 
is cleaved to reduce a six-membered ring by one carbon unit by GrhO6 and 
GrhJ, respectively, generating 7,8-dideoxy-6-oxogriseorhodin C 72. The 
reduction of the keto functionality of 7,8-dideoxy-6-oxogriseorhodin C takes 
place, and the enzymes GrhO3 and GrhO7 catalyse the epoxidation of  
dideoxygriseorhodin C 73 leading to the polyketide griseorhodin A 36. 
Herewith, many of the Grh enzyme functions have now been elucidated but 
the enzymes catalysing the early steps remain uncharacterised.    
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Fig. 24: In year 2009 postulated grh biosynthetic pathway (red lines indicate the 
carbon-carbon bonds cleaved during the biosynthesis).1 
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Previous studies by Dr. Kathrin Reinhardt and Zeynep Yunt characterised 
the griseorhodin A post-PKS enzymes and gave insights concerning the 
interesting post-PKS steps, especially how the spiroketal moiety is formed;1, 
123
 this functionality is responsible for the telomerase inhibiting activity of 
griseorhodin A.1, 120  
 
However, some enzymes still remained uncharacterised in griseorhodin A 
biosynthesis. Two of them, GrhU and GrhV, are further investigated in the 
present study by gene knock-outs and investigations of the accumulated 
compounds by high pressure liquid chromatography (HPLC), LH20 
chromatography, mass spectrometry (MS) and nuclear magnetic resonance 
(NMR) 
 
A further goal was to gain deeper insights into the early biosynthetic steps of 
griseorhodin A biosynthesis. The early steps in griseorhodin A biosynthesis 
are encoded by minimal PKS genes, grhC, grhA, grhB and the three cyclase 
genes grhE, grhQ and grhT25. In the present study, the generated mutants 
of the early griseorhodin A genes are investigated by conjugation and 
heterologous expression in the host organism S. albus and analysed for the 
production of secondary metabolites by HPLC, HRMS and NMR. 
 
Thus, the main aims of the study were: 
 
• To analyse secondary metabolite production of the ∆grhU and ∆grhV 
mutants  
•  To isolate and analyse the secondary metabolites produced by the 
∆grhU and ∆grhV mutants to characterise their functions in 
griseorhodin A biosynthesis 
• To subclone the suspected early griseorhodin A biosynthetic genes 
into a suitable vector for the heterologous expression in the host 
organism S. albus  
3 Aims of study                     
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• To generate gene knock-outs by deleting cyclases and all tailoring 
genes on the cosmid pMP31 using homologous recombination 
technique for heterologous expression in the host organism S. albus 
• To propose a biosynthetic model from the obtained genetic and 
chemical data 
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4 Results and discussion 
 
4.1 Characterisation of the early griseorhodin A genes  
 
In the present study, heterologous expression was applied to investigate 
the early griseorhodin A biosynthetic steps by combining the grh minimal 
PKS and grh cyclase genes from the griseorhodin A biosynthetic gene 
cluster. Several previous studies have revealed that minimal PKSs 
expressed alone are able to generate metabolite shunt products.45, 52 To 
date, the most impressive minimal PKS compound library was obtained by 
expressing the whiE minimal PKS, resulting in a diverse library comprising 
more than 30 polyketides differing in chain lengths and cyclisation 
patterns.45 The addition of cyclase genes to the minimal PKS genes could 
lead to more advanced polyketides and give insights into the formation of 
specific polyketide ring structures, as was the case in the expression of the 
whiE minimal PKS with whiE cyclase genes.45  
 
4.1.1 Sequence analysis of the early-stage griseorhodin A 
biosynthetic proteins 
 
Table 1 lists the comparative results for GrhC, GrhE, GrhQ, GrhA, GrhB 
and GrhT with known sequences in the NCBI database using BLAST 
analysis (search with blastp). 
 
Table 1: Proposed functions of the ORFs shown in Figure 23. 
Protein  AS 
Proposed 
function 
Protein/organism/ 
accession number   
Similarity/ 
Identity [%] 
 
GrhC 
 
86 ACP 
ORF3, S. rochei124/ 
BAA87909 
63/58 
 
GrhE 
 
323 CYC 
SimA5, S. antibioticus125/ 
AF324838  
51/35 
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GrhQ 
 
123 CYC 
 
RubE, S. collinus 
(unpublished)/ 
AGG03065 
89/78 
 
GrhA 
 
426 KSα 
 
RubA , S. collinus 
(unpublished)/ 
AGG03067 
91/85 
 
GrhB 
 
420 KSβ 
 
RubB, S. collinus 
(unpublished)/ 
AGG03068 
83/77 
 
GrhT 
 
402 
Bifunctional 
CYC-3-
oxoacyl-ACP 
reductase 
RubF, S. collinus  
(unpublished)/ 
AGG03070 
77/69 
 
All of the homologues encode for known proteins that were subsequently 
cloned for heterologous expression.  
 
4.1.2 Clone constructions for the minimal PKS and cyclase 
expressions 
 
In order to investigate the role of genes grhC, grhA, grhB, grhT, grhE and 
grhQ, each gene was individually PCR amplified from the cosmid pMP31 
containing the complete grh gene cluster (Appendix 8.1). They were cloned 
with their native ribosomal binding sites (RBSs) and with integrated 
restriction sites MfeI and EcoRI into the E. coli cloning vector pBluescript 
SK+ (pSK+) and subsequently into the integrative E. coli-Streptomyces 
shuttle vector pKJ55. PCR conditions were optimised for each step, and the 
products were confirmed by gel electrophoresis (Figure 25). 
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M bp 1         2         3         4         5
 
 
Fig. 25: Agarose gel of PCR-amplified early grh genes from the cosmid pMP31. 
 
Appropriately sized DNA fragments were identified using the 100 bp DNA Ladder 
extended (Roth, Karlsruhe, Germany) that is denoted as Mbp. Lanes 1: grhC, 2: 
grhAB 3: grhT, 4: grhE and 5: grhQ.  
 
In each case a PCR product of the correct size was obtained. They were 
first cloned into the E. coli vector pSK+ for sequence analysis. Positive 
inserts were further cloned into the EcoRI restriction site of the E. coli-
Streptomyces shuttle vector pKJ55 using the compatible restriction 
enzymes EcoRI and MfeI. This resulted in a successive cloning strategy of 
the grh minimal PKS and the grh cyclases into pKJ55 (Figures 26 and 27). 
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pSK+
2961 bp
f1(+) ori
lacZ´
pUC ori
P lac
Amp R
Eco RV (698)
Individual PCR 
amplifications of the minimal 
PKS (grhA, grhB and grhC) 
with restriction sites
MfeI/EcoRI
TA cloning
restriction with 
MfeI/EcoRI
pKJ55
5894 bp
permE*
int
attP AprR
oriT
Eco RI (675)
Restriction with EcoRI
and ligation with grhABC
pMP31
cos
AprR
SV 40 ori
Int
attP
OriT
Complete grh cluster
pME2
5629 bp
pUC ori
grhAB
Amp R
P lac
f1(+) ori
MfeI (699)
EcoRI (3361)
EcoRI (3370)
pME5
8863 bp
permE*
grhC
grhAB
int
attP
AprR
oriT
EcoRI (3644)
EcoRV (671)
pME1
3284 bp
pUC ori
grhC
Amp R
P lac
f1(+) ori
MfeI (699)
EcoRI (1016)
EcoRI (1025)
 
 
Fig. 26: Cloning strategy of the grh minimal PKS. 
 
The grh minimal PKS genes were individually PCR-amplified from the cosmid pMP31 
containing the complete grh gene cluster and TA-cloned126 (insertiom of 3’ T 
overhangs into the pSK+ vector for subsequently cloning of the PCR-amplified 
insert) for sequencing. Finally, the inserts were subcloned into the E. coli-
Streptomyces shuttle vector pKJ55. 
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pSK+
2961 bp
f1(+) ori
lacZ´
pUC ori
P lac
Amp R
Eco RV (698)
Individual PCR amplifications 
of the putative cyclases grhE, 
grhT and grhQ with 
restriction sites MfeI/EcoRI
TA cloning
restriction with 
MfeI/EcoRI
restriction with 
MfeI/EcoRI
Restriction of pME5 with EcoRI
and ligation with grhE, grhT and 
grhQ
pMP31
cos
AprR
SV 40 ori
Int
attP
OriT
Complete grh cluster
pME8
4307 bp
f1(+) ori
pUC ori
grhT
P lac
Amp R
MfeI (699)
EcoRI (2039)
EcoRI (2048)
pME9
3420 bp
f1(+) ori
pUC ori
grhQ
P lac
Amp R
MfeI (699)
EcoRI (1152)
EcoRI (1161)
pME10
3976 bp
f1(+) ori
pUC ori
grhE
P lac
Amp R
MfeI (699)
EcoRI (1708)
EcoRI (1717)
pME5
8863 bp
permE*
grhC
grhAB
int
attP
AprR
oriT
EcoRI (3644)
EcoRV (671)
pME11
10209 bp
permE*
grhC
grhAB
int
attP
grhT
AprR
oriT
EcoRI (4985)
EcoRV (671)
pME12
9872 bp
permE*
grhC
grhAB
int
attP
grhE
AprR
oriT
EcoRI (4648)
EcoRV (671)
pME13
10650 bp
permE*
grhC
grhAB
int
attP
grhT
grhQ
AprR
oriT
EcoRI (5426)
EcoRV (671)
 
 
Fig. 27: Cloning strategy of the grh cyclases into the grh minimal PKS vector pME5. 
 
The grh cyclase genes were individually PCR-amplified from the cosmid pMP31 
containing the complete grh gene cluster and TA-cloned for sequencing. Finally, the 
inserts were subcloned into the grh minimal PKS vector pME5.  
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The determination of positive clones was carried out by restriction analysis. 
The resultant constructs are listed in Table 11. The constructs were 
subsequently conjugated into the host organism S. albus (section 5.7.3) for 
further investigation in heterologous expression.  
 
4.1.3 Expressions of early griseorhodin A genes 
 
Heterologous expression of the minimal PKS genes grhC, grhA and grhB 
and the coexpression of the cyclase genes grhT, grhE and grhQ with the 
minimal PKS in the host organism S. albus were investigated. The 
production of secondary metabolites was monitored by HPLC.  
 
4.1.3.1 grh minimal PKS expression 
 
The grh minimal PKS is highly similar to other type II minimal PKSs. 
However, a unique feature of the grh minimal PKS is its disconnectivity of 
genes within the cluster; the ACP gene grhC is located 26 kb upstream 
from the KSα and KSβ genes grhA and grhB. Two similar examples are 
found in the daunorubicin and R1128 biosynthetic gene clusters.40, 42 The 
HPLC trace from heterologous expression of the grh minimal PKS using 
solid 2CM media in the host organism S. albus is shown in Figure 28. 
4038363432302826242220181614121086420
grhABC
RT in min
 
Fig. 28: HPLC trace from the heterologous expression of the grh minimal PKS in S. 
albus using solid 2CM media at 254 nm. 
 
The expression of the grh minimal PKS did not result in the production of 
detectable amounts of polyketides as judged by HPLC (section 5.15.4.1, 
method 1). To further investigate the potential for grh minimal PKS 
expression, different media such as MS, TSB, LB and R5 in liquid and solid 
forms were tested. The use of different nutrient media did not have any 
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effect on the production of the secondary metabolites by the grh minimal 
PKS (data not shown).  
 
One reason for the extremely low production of polyketides could be the 
metabolic conditions of the host organism S. albus. Through the integration 
of foreign DNA into the S. albus genome, over-producing strains and strains 
with little or no production of polyketides can result.127 This has been 
observed in a previous study where different clones of the same mutants 
produced different levels of polyketides.1 To overcome this challenge, 
several conjugations were performed with many screenings for arising 
exconjugants to identify a clone that had increased production of secondary 
metabolites. Despite many attempts, the expression of pME5 did not 
produce detectable polyketides or shunt products. The failure of grh 
minimal PKS expression is in high contrast to other type II PKS systems 
investigated to date (section 2.2).  
 
Another reason for this unsual observation could be that the grh minimal 
PKS only functions properly or is sufficiently stabilised in the presence of 
additional pathway enzymes.  Similar results were observed in the case of 
enterocin biosynthesis.66, 81 It was shown that the enc minimal PKS does 
not yield polyketides unless the functional endogenous ketoreductase EncD 
is co-expressed. The enc minimal PKS expression alone did not lead to 
polyketide production. Co-expression with the homologous actinorhodin KS 
or with the encD gene harbouring active site mutations did not improve 
expression. This indicates that the enc minimal PKS requires EncD to serve 
a catalytic role to produce a functional enterocin PKS complex. To further 
investigate if the performance of the grh minimal PKS is context dependent, 
coexpressions with grh putative cyclase genes grhE, grhT and grhQ were 
carried out, which likely form a complex with the minimal PKS at the early 
biosynthetic stage. 
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4.1.3.2 Co-expressions of grh cyclases with the grh minimal PKS 
 
In aromatic polyketide synthesis, at least two cyclases are required for 
cyclisation of the poly-β-keto chain.31 For griseorhodin A biosynthesis, the 
putative cyclase genes grhT, grhE and grhQ were identified using BLAST 
(blastp) (Table 7).25    
 
The grhE gene was found to encode a protein highly homologous to 
bidomain CYCs. These are known to perform C7-C12 first-ring cyclisations 
as seen with ActVII.32 The second cyclase gene grhQ from the griseorhodin 
A gene cluster possesses similarity to the rubromycin cyclase gene rubE, 
tetracenomycin gene tcmI, and to the jadomycin gene jadI, indicating a 
putative cyclase for third- and fourth-ring cyclisations. The gene grhT 
encodes a protein comprised of two halves homologous to CYCs and 
oxidoreductases, respectively, and was found to be highly similar to RubG 
encoded by the rubromycin gene cluster. Furthermore, the cyclase domain 
possesses the strongest similarity to the C9-C14 first- and second-ring 
cyclase protein, TcmN from tetracenomycin biosynthesis (section 2.3.1). 
The HPLC traces from heterologous expressions of the grh minimal PKS 
with grhE, grhT and grhTQ using solid 2CM media in the host organism S. 
albus are shown in Figure 29. 
 
302826242220181614121086420
grhABCT
grhABCTQ
grhABCE
RT in min
 
Fig. 29: HPLC traces from the heterologous expressions of grh minimal PKS with 
grhE, grhT and grhTQ in S. albus using solid 2CM media at 254 nm. 
 
          4 Results and discussion       
  44 
The co-expression of the grh minimal PKS genes with grhE, grhT and 
grhTQ did not result in the production of detectable amounts of polyketides 
by HPLC (section 5.15.4.1, method 2). To further investigate the potential 
for co-expression of the cyclases with the minimal PKS, the same media 
were tested as described in section 4.4.3.1. No secondary metabolite 
production was observed in any of these nutrient media for the mutants 
(data not shown). As described in section 4.1.3.1, several conjugations 
were performed with many screenings for exconjugants to identify a clone 
that had increased production of secondary metabolites. Despite many 
attempts, coexpressions of the cyclases with the grh minimal PKS did not 
result in the detectable production of polyketides or shunt products.  
 
The encoding of both GrhE and GrhT in the griseorhodin A biosynthetic 
cluster is unsual as both enzyme types perform the first ring cyclisation of 
open polyketide precursors. The ActVII type, corresponding to GrhE, 
promotes C7-C12 cyclisation while the TcmN type, corresponding to GrhT, 
is responsible for C9-C12 cyclisation. Compounding this fact, the presence 
of both types should theoretically result in a mixture of differently cyclised 
products.25 Furthermore, no ActVII homologue is known from other clusters 
with similar sets of CYCs. This suggests that either GrhE carries out either 
chemistry different to ActVII or is inactive25. It was therefore hoped that an 
inactivation study of grhE could assist the functional elucidation of GrhE 
during the early biosynthetic steps of griseorhodin A (section 4.6.3.1). 
 
Surprisingly, the grh minimal PKS with grhT did not produce expected shunt 
product such as RM80 23.52, 56 Similar results were obtained in the 
examination of resistomycin biosynthesis.128 Resistomycin shares early 
biosynthetic steps with linear decaketide tetracenomycin and the first ring 
closure is identical in both pathways. The rem minimal PKS expression with 
RemI (possessing high sequence similarity to TcmN like GrhT) did not lead 
to production of the expected shunt product RM80 23. The results indicated 
that at least one additional cyclase is required for efficient polyketide 
formation and/or release of the polyketide intermediate. This supports the 
hypothesis that the multienzyme complex forms a pocket in which the 
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polyketide is then fully cyclised. This is in contrast to a sequential 
cyclisation of the polyketide chain by individual enzymes. Concluding this, 
an inactivation study of the gene grhT is necessary to further investigate its 
function in the early biosynthesis of griseorhodin A (section 4.5.3.2). 
 
The expression of the grh minimal PKS with grhT and additionally the 
cyclase gene grhQ did not yield detectable products. This could suggest 
that the presence of a multienzyme complex for griseorhodin A biosynthesis 
is also required as discussed above, where an additional stabilising enzyme 
might be required. One such potential candidate in the grh gene cluster 
could be GrhS, which possesses strong homology to WhiE-ORFII and 
TcmJ.45, 129 These types of enzymes seem to stabilise the minimal PKS 
protein assembly.25 The synergistic actions of cyclases and other 
stabilising/tailoring enzymes may be a general mechanism for longer 
polyketides as was shown in pradimicin biosynthesis.130 The study showed 
that an alternative modification step before the cyclisation of the C-, D- and 
E-rings of the pradimicin takes place (Figure 30). The pdm minimal PKS 
and the cyclase PdmD form 74 followed by the monooxygenase PdmH and 
the two cyclases PdmK and PdmL that oxidise the B-ring and cyclase the 
C- and D-rings in 75. Deletion of any of these enzymes abolished all ring 
formations, confirming that the enzymes cannot act independently without 
their associated partners. This was the first example of multiple cyclases 
and a monooxygenase working in concert for the regioselective tailoring of 
a polyketide backbone. In the study, it was speculated that the sequential 
binding and tailoring of the long poly-β-ketones by individual enzymes may 
not be fast enough to prevent spontaneous cyclisations of the reactive 
backbone. A multienzyme complex can effectively act on the entire length 
of the uncyclised polyketide to lock the reactive backbone and suppress 
aberrant cyclisations. Griseorhodin A is one of the longest aromatic 
polyketides with 25 carbon atoms, and therefore it could require additional 
enzymes for stabilisation of its polyketide chain. An inactivation study may 
provide more insights into cyclisation mechanism of the gene grhQ in early 
griseorhodin A biosynthesis (section 4.4.3.2).  
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Fig. 30: Early steps in pradimicin A biosynthesis.130 
 
 
A further possible reason for the previous unsual results could be that the 
early griseorhodin A genes are not transcribed. To test this, transcriptional 
analysis of grh minimal PKS was carried out. 
 
4.2 Transcriptional analysis of the grh minimal PKS 
 
Due to the unexpected results in sections 4.3.3.1 and 4.3.3.2, the 
functionality of the grh minimal PKS required testing whether the mRNA 
from the grh minimal PKS is transcribed. Therefore, grh minimal PKS RNA 
was isolated and the cDNA synthesised using reverse transcriptase-PCR 
(RT-PCR).   
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4.2.1 Isolation of RNA from MP31 and ME5  
 
RNA was isolated from MP31 fermented in MS liquid nutrient media as well 
as from ME5 fermented in liquid MS, TSB and LB nutrient media. The RNA 
isolations were confirmed by gel electrophoresis (Figure 31).  
 
1      2      3      4  Mbp
 
 
Fig. 31: Agarose gel of RNA isolation. 
 
RNA was isolated from the cosmid pMP31 and from the minimal PKS grown in the 
media MS, TSB and LB. Appropriately sized RNA fragments were identified using 
the 100 bp DNA Ladder Extended (Roth, Karlsruhe, Germany) that is denoted as 
Mbp.  Lanes 1: MP31 in MS; 2: ME5 in MS; 3: ME5 in TSB and 4: ME5 from LB. 
 
In each case RNA was successful isolated. The RNA was then further used 
for RT-PCR. 
 
4.2.2 RT-PCR 
 
RT-PCR was used to amplify grhC and a portion of grhAB from MP31 and 
ME5, and as a positive control, DNA from the cosmid pMP31 and the 
plasmid pME5 were used (Figure 32). 
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Mbp 1     2     3     4     5    6 7     8     9  10   11  12   12
grhC
330 kb
grhAB
500 kb
 
 
Fig. 32: Agarose gel of the RT-PCR. 
 
The appropriately sized DNA fragments were identified using the 100 bp DNA Ladder 
Extended (Roth, Karlsruhe, Germany) that is denoted as Mbp. Lanes 1: grhC from 
MP31 ; 2: grhC from ME5 in MS; 3: grhC from ME5 in TSB; 4: grhC from ME5 in LB; 
and the positive controls for grhC  5: cosmid pMP31 and 6: plasmid pME5; 7: portion 
of grhAB from MP31; 8: portion of grhAB from ME5 in MS; 9: portion of grhAB from 
ME5 in TSB;10: portion of grhAB from ME5 in LB and the positive controls for grhAB 
11: cosmid pMP31 and 12: plasmid pME5. 
 
For the minimal PKS, the RT-PCR resulted in successful amplification with 
grhC-specific primers. Concluding this, the gene grhC is transcribed using 
the ermE* promoter in the vector pKJ55. However, the amplification of the 
genes grhA and grhB and their positive controls failed. Therefore, RT-PCR 
conditions were varied for optimisation of grhA and grhB gene amplification 
(section 4.2.3). 
 
 
4.2.3 Optimisation of the RT-PCR 
 
The conditions used for RT-PCR were varied to optimise the resulting 
products. This was accomplished through varying the times and 
temperatures for PCR amplification at various stages. First of all, new RT 
primers for grhA and grhB were designed, targeting different areas of the 
genes and possessing different annealing temperatures. By changing the 
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annealing temperatures the specificity of primer binding can be influenced. 
Here, the annealing temperature was decreased in order to decrease the 
binding specificity of the primers on the DNA template. Furthermore, the 
temperature for cDNA synthesis was varied between 45° C and 55° C to 
improve the cDNA synthesis. However, these alterations did not have any 
influence on the amplification and no bands for grhA and grhB were 
obtained. At this point, no conclusion can be drawn whether the genes grhA 
and grhB are functional in the construct pME5, as the positive controls 
failed during the optimisation. Thus, to gain more insights into the early 
steps of griseorhodin A biosynthesis, inactivation studies of the putative grh 
cyclase genes were performed. 
 
4.3 Early griseorhodin A biosynthetic studies by in-frame 
gene deletions 
 
4.3.1 Construction of early griseorhodin A gene knock-outs 
 
In order to further investigate early griseorhodin A biosynthesis, the cyclase 
genes grhE, grhT and grhQ, as well as post-PKS genes from grhH to grhP 
and from grhH to grhQ, respectively, had to be deleted on the cosmid 
pMP31. Therefore, λ-Red recombineering was applied to generate in-frame 
gene deletions. In this technique, a gene knock-out is performed in a one-
step directed insertion via a double crossover of linear DNA fragments into 
the target DNA (Figure 33).131  
          4 Results and discussion       
  50 
Circular DNA:
Cutout of pMP31 grhQgrhP grhS
5´
3´
3´
5´
Streptomycin resistance gene5´
3´
3´
5´
Linear DNA:
Extended resistance 
cassette by PCR 
Streptomycin resistance genegrhP grhS5‘3´
3´
5´
grhP grhS5´3´
3´
5´
-
Double crossov er
Circular DNA:
Cutout of pME25.1
Circular DNA:
Cutout of pME25
α-Red-mediated
recombination
Removal of the resistance
cassettevia SpeIand religation
SpeI
SpeI
 
 
Fig. 33: Schematic overview of the λ-Red-mediated recombination technique for 
deleting the gene grhQ in the grh gene cluster.  
 
Therefore, the streptomycin resistance cassette containing homologous 
areas to the target DNA and the restriction sites for SpeI was amplified 
individually for each gene knock-out. The size of the product was confirmed 
by gel electrophoresis (Figure 34). Figure 34 shows only one cassette as 
the size of each cassette was the same for each gene knock-out. 
     
M bp 1        
 
Fig. 34: Agarose gel of the PCR amplified streptomycin resistance cassette from the 
vector pIJ778. 
 
The appropriately sized DNA fragment was identified using the 100 bp DNA Ladder 
Extended (Roth, Karlsruhe, Germany) that is denoted as Mbp. Lane 1: streptomycin 
resistance cassette.  
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In each case the correct size of the resistance cassette was obtained. For 
λ-Red recombineering, the resistance cassettes were inserted into the 
cosmid pMP31 using electroporation (section 5.7.2). The determination of 
the positive clones carrying the streptomycin resistance cassette was 
confirmed by colony PCR and restriction analysis. The cassette was then 
removed to avoid polar effects on the transcription of the downstream 
genes131 using the restriction enzyme SpeI and the determination of 
positive clones was again carried out by colony PCR and restriction 
analysis.  
 
The deletion constructs resulted in cyclase ∆grhT (pME23), ∆grhE 
(pME24), ∆grhQ, (pME25) mutants (Table 11), as well as in post-PKS 
∆grhH-P (pME26) and ∆grhH-Q mutants (Table 11), whereas in this clone 
the cyclase gene grhQ was additionally deleted to the post-PKS genes 
grhH-P. 
 
4.3.2 Expression of the cyclase gene knock-outs and the post-
PKS gene knock-outs 
 
Heterologous expression of the cyclase gene ∆grhT, ∆grhE and ∆grhQ 
mutants and the post-PKS ∆grhH-P and ∆grhH-Q mutants in the host 
organism S. albus were investigated and the production of the secondary 
metabolites was monitored by HPLC.  
 
4.3.3 Cyclase gene knock-outs expression in S. albus and the 
analysis of the secondary metabolic production 
 
4.3.3.1 Analysis of ∆grhE (predicted C7-C12 cyclase) 
 
The HPLC traces and UV profiles from heterologous expressions of the 
∆grhE mutant and the cosmid pMP31 using solid 2CM media in the host 
organism S. albus are shown in Figure 35.  
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Fig. 35: HPLC traces and UV profiles from the heterologous expression of the 
complete grh gene cluster and ∆grhE in S. albus using solid 2CM media at 254 nm. 
 
Deletion of grhE in the griseorhodin A gene cluster did not affect 
griseorhodin biosynthesis; the polyketide was still produced by the ∆grhE 
mutant. Concluding this, GrhE does not play any significant role in 
griseorhodin A biosynthesis and confirms the prediction that the enzyme is 
not needed for griseorhodin A biosynthesis (section 4.3.3.2). Furthermore, 
this result confirmed the functionality of the gene knock-out technique 
applied in the present study. 
 
4.3.3.2  Analysis of ∆grhT (C9-C14 cyclase) and ∆grhQ   
 
The similarity of grhQ to the genes rubE, tcmI and jadI indicates that grhQ 
is a putative cyclase for bent third- (such as angucyclines, Fig. 10)31 and 
fourth-ring (such as tetracenomycins, Fig. 9)31 cyclisations and could 
therefore generate a structurally related cyclised moiety. To investigate the 
functions and the order of the cyclisation steps, individual inactivations of 
4 Results and discussion                                                        
53    
the two other putative cyclase genes grhT and grhQ in grh gene cluster 
were performed and the heterologous expressions were investigated by 
HPLC. 
 
The HPLC traces from heterologous expressions of the ∆grhT and ∆grhQ 
mutants using solid 2CM media in the host organism S. albus are shown in 
Figure 36. 
 
4038363432302826242220181614121086420
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Fig. 36: HPLC traces from the heterologous expressions of ∆grhT and ∆grhQ in S. 
albus using solid 2CM media at 254 nm. 
 
Remarkably, the expression of the ∆grhT and ∆grhQ mutants did not result 
in the production of detectable amounts of polyketides by HPLC. To further 
investigate the potential of the mutant expressions, different media such as 
MS, TSB, LB and R5 in liquid and solid forms were tested. The use of 
different nutrient media did not have any effect on the production of 
secondary metabolites (data not shown). As in the earlier experiments, 
several conjugations for the clones were carried out and many screenings 
for exconjugants were performed to identify appropriate clones that could 
result in improved production of secondary metabolites. Despite many 
attempts, the expression of the ∆grhT and ∆grhQ mutants did not result in 
detectable production of polyketides or shunt products. 
 
Deletion of grhT in the griseorhodin A gene cluster abolished griseorhodin 
A biosynthesis; the polyketide or some shunt products were not detected 
and is therefre in agreement with the result from the earlier characterisation 
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approach (section 4.3.3.2). Similar results were generated by a study by 
Ostash and co-workers in the investigation of landomycin cyclases and 
their effect on landomycin biosynthesis.132 The inactivation of the putative 
landomycin cyclase LndL led to the abolishment of biosynthesis, where 
neither intermediates nor novel metabolites were detected. The lnd minimal 
PKS lndABC which is essential for the polyketide biosynthesis, could be not 
affected by the inactivation of LndL as it located downstream. This applies 
for the grh minimal PKS as well as it is located upstream of the cyclase 
gene grhT. Compounding these results, this nonproducing phenotype could 
not arise from an interrupted polyketide pathway. Furthermore, it was 
previously speculated that each enzyme would have a single function, but 
many genetic experiments have shown that many components have more 
than one role and that these depend on other components present in 
PKSs.8, 32 Current results support the speculation that components having 
several roles could exist and explain the absence of detectable amounts of 
polyketides or shunt products for the ∆lndD and ∆grhT mutants.  
 
The inactivation of the other putative cyclase, GrhQ, led to the abolishment 
of griseorhodin A production. This is also in agreement with the result from 
the earlier characterisation approach (section 4.3.3.2). This result could be 
due to the presence of an operon within the griseorhodin A gene cluster 
where grhQ is located. In the study by Sandmann et al., aurachin (aur) 
biosynthesis was investigated and inactivation of gene(s) in a putative aur 
operon resulted in abolishment of the biosynthesis.133 Another example for 
a presence of an operon within polyketide core genes is in the lysolipin (llp) 
biosynthesis gene cluster.134 It contains three putative cyclases whose start 
and stop codons overlap with the llp minimal PKS and indicates a core llp 
operon. However, there are no investigations thus far concerning this 
operon and its genes. In the grh gene cluster, GrhQ, GrhS, GrhA and GrhB 
seem to be translationally coupled due to the overlapping of their start and 
stop codons by 4 nt.25 This could indicate that the grh core cluster forms an 
operon that directs tight co-expression of the enzymes. Under this 
hypothesis, the genes are either expressed together or not at all when one 
gene is missing, e.g. through inactivation of GrhQ. To further investigate 
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early griseorhodin A biosynthesis, two new mutants, ∆grhH-P and ∆grhH-
Q, were generated, where in the first mutant all tailoring genes from grhH to 
grhP were deleted and in the second mutant the mutation was extended 
through grhQ.      
 
4.3.4 Expressions of tailoring gene knock-outs in S. albus and 
the analysis of the secondary metabolite production 
 
4.3.4.1 Analysis of ∆grhH-P 
 
The ∆grhH-P mutant produced a complex compound mixture of secondary 
metabolites in solid 2CM media. The HPLC traces and UV profiles from the 
∆grhH-P mutant were compared with the ∆grhM mutant using solid 2CM 
media in the host organism S. albus as shown in Figure 37. 
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Fig. 37: HPLC traces and UV profiles from heterologous expressions of ∆grhM and 
∆grhH-P in S. albus using solid 2CM media at 254 nm. 
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In the present study, the grhM and all post-PKS genes from grhH to grhP 
were deleted in the ∆grH-P mutant, while the ∆grhM mutant contained all 
grh genes except grhM. The ∆grhM mutant was constructed in a previous 
study by Dr. Kathrin Reinhard using the λ-Red recombineering technique.1, 
131
 Comparison with the retention times and the UV profiles of both mutants 
provided evidence that identical compounds were detected in both mutants.  
 
4.3.4.2 Analysis of secondary metabolite production from the 
∆grhM and ∆grhH-P mutants  
 
Secondary metabolite production of the ∆grhM mutant was investigated by 
Zeynep Yunt.123 For 76 in Figure 38, HRESIMS indicated a mass of 
C26H20O8, however a complete structure elucidation by NMR was not 
possible due to the instability of the intermediate and therefore, 76 
represents a speculative structure. Another compound that was isolated 
and fully characterised using HRESIMS and NMR by Zeynep Yunt, was 
structurally identical to KS-691-1 77 (Figure 38). This compound has been 
isolated earlier from the culture broth of S. californicus and is an inhibitor of 
Ca2+ and calmodulin-dependent cyclic nucleotide phosphodiesterase.135 
Comparison of the proposed structures of both compounds, suggests that 
KS-691-1 77 could be derived from 76 by spontaneous oxidation. Due to 
the data obtained by Zeynep Yunt, GrhM was tentatively placed into an 
early biosynthetic enzyme group according to the number of carbon and 
oxygen atom of the intermediate. The rationale was that the level of 
oxygenation should increase while the number of the carbon atoms should 
decrease to 25 en route to 36. Identification of compounds that contain a 
much smaller number of oxygen atoms (7-10) than 36 (12 oxygen atoms), 
consistent with an upstream biosynthetic position, assists in allocation of 
corresponding enzymes during polyketide assembly. Furthermore, GrhM 
homologues are found in other pentangular biosynthetic pathways. E. g., 
FdmM, a GrhM homologue from the fredericamycin A biosynthesis, was 
investigated by in-frame gene deletion and the study suggested that the 
enzyme is responsible for the hydroxylation of C6 in the pentangular core 
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during the fredericamycin A biosynthesis.136 Concluding this, the proposed 
compound structures 76 and 77 represent very likely very early 
intermediates in the griseorhodin A biosynthesis and indicates an early 
oxygenase role for GrhM during griseorhodin A biosynthesis.  
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Fig. 38: Speculative structure 76 and KS691-1 77 isolated from the ∆grhM mutant.123, 
137
 
 
For the secondary metabolite analysis of ∆grhH-P, 10 L of liquid TSB media 
was fermented and the cells and the media extracted with 100% EtOAc 
with an acidifying step (sections 6.15.1.2 and 6.15.1.2.1) In the first 
purification step, a semi-praparative HPLC was used (section 5.15.4.3) and 
two fractions were obtained, ME13 and HP, which required further 
purifications. Fraction HP was purified using LH20 (section 5.15.3.2) 
resulting in an HPLC profile shown in Figure 39. The final purification step 
was carried out using HPLC (section 5.15.4.2) resulting in compound HP1 
(Table 7).  
4038363432302826242220181614121086420
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Fig. 39: HPLC traces of the fraction HP after LH20 separation at 254 nm. 
 
The fraction ME13 was directly separated by semi-preparative HPLC using 
a gradient system (section 5.15.4.3) at the Kekulé-Institute HPLC pool, 
resulting in seven new fractions ME13_1 to ME13_7 (Figure 40). 
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Fig. 40: HPLC trace of the fraction ME13 from semi-preparative HPLC at 254 nm. 
 
These fractions were analysed by HPLC (section 5.15.4.2). The fraction 
ME13_2 was chosen for further purification as the compounds in the other 
fractions possessed too similar retention times for a further separation. 
Work on fraction ME13_2 led to a separation of three pure compounds 
ME13_2_1, ME13_2_2 and ME13_2_3 (Figure 41, Table 2).  
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Fig. 41: Cutout of the HPLC trace of fraction ME13_2 at 254 nm. 
 
The arrows indicate the separated compounds as indicated in Table 2. 
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In the present study, HPLC and LH20 were used to separate fractions from 
the crude cellular extract of the ∆grhH-P mutant. It resulted in four pure 
compounds followed by a HRESIMS analysis (Table 2). 
 
Table 2: Compounds isolated from the mutant ∆ghrH-P using LH20 and HPLC with 
retention times, yields, masses determined by HRESIMS in the positive (+) or 
negative (-) mode and proposed molecular formulas.  
Compound Retention time (tR) [min] 
 
Yield[µg] 
 
Mass 
m/z (M+H)+ 
m/z (M-H)- 
Proposed  
molecular 
formula 
Griseorhodin A 19.0 - 509.0720 C25H16O12 
HP1 24.9 200 520.0714(+) C19H20O17 
ME13_2_1 25.0 400 460.1109(-) C26H20O8 
ME13_2_2 25.8 300 n.d.a n.d.a 
ME13_2_3 27.4 400 459.1034(-) C26H20O8 
UV and HRESIMS spectra are presented in Appendix 8.3 and 8.4. a No determination 
for the mass.  
 
The molecular formula of C19H20O17 for HP1 proposes an early intermediate 
in the griseorhodin A biosynthesis due to lower amount of carbon atoms 
than in griseorhodin A. Therefore, HP1 was characterised by cryo NMR and 
promising 1H- and COSY spectra were recorded. However, to obtain 2D 
NMR data using HSQC and HMBC spectroscopy techniques for a complete 
structure elucidation, the yield of 200 µg was insufficient and the molecule 
could not be further investigated during the present study. The masses of 
the compounds ME13_2_1 and ME13_2_3 possess the same proposed 
molecular formula than the proposed molecular formula (C26H20O8) of the 
speculative intermediate 76 isolated in a previous study (Figure 38).1 They 
predict the same or similar structure for ME13_2_1 and ME13_2_3.  
However, for both, ME13_2_1 and ME13_2_3, a preliminary 1H NMR 
showed no representative –CH2 groups around 2 ppm and no protons 
bound on the double bonds were observed between 6 and 7 ppm. One 
reason for this could be the relatively small amount of the isolated 
compounds. 
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Taken together, the previous HRESIMS and NMR data for the ∆grhM 
mutant, the present HRESIMS data for the ∆grhH-P mutant and the 
comparison of presence of the genes in both mutants propose an early 
oxygenase role of GrhM in the griseorhodin A biosynthetic pathway.  
 
In order to get more insights into the early biosynthetic steps of 
griseorhodin A, many attempts to individually delete more genes (grhT, 
grhU and grhV) in the ∆grhH-P mutant were carried out, but all of them 
failed. The conditions during λ-Red recombineering were varied as much as 
possible; however, there was no success. As the putative grh cyclase gene 
grhQ is adjacent to grhP (section 2.5, Figure 23), it could be additionally 
deleted by extending the gene mutant ∆grhH-P to grhQ. 
 
4.3.4.3 Analysis of ∆grhH-Q 
 
The HPLC trace from heterologous expression of the ∆grhH-Q mutant in 
the host organism S. albus in 2CM media is shown in Figure 42. 
 
∆grhH-Q
4038363432302826242220181614121086420
RT in min
 
Fig. 42: HPLC trace from heterologous expression of ∆grhH-Q in S. albus using 
solid 2CM media at 254 nm. 
 
The peak between 22 and 24 minutes in the trace originates from the extraction with 
95:5:1 EtOAC:MeOH:AcOH and is not relevant to secondary metabolite analysis. 
 
The expression of the ∆grhH-Q mutant did not result in the production of 
detectable amounts of polyketides by HPLC (section 6.15.4.1). To further 
investigate the potential of the mutant expression, the same media were 
tested as described in section 4.5.1. No effect was observed on the 
production of secondary metabolites in any of these nutrient media for 
∆grhH-Q (data not shown). As in earlier experiments, several conjugations 
for the clones were carried out and many screenings for exconjugants were 
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performed to identify appropriate clones that could result in improved 
production of secondary metabolites. Despite many attempts, the 
expression of ∆grhH-Q did not produce detectable polyketides or shunt 
products. 
 
The extension of inactivation to the putative cyclase gene grhQ in ∆grhH-P 
led to the abolishment of griseorhodin A production and no detectable 
amounts of polyketide or shunt products were detected. This result is in 
agreement with the experiment in section 4.3.3.2, where the cyclase gene 
grhQ was independently inactivated, leading to an abolishment of 
griseorhodin A biosynthesis. Furthermore, the co-expression with the grh 
minimal PKS in section 4.4.3.1 did not result in detectable amounts of 
polyketide shunt products. In contrast to these results, the heterologous 
expression of ∆grhH-P produced a complex mixture of secondary 
metabolites. This mutant harbours all potential early grh genes, including 
the grh minimal PKS, grhQ and as well as the potential stabilising gene 
grhS. Therefore it is highly likely that a functional protein complex is 
relevant at the early stage of griseorhodin A biosynthesis. Furthermore, the 
results indicate that GrhQ is necessary but still insufficient for a functional 
PKS, since GrhABCQ does not produce secondary metabolites. To date, 
griseorhodin A is one of the longest aromatic polyketides and, therefore, it 
could likely require synergistic actions of cyclases and other stabilising 
enzymes such as GrhQ and GrhS for its polyketide. The additional proteins 
could form a pocket with the grh minimal PKS in which the multienzyme 
complex can act and stabilise the entire polyketide assembly 
simultaneously.  
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4.4 Griseorhodin A biosynthetic studies by in-frame gene 
deletions 
 
4.4.1 Sequence analysis of the griseorhodin A proteins GrhU 
and GrhV 
 
Table 3 lists the comparative results for GrhU and GrhV with known 
sequences in the NCBI database using “Basic Local Aligment Search Tool” 
(BLAST) analysis (search with blastp). 
 
Table 3: Proposed functions of the grh ORFs shown in Figure 23.  
Protein AA 
Proposed 
function 
Protein/organism/compound 
produced 
Similarity/ 
Identity [%] 
 
GrhU 
 
107 Unknown 
RubH/S.collinus 
(unpublished)/rubromycin 
LlpOIII/S. tendae/lysolipin,134 
PdmH/Actinomadura 
hibisca/pradimicin138 
83/72 
80/67 
 
GrhV 
 
102 Unknown 
RubT/S. collinus (unpublished) 
FdmQ/S. griseus/fredericamycin139 
LlpOII/S. tendae134 
BenJ/Streptomyces sp. 
A2991200/benastatin A43 
ORF9/Actinomadura 
hibisca/pradimicin138 
78/70 
66/45 
66/47 
65/47 
54/38 
 
At the beginning of the present study, none of the homologues encode 
characterised proteins and therefore they represented interesting targets for 
functional elucidations.  
 
For the uncharacterised genes, grhU and grhV, in the griseorhodin A gene 
cluster, the ∆grhV (KR58) and ∆grhU (KR61) mutants were constructed by 
Dr. Kathrin Reinhardt using the λ-Red recombineering technique.1 In this 
technique, a gene knock-out is performed in a one-step directed insertion 
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via a double crossover of linear DNA fragments into the target DNA (Figure 
43).131 
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Fig. 43: Schematic overview of the λ-Red-mediated recombination technique for 
deleting the gene grhU in the grh gene cluster. 
 
In the present study, secondary metabolites resulting from the heterologous 
expressions of ∆grhU and ∆grhV mutants in S. albus were to be isolated 
and analysed to elucidate the functions of these genes in griseorhodin A 
biosynthesis. 
 
4.4.2 Secondary metabolite analysis of the ∆grhV mutant by 
LH20 chromatography, HPLC and HRMS 
 
A portion of freeze-dried ∆grhV mutant cells were extracted as decribed in 
section 5.15.1.2.2. The extraction resulted in 250 mg of the crude cell 
extract and it was analysed by HPLC (section 5.15.4.2, Figure 44).  
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Fig. 44: Cutout of the HPLC chromatogram of the ∆grhV crude extract cell at 254 nm.  
 
The box on the right side magnifies the area from 23 minutes to 26 minutes that 
contain potential interesting compounds from griseorhodin A biosynthesis. 
 
The analytical HPLC analysis of the cellular crude extract indicated a 
complex compound mixture where compounds with higher amounts have 
retention times below 10 minutes. Potential interesting compounds from 
griseorhodin A biosynthesis come between 23 minutes and 26 minutes. 
This area is magnified in the box on the right side of the HPLC 
chromatogram in Figure 44. The crude cell extract was then subjected to a 
LH20 chromatography column (section 5.15.3.2), resulting in fractions 1 to 
121, where every fifth fraction was analysed by HPLC (section 5.15.4.2). 
HPLC analysis indicated these fractions contained both pure compounds as 
well fractions requiring more purification steps. However, only fractions 103 
to 120 contained potential interesting compounds for the griseorhodin A 
biosynthesis and only these were further investigated. The fractions 103 
and 104 contained the same pure compound by comparing the retention 
times (24.9 min) and the UV profiles (Appendix 8.3). These fractions were 
combined (labelled as 103 in Table 4), dried and stored at 4°C. The 
fractions from 106 to 109 were combined and further purified by HPLC 
(section 5.15.4.2). These fractions contained one main compound at the 
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retention time of 24.0 min which was isolated (labelled as 106 in Figure 45 
and Table 4). 
 
  
106
RT in min
 
 
Fig. 45: Cutout of the HPLC chromatogram from combined fractions 106-109 at 254 
nm.  
 
The arrow with the number indicates the isolated compound 106 (Table 4) 
 
Fractions 105 and 110 to 120 were combined for further purification by 
HPLC (section 5.15.4.2). These samples contained five main fractions with 
retention times of 23.8 min, 24.2 min, 24.7 min, 25.4 min and 26.0 min, all 
of which which were isolated (110_1 to 110_5, Table 4). However, these 
fractions were not checked for purity due to very small amounts of 
compound (less than 50 µg). The rest of the fractions from the column and 
HPLC were not further analysed due to the complexity of the mixtures and 
the time scope of the project.  
 
In the present study, the LH20 chromatography in conjuction with HPLC 
resulted in two pure compounds from the ∆grhV mutant. 106 and other 
compounds were not further investigated by HRESIMS due to the time 
scope of the project (Table 4). 
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Table 4: Compounds isolated from the ∆grhV mutant via LH20 chromatography and 
HPLC with retention times, yields, masses and proposed molecular formulas. 
Compound Retention time (tR) [min] 
 
Yield[µg] 
 
Mass 
m/z (M+H)+ 
Proposed  
molecular 
formula 
Griseorhodin A 19.0 - 509.0720 C25H16O12 
103 24.8 700 µg 475.0982 C26H18O9 
106 24.0 50 µg n. d.a n.d.a 
110_1  n. d.a Less than 50 µg b n. d.
a
 n. d.a 
110_2 n. d.a Less than 50 µg* n. d.
a
 n. d.a 
110_3 n. d.a Less than 50 µg* n. d.
a
 n. d.a 
110_4 n. d.a Less than 50 µg* n. d.
a
 n. d.a 
UV and HRESIMS spectra are represented in Appendix 8.3.1. a These compounds 
were not further investigated by HRESIMS due to the time scope of the project. 
 
No structure was elucidated for 103 due to the time scope of the project 
and therefore, no conclusion can be drawn. However, the proposed 
molecular formula of C26H18O9 could indicate a carboxylated quinone 
compound of 83, 84 or 85 (Figure 58) due to the higher amount of carbon 
and the lower amount of oxygen atoms. 
 
4.4.3 Secondary metabolite analysis of the ∆grhU mutant by 
LH20 chromatography, HPLC and HRMS  
 
A portion of freeze-dried ∆grhU mutant cells were extracted as decribed in 
section 5.15.1.2.2. The extraction resulted in 350 mg of the crude extract 
that was analysed by HPLC (Figure 46).  
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Fig. 46: Cutout of the HPLC chromatogram of the cell crude extract isolated from 
∆grhU at 254 nm.  
 
The numbered arrows indicate pure peaks in the cellular crude extract.  
 
The analytical HPLC analysis indicated a complex compound mixture. The 
potentially interesting compounds for the griseorhodin A project come 
between 15 minutes and 25 minutes.  
 
350 mg of the cellular crude extract were separated on a LH20 
chromatography column (section 5.15.3.2). This column resulted in 63 
collected fractions, of which every fifth fraction was analysed by HPLC 
(section 5.15.4.2). The HPLC analysis indicated fractions containing pure 
compounds as well fractions that required more purification steps. 
 
Fraction 41, labelled with an arrow and the number 41 in the crude extract 
HPLC chromatogram (Figure 46), was isolated and contained a pure solid 
orange compound ( labelled as 41 in Figure 46 and Table 5) with a 
retention time of 16.0 min. Fractions 61 and 62 contained the same 
compound, labelled with a red arrow and the number 61 in the crude extract 
HPLC chromatogram, (labelled as 61 in Figure 46 and Table 5) by 
comparing the retention times (24.9 min) and the UV profiles.  
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For the second LH20 chromatography, fractions 51 to 60 from the first 
column were combined and it resulted in fractions 64 to 94 from the second 
column. The fractions were then analysed by HPLC (section 5.15.4.2). The 
analysis indicated fractions again containing pure compounds as well as 
fractions that required more purification steps. The comparison of fractions 
90-93 showed one main peak at 19.4 min. The fractions were combined 
and the main peak was isolated, labelled with a red arrow and the number 
90 (labelled as 90 in Figure 47 A and Table 5). Fractions 82 to 86 and 
fraction 89 were combined and further purified by HPLC (section 5.15.4.2). 
These fractions contained two main compounds at the retention time of 
19.7 min, labelled with a red arrow and the number 19.7 (labelled as 19.7 in 
Figure 47 B and Table 5) and at 24.8 min, labelled with a red arrow and 
labelled as 61_U (labelled as 61_U in Figure 47 B and Table 5) that were 
both isolated. Unfortunately, the first fraction at 19.7 min was lost due to 
instability. The second fraction, labelled as 61_U, was compared to 
compound 61 from the first column due to its same retention time at 24.9 
min. Further comparison of the UV profile confirmed that 61_U is the same 
compound as 61 and therefore the fractions were combined.  
A B
90
19,7
61_U
RT in min RT in min
 
 
Fig. 47: Cutouts of the HPLC chromatograms for fractions 90-93 (A) and 82-86 and 
89 (B) at 254 nm.  
 
The peaks with the arrows and numbers 90, 19.7 and 61_U indicate the isolated 
compounds (Table 5).  
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Fractions 40 and 42-50 from the first LH20 column and fractions 39-44 from 
the second LH20 column contained several peaks and were combined for a 
separation on a third LH20 column. 37 fractions were collected and 
analysed by HPLC (section 5.15.4.2). Fractions 18-25 contained several 
peaks and three compounds were isolated, resulting in compounds 18_1, 
18_2 and 18_3 (data not shown; Table 5). Fractions 31-37 contained two 
peaks at the retention times of 17.4 min and 20.8 min that were isolated by 
HPLC (section 5.15.4.2). This resulted in two solid pure compounds, U31_1 
and U31_2; U31_2, however was lost due to instability (Table 5). The rest 
of the fractions from the columns and HPLC were not further analysed due 
to the complexity of the mixtures and the time scope of the project.  
 
In the present study, the LH20 chromatography in conjuction with HPLC, 
resulted in seven pure compounds from the ∆grhU mutant. 41, 61 
(combined with 61_U) and 90 were further investigated by HRESIMS. The 
other compounds (U31_1, 18_1, 18_2, 18_3) were not further investigated 
by HRESIMS due to the time scope of the project and two compounds were 
lost due to instability (Table 5). 
 
Table 5: Compound isolated from the ∆ghrU mutant via LH20 chromatography with 
retention times, yields, masses and proposed molecular formulas.  
Compound Retention time (tR) [min] 
 
Yield[µg] 
 
Mass 
m/z (M+H)+ 
Proposed  
molecular 
formula 
MP31/grh A 19.0 - 509.0720 C25H16O12 
41 16.0 700 µg No mass founda - 
61 combined 
with 61_U 24.9 600 µg 
No mass 
founda - 
90 19.8 300 µg No mass founda - 
U31_1 17.4 100 µg n.d.a n.d.a 
18_1 15.8  50 µg n.d.a n.d.a 
18_2 19.3  50 µg n.d. a n.d.a 
18_3 20.9  50 µg n.d.a n.d.a 
19.7/U31_2 - 
Were lost 
due to 
instability 
n.d.a n.d.a 
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UV spectra are represented in Appendix 8.3. a These compounds were not further 
investigated by HRESIMS due to the time scope of the project. 
 
The preliminary HRESIMS analyses did not indicate potential masses for 
the ∆grhU mutant and due to the time scope of the project, no further 
investigations of the isolated compounds were carried out. 
 
4.4.4 Secondary metabolite analysis of the ∆grhV mutant by 
HPLC and HRMS 
 
For secondary metabolite analysis of the ∆grhV mutant, the MS, TSB and 
LB media were tested and the best production resulted in the liquid TSB 
media. For further investigation, 10 L of TSB media were fermented and the 
cells and the media extracted with 100% EtOAc (sections 6.15.1.2 and 
6.15.1.2.1). The extraction resulted in complex compound mixtures (Figure 
48). 
4038363432302826242220181614121086420
∆grhV media 
extract
∆grhV cell
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Fig. 48: Representative HPLC chromatograms of the ∆grhV cellular and TSB media 
crude extracts at 254 nm.  
 
Retention time (RT) in minutes is denoted in minutes (min). 
 
In the first purification step, the crude extracts were tested and run using 
silica gel flash chromatography (section 5.15.3.1) followed by preparative 
HPLC (section 5.15.4). The preparative HPLC separation resulted in four 
fractions from the cell extracts collected from 7.5 to 9 min (KR58Z1), from 
10 min to 12 min (KR58Z2), from 14 min to 16 min (KR58Z3) and from 17 
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min to 20 min (A in Fig. 49) and four fraction from the media extracts 
collected from 7.5 to 9 min (KR58M1), from 10 min to 12 min (KR58M2), 
from 14 min to 16 min (KR58M3) and from 17 min to 20 min (KR58M4) (B 
in Figure 49).  
302826242220181614121086420
RT in min
KR58Z1
KR58Z2
KR58Z3
KR58Z4
302826242220181614121086420
RT in min
KR58M1
KR58M2
KR58M3
KR58M4
A
B
 
Fig. 49: Preparative HPLC traces of ∆grhV at 254 nm. 
 
(A) cell crude extract from ∆grhV and (B) media crude extract from ∆grhV 
 
The resulting preparative HPLC fractions KR58M1, KR58M1, KR58M3, 
KR58M4, KR58Z1, KR58Z2, KR58Z3 and KR58Z4 were monitored by 
HPLC (section 5.1.4.1) and it indicated two to four compounds being 
present in the fractions KR58M1, KR58M2, KR58Z2 and KR58Z4 as 
collected by preparative HPLC (Figure 50 and Figure 51). These fractions 
were then further separated by semi-preparative HPLC (section 5.15.4.3) at 
the Kekulé-Institute HPLC pool. Semi-preparative HPLC led to an improved 
separation of the compounds in the fractions and the following fractions 
were obtained from the media fractions KR58M1 and KR58M2: KR58M1_1, 
KR58M1_2, KR58M1_3 KR58M1_4, KR58M2_1, KR58M2_2, KR58M2_3, 
and KR58M2_4 (data not shown). The following fractions were obtained 
from the cellular fractions KR58Z2 and KR58Z4: KR58Z2_1, KR58Z2_2, 
KR58Z2_3 KR58Z2_4, KR58Z4_1, KR58Z4_2 and KR58Z4_3 (data not 
shown). The fractions from KR58M3, KR58M4, KR58Z1 and KR58Z3 were 
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separated by semi-preparative HPLC too, leading to new fractions (data not 
shown). However, these were not further investigated due to the time scope 
of the project. 
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Fig. 50: Representative HPLC chromatograms of the fractions KR58M1, KR58M2, 
KR58Z2 and KR58Z4 containing several compounds in each fraction at 254 nm. 
 
The numbers at the peaks indicate the new fractions within each fraction leading to 
the fractions KR58M1_1, KR58M1_2, KR58M1_3 KR58M1_4, KR58M2_1, KR58M2_2, 
KR58M2_3, KR58M2_4, KR58Z2_1, KR58Z2_2, KR58Z2_3 KR58Z2_4, KR58Z4_1, 
KR58Z4_2 and KR58Z4_3. 
 
 
 
The new fractions KR58M1_1, KR58M1_2, KR58M1_3 KR58M1_4, 
KR58M2_1, KR58M2_2, KR58M2_3, and KR58M2_4, KR58Z2_3 
KR58Z2_4, KR58Z4_1, KR58Z4_2 and KR58Z4_3 were monitored by 
HPLC (section 5.15.4.2), indicating impure compounds (data not shown). 
They required further separations using HPLC (section 5.15.4.2). Figure 50 
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illustrates the separation scheme of the media and cell fractions from 
∆grhV. 
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Fig. 50: Separation scheme of the media and cell fractions from ∆grhV. 
 
(A) KR58M1 and KR58M2 and (B) KR58Z2 and KR58Z4. 
 
Figure 52 shows representative the final separations of fractions of 
KR58Z4_3 and KR58M2_4, each resulting in two pure compounds 
KR58Z4_3_1 and KR58Z4_3_2 (Figure 52 A, Table 6) and KR58M2_4_1 
and KR58M2_4_2 (Figure 52 B, Table 6), respectively  
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Fig. 52: Cutouts of the representative HPLC chromatograms from separations of 
fractions Z4_3 (A) and KR58M2_4 (B) at 254 nm.  
 
The chromatograms represents the separation of fractions KR58Z4_3 and 
KR58M2_4 resulting in the pure compounds Z4_3_1, Z4_3_2, KR58M2_4_1 and 
KR58M2_4_2 (Table 6).  
 
Finally, the sequential fractional separations led to 15 pure compounds 
from the ∆ghrV mutant via HPLC and these were further investigated by 
HRESIMS (Table 6). 
 
Table 6: Compounds isolated from the ∆grhV mutant via HPLC with retention times, 
yields, masses and proposed molecular formulas.  
Compound Retention time (tR) [min] 
 
Yield[µg] 
 
Mass 
m/z (M+H)+ 
Proposed  
molecular 
formula 
Griseorhodin A 19.0 - 509.0720 C25H16O12 
KR58M2_3_1 24.0  1200 µg No mass found - 
KR58M2_4_2  25.0 500 µg 438.1128/ 853.2232 
C25H19O6/ 
C50H38O12 
KR58Z2_2 24.0 400 µg 453.0994 C27H16O7 
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KR58M1_4_2  25.0  300 µg 415.1216 C25H19O6 
KR58M1_1  23.7 300 µg 448.1120 C21H20O11 
KR58Z2_3_3  24.3 300 µg 415.1244 C18H22O11 
KR58Z4_3_1  25.0 200 µg 415.1248 C18H22O11 
KR58Z2_3_2  24.3 200 µg No mass found - 
KR58M2_4_1  24.0 200 µg 460.1110 C26H20O8 
KR58M2_2_1  23.4 200 µg 501.1130 C28H20O9 
KR58Z4_1  24.0 100 µg 453.0991 C27H16O7 
KR58M1_4_3  27.6 100 µg No mass found - 
KR58Z4_3_2  27.6 100 µg No mass found - 
KR58Z2_3_1  24.0 100 µg 453.0991 C27H16O7 
KR58Z2_3_4  25.0 50 µg No mass found  - 
UV and HRESIMS spectra are represented in Appendix 8.3 and 8.4. Griseorhodin A is 
used for the comparison with the other compounds.   
 
The compound KR58M2_4_2, which originated from the major peak in the 
mixture (Figure 52), was analysed by the positive-ion ESI mass 
spectrometry, showing two main peaks at m/z = 438 and 853. Their 
presence indicated a sodiated radical cation140 (M+·) and its sodiated 
dimeric form [2M+Na]+. To determine the molecular formulas of these two 
ions, HRESIMS was performed and the following molecular formulas were 
proposed: C25H19O6Na (m/z 438.1061 calcd. 438.1074) and C50H38O12Na 
(m/z 853.2232, calcd. 853.2255) respectively (Figure 53 A). A further 
analysis by a MS/MS measurement was carried out using 853 as the parent 
mass that confirmed this hypothesis. The MS/MS spectrum showed the 
pseudomolecular ion peak [M+Na]+ at m/z = 439.1146 corresponding to the 
monomer form (Figure 53 B). The compound was further characterised by 
cryo NMR (section 4.1.2.1.1). 
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Fig. 53: Mass spectra of KR58M2-4-2. 
 
(A) HRESIMS and (B) MS/MS spectra of KR58M2_4_2 in the ranges of m/z 0-1500 
and 0-900 respectively. 
 
For the compound KR58M2_4_1, m/z = 460.1110 was identified that 
corresponds to C26H20O8 and therefore could be the carboxylated product 
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of KR58M2_4_2. The mass of the compound KR58M1_4_2 (m/z = 
415.1216) indicates the proposed molecular formula of C25H19O6 
corresponding to C50H38O12, possessing the same molecular formula and 
the retention time as KR58M2_4_2. However, the different UV profiles 
indicate configurational changes (Appendix 8.3). The rest of the identified 
masses and the corresponding molecular formulas have a higher number of 
carbon atoms and a lower number of oxygen atoms than griseorhodin A. 
Therefore, they could represent early intermediates of griseorhodin A 
biosynthesis. However, for final conclusions of the intermediates, 
characterisations by NMR are required. Due to time scope of the project, 
repetitions of HRESIMS analyses were not further carried out, for the 
compounds where a mass was not found.  
 
4.5 Structure elucidation by NMR 
 
Structure elucidation was carried out by NMR in the research group of 
Murray Munro and John Blunt at the University of Canterbury (Department 
of Chemistry) in Christchurch, New Zealand. Due to the small amount of the 
samples, capillary probe NMR (capNMR) was chosen as a method for the 
structure elucidation. 
 
4.5.1 An introduction into capillary probe NMR  
 
A capillary probe has a flow cell that typically possesses a flow rate in the 
NMR probe of 1-50 µL/min and a sample volume in the range of 1-10 µL.141 
Therefore, the capillary probe is sometimes known as a capillary microflow 
probe, although a capillary probe can also have a much larger volume 
capacity. CapNMR probes were designed to obtain NMR spectra on mass-
limited samples. The probes allow the acquisition of quality spectra from 
low sample amounts such as 20 µg.142 CapNMR can also be used for larger 
amount to achieve the same signal-to noise (s/n) ratio in a shorter period of 
time.143 The first small volume NMR flow probes were constructed in the 
laboratories of Sweedler and Albert in the 1990s.144-146 These were 
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designed for coupling to capillary electrophoresis (CE) and capillary HPLC 
(capLC) to handle the small volumes associated with these techniques.  
 
4.5.2 Analysis of the mutants utilising capNMR 
 
Several pure compounds obtained during isolations from the ∆grhV and 
∆grhU mutants (Tables 2, 4 and 5) were subjected to capNMR (section 
5.15.6.1) for structure elucidation. Many 1D and 2D spectra were recorded 
testing different deuterated solvents such as CD3Cl, CD3OD and DMSO-d6. 
However, it was not possible acquire any sensible spectra; broad signals 
and low sensitivity were acquired (data not shown). Furthermore, the fact 
that samples were more or less irreversibly absorbed onto the silica of the 
interior of the probe made the analysis even more challenging. 
 
Broadened signals come from two common sources: slow exchange 
(rotamers) near the Larmor frequency of the NMR signals and the presence 
of paramagnetic species including transition metal ions and organic 
radicals.147 Slow exchange happens if compounds are reactive with MeOH. 
In order to avoid reversible Michael additions with CD3OD, NMR spectra 
were recorded in DMSO-d6, but the phenomena of broad signals still 
appeared. Furthermore, the broad signals could also indicate a 
paramagnetic contamination within the samples due to the presence of 
metal ions such as Fe(II) and Fe(III). These are likely candidates since the 
naphthoquinones are good chelators.147 The way to eliminate this is to pass 
the samples through Chelex mixed bed ion exchange resin. Another 
possibility is the presence of free radicals generated from autoxidation; the 
highly coloured naphthoquinones could be O2 sensitizers under normal 
laboratory lighting and thereby limit the ability to record high quality 
spectra.147 To eliminate this and other possible exchange processes, the 
OH groups of the compounds can be converted into methyl esters.147    
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4.5.2.1 Diazomethane derivatisation 
 
Due to the difficulties encountered during the NMR data acquisition using 
capNMR, the sample KR58Z4_1 was derivatised with diazomethane. 
Diazomethane converts naphthoquinones (the OH groups are capped as 
OMe groups) into methyl esters and the derivatised compounds become 
less polar, which are less sticky and easier to handle.147  
 
Diazomethane was prepared by hydrolysis of an ethereal solution of an N-
methyl nitrosamide with aqueous base (section 5.16). The precursor was N-
methyl-N-nitroso-p-toluenesulfonamide (Diazald).148 
 
The sample was derivatised with diazomethane and, as a positive control 
for this reaction, phenol was derivatised simultaneously. After the 
derivatisation, both compounds were analysed using HPLC (section 
5.15.4.2; Figure 54 A-D). The analysis suggested successful derivatisation 
of the compounds, producing later eluting peaks, indicating the 
incorporation of methyl esters into the molecules (labelled with stars in 
Figure 54 C and D). The derivatised sample was then collected using HPLC 
(section 5.15.4.2) and subjected to capNMR for structure elucidation. 
However, this did not improve the measurement as broad signals were still 
present (data not shown) and structure elucidation by capNMR was not 
possible. 
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Fig. 54: HPLC chromatograms of phenol (A) and KR58Z4_1 (B) and the derivatised 
samples phenol (C) and KR58Z4_1 (D) at 254 nm.  
 
The stars represent the derivatised compounds. 
 
In the present study, cryogenic NMR was chosen as a second NMR type to 
carry out further structur elucidations of the compounds. It is suitable for low 
amounts of samples as well and acquires NMR data at a very cold 
temperature. This part of the project was carried out with our cooperation 
partner at the University of Naples in the group of Prof. Mangoni, using a 
700 MHz cryogenic NMR.  
 
4.5.2.2 Introduction into cryogenic NMR 
 
Cryogenic NMR (cryo NMR) is a NMR technique that is suitable for low 
amounts of sample material. It typically uses a 3 or 5 mm diameter probe 
that is designed with cryogenically cooled coils at temperatures reaching        
-248°C (25 K). 149 Thermal noise is reduced, thereby increasing sensitivity 
up to 3-4 times in s/n ratio compared to conventional NMR (warm probe). 
To hold the temperature, helium gas provides the probe and the electronic 
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circuitry housed in the probe body, such as the preamplifier, with cold 
helium gas (~10 K) that is then heated in the probe to 25 K.150 
 
4.5.2.2.1  Structure elucidation by cryogenic NMR 
 
To further characterise the compound KR58M2_4_2, cryogenic NMR was 
performed and analysed by Dr. Roberta Teta at the University of Naples. 
The NMR experiments were carried out in CD3OD. Both 1D and 2D NMR 
spectra were acquired using a Varian cryo probe with 700 MHz and 175 
MHz (section 5.15.6.2). The resulting data are summarised in Figure 55 
and Table 7. The 13C NMR spectrum displayed a signal at 209.2 ppm 
indicating the presence of a carbonyl group. The presence of an aldehyde 
function could be excluded as there was no correlation signal in the HSQC 
spectrum between the carbonyl carbon and the aldehydic proton. 
Therefore, this keto function was determined as a starting pojnt for the 
structure determination. The corresponding keto carbon (C-16) was 
coupled in the HMBC spectrum with the three methyl protons at 2.22 ppm 
(Hα,β,γ-17) and the two equivalent methylene prontons at 3.68 ppm (H-15). 
These were coupled with a quarternary carbon atom at 137.3 (C-3) and 
showed two intense correlation peaks with carbons at 116.7 and 121 ppm. 
The HSQC spectrum showed corresponding aromatic protons at 6.64 (H-2) 
and 6.68 (H-4) ppm. The position of H-2 and H-4 in the first aromatic ring 
was determined as meta, as the ortho position could be excluded based on 
the multiplicity of the corresponding proton signals (singlets) and no COSY 
correlation was observed between those hydrogens. The para position was 
also excluded due to the presence of the HMBC 3J correlation between C-2 
and H-4. A long-range coupling was observed between H-2 and C-1 at 
150.0 ppm and the downfield chemical shift of the aromatic carbon 
suggested it to be connected to an OH group. The observation of the 
couplings of both H-2 and H-4 with the carbon at 120.5 ppm and the 
coupling of H-4 with the carbon at 143.3 ppm allowed the assignment as C-
14b and C-4a, respectively. C-4a coupled to two methylene protons at 2.75 
ppm (Hα,β-5) and one proton at 3.70 ppm (Hα-6). The protons Hα,β-5 
correlated with the same Hα-6 and with the proton at 2.74 ppm with Hβ-6 
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and furthermore, a correlation peak between Hα,β-5 and Hα-6 was visible in 
the COSY spectrum. Hα-6 was coupled with the carbon at 125.4 ppm and 
140.9 ppm. Hα,β-5 showed only a coupling with the carbon at 125.4 ppm. 
Thus, these carbons were defined as C-6a and C-14a. In addition to that, 
Hα-6 showed a 3J correlation with the hydroxy carbon at 159.0 ppm. 
Essential information about the complete structure was obtained by the 
analysis of the HMBC couplings of the proton at 4.48 ppm, identified as H-
13. This proton coupled with the carbon at C-13 (C-13´) at 58.3 ppm, thus 
supporting the dimeric characteristic of the molecule. Furthermore, H-13 
was coupled with the carbon at 109.6 ppm (C-12) and 121.4 ppm (C-14). 
Their corresponding protons were defined by the HSQC spectrum as H-12 
at 6.26 ppm and H-14 at 6.70 ppm. H-14 was strongly overlapped to H-4 
and coupled in HMBC with C-14b. Concluding this data, the identified 
structure is unknown to date. This unsual molecule was assigned as 
13,13´-fused bis-tridecaketide dimer 78 (Figure 55). The compound is 
structurally related to the benastatin A dimer 79 (Figure 56).151 However, 78 
is decarboxylated at H-2 which might have occured during the extraction 
process. Interestingly, HRESIMS analyses (Table 2) also indicated the 
mass of C26H20O8 for KR58M2_4_1 that could be the carboxylated product 
of 78. 79 (Figure 56) was isolated from the benastatin biosynthetic pathway 
in the absence of BenF. BenF encodes a novel C-methyltransferase that 
catalyses a geminal bismethylation in the benastatin A biosynthetic 
pathway at the position corresponding to C13 in 78.151  
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Fig. 55: 13,13´-fused bis-tridecaketide dimer 78. 
 
All HMBC couplings are shown in arrows. Each colour represents couplings 
originating from the same proton. 
 
 
Table 7: Summary of the NMR data for 13,13´-fused bis-tridecaketide dimer 78 from 
S. albus KR58. 
Position 13C 1H (J[Hz]) COSY 
 
HMBC 
 
1 157.0    
2 116.7  6.64 (s)  1, 4, 14b, 15 
3 137.3     
4 121.5  6.68 (s) 3,68 2, 4a, 5, 14b, 15 
4a 143.3     
5  30.5  2.75 (dd, 11.6, 5.6 ) 6,68, 3,01 4, 4a, 6, 6a 
6 21.2  3.07 (ddd, 14.8, 5.1, 5.1) 2,75, 6,68 4a, 5, 6a, 5, 14a 
  2.74a   
6a 125.4     
7 159.0     
7a 115.1     
8 190.0     
8a 111.7     
9 173.7     
10 102.6  6.12 (s)  8a, 11, 12 
11 165.8     
12 109.6  6.26a    
12a 146.3     
13 58.3  4.48 (br. S)  7a, 8a, 12, 12a, 13a, 13´, 14 
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13a 138.8     
14 121.4  6.70 (s)  14b 
14a 140.9     
15 51.4  3.68 (s) 2,22, 6,64, 6,68 2, 3, 4, 16, 17 
16 209.2     
17 29.1  2.22 (s) 3,68 16, 15 
The data was acquired in CD3OD. a Overlapping signal. 
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Fig. 56: 13,13´-fused bis-nor-benastatin A 79. 
 
Both dimers (78 and 79) resemble various plant-derived bisanthrones.152 
An important example for this is emodin bianthrone 80, the proposed key 
intermediate in hypericin 81 biosynthesis (Figure 57).153 81 is a 
naphthobianthrone compound produced in the dorsal leaf glands of 
Hypericum perforatum L., commonly known as St. John´s wort, and it has 
been tested positively in numerous studies for the treatment of mild and 
moderate depression.153-155 Nonsubstituted anthrones are highly unstable 
and rapidly oxidise to quinones and dimeric products through benzyl 
radicals.153, 156-158 In these reactions no biocatalysts are required in contrast 
to enzymatic aryl couplings.159, 160  
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Fig. 57: Emodin bianthrone 80 and hypericin 81.153, 154 
 
In the case of benastatin A, the absence of BenF led to alternative reaction 
channels such as quinone formation and dimerisation.151 It was speculated 
that the geminal bismethylation of the benastatin anthrone precursor by 
BenF blocks quinone formation and oxidative dimerisation during the 
polyketide assembly.151 GrhV homologues are found in other pentangular 
biosynthetic pathways such as pradimicin (PdmI), benastatin (BenJ), 
rubromycin (RubT), lysopilin (LlpOII) and fredericamycin (FdmQ), but none 
of them encode characterised proteins (Table 3). Given the structural and 
biosynthetic resemblance, the presence of these genes encoding unknown 
functions in the gene clusters and the fact that the molecules from 
pradimicin A, griseorhodin A, rubromycin and fredericamycin A biosynthetic 
pathways are considered to be among the most heavily oxidised aromatic 
polyketides known to date,25 these findings support the hypothesis that 
such genes play roles in oxidative steps during polyketide assembly. 
However, very little is known about the oxygenation of aromatic polyketide 
natural products derived from polyketide chains longer than 18 carbons and 
to date, GrhV homologues have not been investigated by e.g inactivation 
studies. The intermediate of ∆grhV mutant contains a low number of 
oxygen atoms and a higher number of carbon atoms than griseorhodin A, 
indicating a very early involvement of the enzyme in griseorhodin A 
biosynthesis. Therefore, the results of this study suggest that GrhV could 
catalyse the first quinone formation in ring A 83 in Figure 58, B 84 in Figure 
58 or C 85 in Figure 58, followed by oxygenations of the other rings by 
griseorhodin oxygenases such as GrhO8 and GrhO9, as their HRESIMS 
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data indicated in a previous study.1 In the absence of GrhV, the highly 
unstable anthrone-like precursor 82 is oxidised through a benzyl radical 86 
to the carboxylated dimeric product 87 (Figure 58). Compound 87 could 
have converted into 78 during extraction process, suggesting that 78 is the 
decarboxylated product of 87.  
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Fig. 58: The proposed reaction pathway for GrhV.  
 
To our knowledge, the present study gives first insights into the function of 
GrhV as a novel oxygenase and its homologues found in other pentangular 
biosynthetic pathways.  
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4.6 Summary and outlook 
 
In the present study, early biosynthetic steps of the telomerase inhibitor 
griseorhodin A 36 were investigated utilising heterologous expression and 
in-frame gene deletions by subsequently analysis of secondary metabolites 
generated as well as functions of the uncharacterised enzymes GrhV and 
GrhU. 
 
The present study investigated the early biosynthesis of griseorhodin A by 
heterologous expression and gene inactivation studies using λ-Red-
mediated recombineering. Generated constructs were conjugated into the 
host organism S. albus for heterologous expression. Secondary metabolite 
productions were investigated by HPLC, HRMS and cap and cryo NMR. 
The early griseorhodin A genes comprise of the grh minimal PKS genes 
grhA (KSα), grhB (KSβ) and grhC (ACP) as well as the cyclase genes grhE, 
grhQ and grhT.  
 
Heterologous expression was applied to express the grh minimal PKS 
independently and with grh cyclases. These genes were individually 
amplified from the griseorhodin A gene cluster by PCR and subcloned into 
the E. coli-Streptomyces shuttle vector pKJ55. The expression of the grh 
minimal PKS did not result in detectable amounts of polyketides or shunt 
products. This is in clear contrast to other type II minimal PKSs such as the 
tcm, act and whiE minimal PKSs that produce characteristic products such 
as 21-24 (Figure 8). Different media in liquid and solid forms were tested, 
and many screenings were performed to identify a clone that had increased 
production of secondary metabolites. However, no clone producing 
characteristic products was idenfied. Similar results were observed in the 
case of enterocin biosynthesis, namely that the enc minimal PKS requires 
an additional factor, in this case the ketoreductase EncD, to be fully 
functional.81 Therefore, to test whether the performance of the grh minimal 
PKS is context-dependent, co-expressions with putative grh cyclases, 
GrhE, GrhT and GrhQ, were carried out. The expressions with cyclases did 
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not result in the production of detectable amounts of polyketides. This 
suggests that the presence of a multienzyme complex for the griseorhodin 
A biosynthesis is required, where not only grh cyclases are significant, but 
also an additional stabilising enzyme could be required. One such potential 
candidate could be GrhS, which possesses strong homology to enzymes 
stabilising the minimal PKS protein assembly.25 In early biosynthesis of 
pradimicin A, a highly similar polyketide to griseorhodin A, pdm cyclases 
and a monooxygenase work in concert for the regioselectivity tailoring of a 
polyketide backbone and cannot act independently without their associated 
partners.130 Griseorhodin A is one of the longest aromatic polyketides and 
could therefore require additional enzymes for stabilisation of its polyketide 
chain. 
 
Furthermore, due to the unexpected results in the heterologous expression 
of the grh minimal PKS, the functionality of the grh minimal PKS in the E. 
coli - Streptomyces shuttle vector was tested using RT-PCR. In conclusion, 
the gene grhC is transcribed using the ermE* promoter, but no clear result 
could be obtained for grhAB as no bands were obtained for grhAB or its 
positive controls. Another technique to test the functionality of a construct 
could be accomplished by a subsequently cloning of an antibiotic resistance 
cassette into corresponding expression vector.  
 
To gain more insights into the early biosynthetic steps of griseorhodin A, 
putative grh cyclases were individually deleted in the gene cluster and the 
modified clusters were heterologously expressed in S. albus J1074. 
Deletion of grhE did not affect griseorhodin A biosynthesis; the polyketide 
was still produced. Therefore GrhE does not play a significant role in the 
griseorhodin A biosynthesis. Inactivations of GrhT and GrhQ abolished 
griseorhodin A biosynthesis and did not result in the production of 
detectable amounts of polyketides. The current results are in agreement 
with earlier experiments from the heterologous expression approach and 
provide further evidence that GrhQ is needed for a functional protein 
complex.  
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To further investigate early griseorhodin A biosynthesis, two new mutants, 
∆grhH-P and ∆grhH-Q, were generated. In the first mutant, all tailoring 
genes from grhH to grhP were deleted and in the second gene deletion 
mutant the mutation was extended to grhQ. Heterologous expression of the 
∆grhH-P mutant led to production of a complex compound mixture of 
secondary metabolites. It produced identical intermediates to the ∆grhM 
mutant from a previous study for which an early oxygenase role was 
proposed during grioserhodin A biosynthesis. For the ∆grhH-P mutant, four 
pure compounds were isolated. HRESIMS revealed the proposed 
molecular formula of C19H20O17 for the compound HP1, indicating an early 
intermediate in griseorhodin A biosynthesis. Promising 1H and COSY 
spectra were recorded by 700 MHz using cryo NMR. However, 2D NMR 
was not possible due to the small amount of compound (200 µg) and it was 
not further investigated during the present study. The other compounds 
also indicated intermediates in the early steps of griseorhodin A 
biosynthesis pathway. Compouding the results for the ∆grhM and ∆grhH-P 
mutants from the previous and the present study, the role of GrhM could be 
propose an early oxygenase role of GrhM in the griseorhodin A biosynthetic 
pathway. However, for final conclusion, structure elucidation of the 
corresponding intermediates by NMR is required.  
 
In order to obtain more insights into the early biosynthetic steps of 
griseorhodin A, many attempts to individually delete further genes (grhT, 
grhU and grhV) in the ∆grhH-P mutant were carried out, but all of them 
failed. However, putative grh cyclase gene grhQ is adjacent to grhP gene 
and it could be additionally deleted by extending the gene mutant ∆grhH-P 
to grhQ. The heterologous expression of the mutant ∆grhH-Q led to the 
abolishment of griseorhodin A biosynthesis. This is in agreement with the 
grhQ inactivation study. In contrast to these results, heterologous 
expression of ∆grhH-P produced a complex mixture of secondary 
metabolites. This mutant harbours all potential early grh genes, including 
the grh minimal PKS, grhQ and as well as the potential stabilising gene 
grhS. Concluding these results, GrhQ is needed for a protein complex but it 
is still insufficient for a functional PKS, since for GrhABCQ no products 
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were detected. To date, griseorhodin A is one of the longest aromatic 
polyketides and therefore, it could likely require synergistic actions of 
cyclases (GrhQ) and other stabilising enzymes such as GrhS for its 
polyketide assembly. The additional proteins may form a pocket with the 
grh minimal PKS in which the multienzyme complex can act and stabilise 
the entire polyketide assembly simultaneously.  
 
The uncharacterised genes in the griseorhodin A gene cluster, grhU and 
grhV, encode for unknown functions and therefore represent interesting 
targets for functional elucidations. The ∆grhV (KR58) and ∆grhU (KR61) 
mutants were constructed during a previous study using λ-Red 
recombineering and the modified grh clusters were subsequently 
conjugated into S. albus J1074 for heterologous expression.1 Both mutants 
produced complex mixtures of secondary metabolites which were 
investigated by HPLC, LH20, HRESIMS, cap- and cryo NMR. 21 pure 
substances were isolated by different chromatography methods and finally, 
after several analysis approaches, a compound originating from the ∆grhV 
mutant was structure elucidated in the present study. It revelead the 
decarboxylated 13,13´-fused bis-tridecaketide dimer 78 (Figure 59).  
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Fig. 59: 13,13´-fused bis-tridecaketide dimer 78  
 
The results of this study suggest that GrhV is responsible for an oxidative 
modification of the griseorhodin pharmacophore and could catalyse the first 
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quinone formation in the ring A, followed by oxygenations of the other 
rings.1 In the absence of GrhV, the highly unstable griseorhodin anthrone 
precursor A 82 is oxidised through a benzyl radical 83 to the 
decarboxylated product 13,13´-fused bis-tridecaketide dimer 78 via 84. To 
further investigate 78, conformational and stereochemical studies are 
required to assign possible meso (R,S) and racemic configurations 
(R,R/S,S). For compounds originating from the ∆grhU mutant, no structures 
could be elucidated and therefore, no conclusions can be drawn about the 
function of GrhU in the biosynthesis of griseorhodin A. However, the 
present study gives first insights into the function of GrhV and its 
homologues found in other pentangular biosynthetic pathways. 
 
After the early steps in the biosynthetic pathway, collinone 70 is formed and 
three carbon-carbon bonds are cleaved by GrhO5 in cooperation probably 
with GrhO1 leading to the spiro compound lenticulone 71. A further carbon-
carbon bond is cleaved to reduce a six-membered ring by one carbon unit 
by GrhO6 and GrhJ, respectively, generating 7,8-dideoxy-6-
oxogriseorhodin C 72. The reduction of the keto functionality of 7,8-
dideoxy-6-oxogriseorhodin C takes place, and the enzymes GrhO3 and 
GrhO7 catalyse the epoxidation of  dideoxygriseorhodin C 73 leading to the 
polyketide griseorhodin A 36. 
 
The present study investigated the early griseorhodin A biosynthesis and 
figure 60 summarises the updated version of the griseorhodin A 
biosynthetic pathway based on the data obtained from a previous and the 
present study.1, 123 The minimal PKS GrhABC assembles the poly-β-keto 
chain from one acetyl starter unit and from 12 malonyl extension units 
followed by the C19 keto reduction of the chain catalysed via GrhO10 or 
GrhT. In the present study, the heterologous expressions of the early 
grisoerhodin A genes experiments suggest that a multienzyme complex is 
needed for the early griseorhodin A biosynthesis comprised of GrhABCQST 
to generate the pentangular polyketide core structure. To date, griseorhodin 
A is one of the longest aromatic polyketides and therefore, it could likely 
require synergistic actions of cyclases (GrhQ) and other stabilising 
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enzymes such as GrhS for its polyketide assembly. The additional proteins 
may form a pocket with the grh minimal PKS in which the multienzyme 
complex can act and stabilise the entire polyketide assembly 
simultaneously. 
 
The present study also included investigations of other uncharacterised 
griseorhodin A enzymes such as GrhM and GrhV. For GrhM, the previous 
HRESIMS and NMR data from the ∆grhM mutant,1, 123 the present 
HRESIMS data from the ∆grhH-P mutant propose an early oxygenase role 
of GrhM in the griseorhodin A biosynthetic pathway. Another enzyme which 
was investigated during the present study was GrhV. For the ∆ghrV mutant, 
a novel dimer structure was determined and it suggests that GrhV could 
catalyse the first quinone formation in ring A, B or C (Figure 60). The 
structure obtained from the ∆ghrV mutant and the structures obtained from 
the ∆ghrM mutant studies propose, that both enzymes are acting as first 
oxygenases on the pentangular polyketide core structure. However, it 
cannot be concluded which one of the enzymes, GrhV or GrhM, is acting 
first on the pentangular core structure. Compounding this fact, the early 
acting enzymes possess substrate flexibility depending on the intermediate 
present from the previous step. 
 
Analysis of the mutants of the asparagine synthase GrhP, 
methyltransferase GrhL, oxidoreductases GrhO8 and GrhO9 by HRESIMS 
experiments in a previous study indicated variable structures with different 
oxygenations grades.1 Based on HRESIMS data, GrhO8 could act as first 
of the enzymes mentioned1, however for a final conclusion, a complete 
structure of the intermediate is required.  
 
For GrhP, an amide transferase function has been proposed by comparing 
its homologues from other aromatic polyketide biosynthetic gene clusters. 
However, griseorhodin A does not contain an amide linkage and therefore a 
different function than an amide installation for GrhP has been proposed.161  
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Oxygenation by GrhO9 and O-methylation by GrhL takes place on lower or 
higher oxygenated intermediates depending on the intermediate present 
from the previous steps. These results confirm the substrate flexibility of the 
early enzymes acting after the pentangular polyketide core assembly 
through to the uncleaved tridecaketide collinone 70. To date, the timing of 
ring 6 cyclisation remains unclear, but as the ring is still open in the 
griseorhodin A core structure, it can be assumed that the cyclisation takes 
place after oxygenations, but it cannot be concluded after which 
oxygenation step. After the early steps in the biosynthetic pathway, 
collinone 70, is formed and three carbon-carbon bonds are cleaved by 
GrhO5 in cooperation with GrhO1 leading to the spiro compound 
lenticulone 71. A further carbon-carbon bond is cleaved to reduce a six-
membered ring by one carbon unit by GrhO6 and GrhJ, respectively, 
generating 7,8-dideoxy-6-oxogriseorhodin C 72. The reduction of the keto 
functionality of 72 takes place, and the enzymes GrhO3 and GrhO7 
catalyse the epoxidation of dideoxygriseorhodin C 73 leading to the 
polyketide griseorhodin A 36. 
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Fig. 60: The updated version of the biosynthetic pathway of griseorhodin A. 
 
The red lines indicate C-C cleavages during the biosynthesis. 
 
In summary, the present study gives further insights into the early steps of 
griseorhodin A biosynthesis. The results suggest that the presence of a 
multienzyme complex is significant for the assembly of the pentangular 
polyketide core. Furthermore, the allocation of GrhV as a novel oxygenase 
provides new information about how griseorhodin A and other related 
heavily oxidised pentangular polyketides could be formed. 
11
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5 Material and methods 
5.1 Bacterial strains, vectors, primers and clones 
 
The following bacterial strains, vectors, primers, clones and strains were 
used in this study (Tables 8-12).  
 
Table 8: Bacterial strains used in the study. 
 Strains  Characteristics  Reference 
E. coli XL1 blue 
 recA-, thi, hsdR1, supE44, relA1, lacF, 
proAB, laclq, lacZ ∆M15, Tn10 (Tc), TcR
  
Stratagene, 
Amsterdam, 
Netherlands 
E.coli 
BW25113/pIJ790 
 
∆(araD-araB)567, ∆lacZ4787(::rrnB-4), 
lacIp-4000 (lacI+), λ-, rpoS369(Am), rph-1, 
∆ (rhaD-rhaB)568, hsdR514 
pIJ790: [oriR101], [repA101(ts)], araBp-
gam-be-exo 
 
Datsenko and 
Wanner162 
Gust et al.131 
E.coli 
ET12567/pUZ8002 
Dam-dcm-hsdM-  
pUZ8002: RK2 derivative with defective 
oriT (aph) 
 
MacNeil et al. 
163
 
Paget et al.164 
 
 
Streptomyces 
albus J1074 
Expression strain for grh cluster (ilv-1, sal-
2) José Salas
165
 
S. albus MP31 Contains the complete grh gene cluster Li and Piel25 
 
Table 9: Vectors and cosmids used in the study.  
Vector/Cosmids  Characteristics   Reference 
 
pBluescriptSK+ 
(pSK+) 
 
High copy vector, 
ampicillinR 
Fermentas 
 
pIJ778 
 
P1-FRT-oriT-aadA-FRT 
P2, streptomycinR 
Gust et al.131 
pKJ55 
 
Integrating Streptomyces 
E. coli shuttle vector  for 
gene expression 
containing a constutive 
promoter ermE*, 
apramycinR 
Christian Hertweck43 
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pMP31 
 
Integrative cosmid 
based on pSET152 
and pWEB containing 
the grh gene cluster 
 
Aiying Li25 
 
The primers were designed using Vector NTI and were ordered at 
Invitrogen (Karlsruhe, Germany). Upon arrival, the primers were dissolved 
in TE buffer or in ddH2O in order to prepare a 500 µM solution. This was 
then diluted 1:10 (50 µM) with ddH2O for the PCR reaction mix.   
 
Table 10: Primers used in this study.  
 
Primer 
 
Sequence (5´- 3´) Tm [°C] 
ACP_MfeI_for AAACAATTGCACACCTGTCACGACACGACACGAG 63.4 
ACP_EcoRI_rev AAAGAATTCTCAGGCGGTGGCCTGCGGAGACA 71.1 
KSab_MfeI_for CAATTGAGCTGGGCCACGTCGACA 65.8 
KSab_EcoRI_rev GAATTCTCAATGCGTTCGCTCATGTCGTGCTCTCT 66.9 
permE*_for TCCACACGTGGCACCGCGAT 63.9 
E_CYC_MfeI_for AAACAATTGTCGCGTGTGCCGAAGAAAGGAAC 64.0 
E_CYC_EcoRI_rev AAAGAATTCGTTCAGGGCTTCGGCGTGATCACG 67.2 
O2_KR_MfeI_for AAACAATTGGCGGACGACGCAACCAGGACGA 67.8 
O2_KR_EcoRI_rev AAAGAATTCTCACAGGCCGCCGGTGACGC 67.9 
T_CYC-KR_MfeI_for AAACAATTGCGAACCGACCACACCGCCTGAG 65.3 
T_CYC-R_EcoRI_rev AAAGAATTCCGAGTTCCACGGGCCTGTCCTT 63.1 
Q_CYC_MfeI_for AAACAATTGCCAGGCCGGTTCGAGACAGCT 62.2 
Q_CYC_EcoRI_rev AAAGAATTCGTCATCGGCCACCGCCCAGGTTCG 72.1 
O10_KR_MfeI_for AAACAATTGAACATCCACGTCGACGGCTGCGTGT 68.8 
O10_KR_EcoRI_rev AAAGAATTCTCGCGTCGGACACGTCAGAT 58.7 
J_MfeI_for_2 AAACAATTGGACCCCGCCACGATCGATCT 67.8 
J_EcoRI_rev_ME AAAGAATTCTCACGCCTTGACGGCGTTCGT 68.1 
T3  ATTAACCCTCACTAAAGGGA 56.4 
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T7  TAATACGACTCACTATAGGG 53.2 
19bp_MfeI AAACAATTGTGTAGGCTGGAGCTGCTTC 64.9 
20bp_PacI_EcoRI AAATTAATTAAAAAAGAATTCATTCCGGGGATCCGTCGACC 69.6 
O1_MfeI_for AAACAATTGGTGACCCACCGAGGAGGCACCA 64.8 
O1_EcoRI_rev AAAGAATTCTCCGGTCAGGAGCCGATGCT 62.2 
P_MfeI_for AAACAATTGACCGCATCCGTCACGAACGAGA 63.3 
P_EcoRI_rev AAAGAATTCCCTCAGAGCCGCAGGTCGACCC 65.8 
P_EcoRI_rev AAAGAATTCCCTCAGAGCCGCAGGTCGACCC 65.8 
ResCas_Rev TCGCTCTCTCCAGGGGAA 52.4 
P_test_FOR ACTTCGTGCGCCAACGGTTC 59.6 
G-test_FOR ACATCCACGCCAGCGAGAAG 57.4 
F_test_rev ATGCCCCCGAGGGTTTTG 56.8 
A_test_rev GACCGGGTCGAAGTCGCATT 58.5 
S_test_rev GTGTCGACGTGGCCCAGCTC 60.1 
KS_RT GGAGGGCGGGGCCATGCTCC 68.2 
KS_RT_2 CTCGGCATCGACCTGGTCGT 59.5 
KS_RT_3 TGGACGTGGTCTTCGCCGA 59.6 
KS_RT_rev CGCTCATGTCGTGCTCTCTCCTC 60.0 
E_ko_FOR 
CGCGTGTGCCGAAGAAAGGAACGAACACC
GATGCCCGAG 
ACTAGTAAAATGCCGGCCTTTGAATG 
Section 
5.11.1 
E_ko_REV 
AAGGGGCGCACGGGCGGCCGCCGTTCAG
GGCTTCGGCGT 
ACTAGTAAATGTAGGCTGGAGCTGCTT C 
Section 
5.11.1 
T_ko_FOR 
CGACATGAGCGAACGCATTGAGGAGGCCC
GATTCTGATG 
ACTAGTAAAATGCCGGCCTTTGAATG 
Section 
5.11.1 
T_ko_REV 
GGGGGTGCGCGCCGCGCGGGCGGCGGC
CTCGATCCTGGA 
ACTAGTAAATGTAGGCTGGAGCTGCTTC 
Section 
5.11.1 
Q_ko_FOR 
TGGTTCCAGGACCGAAAGCGCAAGGAGGG
CACCGTGCAC ACT 
AGTAAAATGCCGGCCTTTGAATG 
Section 
5.11.1 
Q_ko_REV 
CCAGGTTGACCTTGGCCGGGGTGGCCGC
CGCGGTCGTCA 
ACTAGTAAATGTAGGCTGGAGCTGCTTC 
Section 
5.11.1 
H-P_ko_FOR 
GCAACCCCCCGGTGTGAGGGGGCGGCGG
AGACGATGACA 
ACTAGTAAAATGCCGGCCTTTGAATG 
Section 
5.11.1 
H-P_ko_REV 
CTGGACCGGCCTCCGGCGGCCTCAGAGC
CGCAGGTCGACACT 
AGTAAATGTAGGCTGGAGCTGCTTC 
Section 
5.11.1 
The areas in italics and underlined indicate a digest enzyme site. 
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Table 11: Clones constructed in the study. 
Construct Characteristics Reference 
pME1 Contains the ACP gene grhC in the vector pSK+ from the construct pMP31, size 3.2 kb This study 
pME2 
Contains the KSα and KSβ genes grhA and grhB 
in the vector pSK+ from the construct pMP31, 
size 5.6 kb 
This study 
pME3 Contains the ACP gene grhC in the vector pKJ55 from the construct pME1, size 6.2 kb This study 
pME4 Contains the genes aadA/oriT in the vector pMP27, size 24.9 kb This study 
pME5 
Contains the ACP, KSα and KSβ genes grhC, 
grhA and grhB in the vector pKJ55 from the 
constructs pME1 and pME2, size 5.5 kb 
This study 
pME6 Contains the KR gene grhO2 in the vector pSK+ from the construct pMP31 , size 3.7 kb This study 
pME7 Contains the KR gene grhO10 in the vector pSK+ from the construct pMP31, size 3.7 kb This study 
pME8 Contains the CYC gene grhT in the vector pSK+  from the construct, size 4.3 kb This study 
pME9 Contains the CYC gene grhQ in the vector pSK+  from the construct pMP31, size 3.4 kb This study 
pME10 Contains the CYC grhE in the vector pSK+ from the construct, size 3.9 kb This study 
pME11 
Contains the ACP, KSα, KSβ and CYC genes 
grhC, grhA, grhB and grhT in the vector pKJ55 
from the constructs pME5 and pME8, size 10.2 
kb 
This study 
pME12 
Contains the ACP, KSα, KSβ and CYC genes 
grhC, grhA, grhB and grhE in the vector pKJ55 
from the constructs pME5 and pME10, size 9.8 
kb 
This study 
pME13 
Contains the ACP, KSα, KSβ and CYC genes 
grhC, grhA, grhB, grhT and grhQ in the vector 
pKJ55 from the constructs pME5, pME8 and 
pME9, size 10.6 kb 
This study 
pME14 Contains the J gene grhJ in the vector pSK+ from the construct pMP31, size 3.9 kb This study 
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pME15 
Contains the ACP, KSα, KSβ and J genes grhC, 
grhA, grhB and grhJ in the vector pKJ55 from the 
constructs pME5 and pME14, size 9.8 kb 
This study 
pME16 
Contains the ACP, KSα, KSβ, J and CYC genes 
grhC, grhA, grhB and grhJ and grhT in the vector 
pKJ55 from the constructs pME1, pME2, pME8 
and pME14, size 11.1 kb 
This study 
pME17 
Contains the ACP, KSα, KSβ, J and CYC genes 
grhC, grhA, grhB and grhJ and grhE in the vector 
pKJ55 from the constructs pME1, pME2, pME10 
and pME14, size 10.8 kb 
This study 
pME19 Contains insert aadA/oriT in the vector pSK+, 
size 4.3 kb This study 
pME21 
Contains the asparaginsynthase gene grhP in 
the vector pSK+  from the construct pMP31, size 
4.8 kb 
This study 
pME22 
Contains the oxygenase gene grhO1 in the 
vector pSK+  from the construct pMP31, size 4.4 
kb 
This study 
pME23.1 
Contains the construct pMP31; the CYC gene 
grhT is replaced by the str resistance cassette 
aad, size 48.7 kb 
This study 
pME23 
Contains the construct pMP31; the CYC gene 
grhT is deleted and the str resistance cassette 
aad is removed, size 47.7 kb 
This study 
pME24.1 
Contains the construct pMP31; the CYC gene 
grhE is replaced by the str resistance cassette 
aad, size 46.7 kb 
This study 
pME24 
Contains the construct pMP31; the CYC gene 
grhE is deleted and the str resistance cassette 
aad is removed , size 45.7 kb  
This study 
pME25.1 
Contains the construct pMP31; the CYC gene 
grhQ is replaced by the str resistance cassette 
aad, size 47.3 kb 
This study 
pME25 
Contains the construct pMP31; the CYC gene 
grhQ is deleted and the str resistance cassette 
aad is removed, size 46.3 kb 
This study 
pME26.1 
Contains the construct pMP31;  the grh genes 
between grhG and grhQ are replaced by the str 
resistance cassette aad, size 26.9 kb 
This study 
pME26 
Contains the construct pMP31; the grh genes 
between grhG and grhQ are deleted and the str 
resistance cassette aad is removed , size 25.9 kb 
This study 
pME27.1 
Contains the construct pMP31; the grh genes 
between grhG and grhP are replaced by the str 
resistance cassette aad, size 26.9 kb 
This study 
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pME27 
Contains the construct pMP31; the grh genes 
between grhG and grhP are deleted and the str 
resistance cassette is removed aad, size 25.9 kb 
This study 
pKR58 Contains the construct pMP31; the V gene grhV is deleted, size 47.4 kb Dr. Reinhardt.
1
  
pKR63 Contains the construct pMP31; the U gene grhU is deleted, size 47.4 kb Dr. Reinhardt.
1
 
 
 
Table 12: Strains constructed in this study. 
S. albus strain  Characteristics Reference 
ME1-ME4 Contains pME5 integrated into the S. albus genome This study 
ME5 Contains pME11 integrated into the S. albus genome This study 
ME6  Contains pME12 integrated into the S. albus genome This study 
ME7  Contains pME13 integrated into the S. albus genome This study 
ME8 Contains pME13 integrated into the S. albus genome  This study 
ME9 Contains pME15 integrated into the S. albus genome This study 
ME9 Contains pME16 integrated into the S. albus genome  This study 
ME10 Contains pME17 integrated into the S. albus genome  This study 
ME11-ME13 Contains pME26 integrated into the S. albus genome  This study 
ME14 Contains pME25 integrated into the S. albus genome  This study 
ME15 Contains pME24 integrated into the S. albus genome This study 
ME16 Contains pME23 integrated into the S. albus genome This study 
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S. albusME17 Contains pME27 integrated into the S. albus genome This study 
KR58 Contains pKR58 integrated into the S. albus genome 
PhD thesis,Dr. 
K. Reinhardt 
20091 
KR61 Contains pKR61 integrated into the S. albus genome 
PhD thesis, Dr. 
K. Reinhardt 
20091 
 
5.2  Media and supplements 
 
All media were autoclaved at 121°C before use. Anti biotics and 
supplements were added after the media was cooled down to 55-60°C.  
5.2.1 E. coli cultivation media 
5.2.1.1 LB media126 
 
Sodium chloride      10.0 g  
Tryptone       10.0 g 
Yeast extract          5.0 g 
Agarose (only for solid medium)     15.0 g 
ad 1000 mL ddH2O     
5.2.1.2 SOB media166 
 
Difco Bacto tryptone   20.0 g 
Difco Bacto yeast extract   5.0 g 
NaCl      0.5 g 
KCl      0.186 g 
ad 1000 mL ddH2O   
5.2.2 S.albus cultivation media 
5.2.2.1 2CM media167 
 
NaCl          1.0 g 
K2HPO4         1.0 g 
Soluble potato starch      0.5 g 
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Inorganic salt solution*   1.0 ml 
MgSO4 x 7H2O   2.0 g 
Tryptone    2.0 g 
CaCO3    2.0 g  
(NH4)2SO4    2.0 g 
Agar     22.0 g               
ad 1000 mL ddH2O   
 
* inorganic salt solution  
FeSO4 x 7H2O   1.0 g 
MgCl2 x 6H2O   1.0 g 
ZnSO4 x 7H2O   1.0 g 
ad 1000 mL ddH2O  
 
5.2.2.2 Double strength germination media168 
 
Difco yeast extract   1.0 g 
Difco casaminoacids  1.0 g 
CaCl2 (5 M)   200 µl 
ad 1000 mL ddH2O   
 
5.2.2.3 Soya flour mannitol media (MS media)169 
 
Soya flour  20.0 g 
Mannitol  20.0 g 
Agar   20.0 g 
ad 1000 mL  ddH2O  
 
5.2.2.4 TSB media168 
 
Tryptic soy broth 30.0 g 
ad 1000 mL ddH2O  
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5.2.2.5 R5 media170 
 
Sucrose    103 g 
K2SO4    0.25 g 
MgCl2 x 6H2O  10.12 g 
Glucose   10 g 
Casaminoacids  0.1 g 
Trace element solution* 2 ml 
Yeast extract  5 g 
TES    5.73 g 
ad 1000 mL ddH2O 
 
Aliquots of 100 ml of the solution were added into 250 ml flasks with 2.2 g 
agar and autoclaved. For use, the media was re-melted and the following 
sterile solutions were added: 
KH2PO4 (0.5%)  1.0 ml 
     CaCl2 x 2H2O (5 M)  0.4 ml 
     L-Prolin (20%)  1.5 ml 
     NaOH (1 M)   0.7 ml 
 
* Trace element solution: ZnCl2    40 mg 
    FeCl3 x 6H2O  200 mg 
    CuCl2 x 2H2O  10 mg 
    MnCl2 x 4H2O  10 mg 
    Na2B4O7 x 10H2O  10 mg 
    (NH4)6Mo7O24 x 4H2O 10 mg 
    ad 1000 mL ddH2O   
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5.2.3 TFB I and TFB II solutions 
 
Table 13: TFB I solution. 
TFB I Stock g/100 mL Use for 50 mL Result conc. 
KOAc 5 M 49.125 0.3 mL 30 mM 
CaCl2 1 M 11.098 0.5 mL 10 mM 
KCl 1 M 7.455 5 mL 100 mM 
MnCl2 1M 16.187 2.5 mL 50 mM 
Glycerol 50%--40% 
50 mL + 50 mL 
H2O 15 mL--18.75 mL 15% 
H2O - - 26.7mL--22.95 mL - 
 
 
Table 14: TFB II solution. 
TFB II Stock g/100 mL Use for 50 mL Result conc 
MOPS 1 M 
4.186 g/20 mL 
pH 7.0 with 
NaOH, 
0.2 µm sterile 
filtration 
0.25 mL 10 mM 
CaCl2 1 M 11.098 1.875 mL 75 mM 
KCl 1 M 7.455 0.25 mL 10 mM 
Glycerol 50%---40% 
50 mL + 50 mL 
H2O 7.5 mL---9.3 mL 15% 
H2O - - 15.1mL---13.2 mL - 
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5.2.4 Antibiotics and supplements 
 
Table 15: Antibiotics and supplements used in this study. 
Antibiotic/supplement Final concentrations in media [µg/mL] Solvent  
 E. coli S. albus  
Apramycin 100 100 ddH2O 
Kanamycin 25 - ddH2O 
Ampicillin 50 - ddH2O 
Chloramphenicol 25 - EtOH 
Tetracycline 5 - ddH2O/EtOH 
IPTG 100 - ddH2O 
X-Gal 50 - DMF 
 
5.3 Bacterial cultivation 
5.3.1 E. coli culture 
 
E. coli was cultivated overnight in 5 mL LB media at 37°C and 30°C, 
respectively, with the corresponding antibiotics at 200 rpm. For storage, a 
stock solution was prepared as glycerol cultures. Therefore, 750 µL of an E. 
coli overnight culture were mixed with 750 µl sterile 30% (v/v) glycerol 
solution in a 2-mL cryotube, flash-frozen with liquid nitrogen and stored at -
80°C.  
5.3.2 S. albus culture 
 
S. albus was cultivated using an MS agar. A single colony was streaked out 
on the MS agar plate. After an incubation time of 7-10 days, the spores 
were scraped off the plate using a sterile cotton tip and resuspended in 2 
mL with sterile 20% (v/v) glycerol solution. The suspension was then 
aliquoted into 2-mL cryotubes, flash-frozen with liquid nitrogen and stored 
at -80°C.  
           5 Materials and methods       
                                                                                                                   106 
   
For larger fermentations, S. albus strains were incubated in liquid cultures 
using 500 mL – 2 L baffled Erlenmeyer flasks at 30°C and 200 rpm for 3-5 
days. Different liquid cultures (LB, TSB and MS) were used to obtain 
optimal metabolite production. The liquid cultures were inculated with 
overnight preparatory cultures originating from spore stocks.  
 
5.4 Determination of cell density in bacterial cultures 
5.4.1 E. coli culture 
 
The determination of cell density from liquid media was performed with the 
photometer using one-way cuvettes with path lengths of 1 cm (Sarstedt, 
Nürmbrecht, Germany). The optical density of a liquid culture was 
measured at the wavelength of 600 nm (OD600) with a UV/visible spectral 
photometer (Eppendorf, Hamburg, Germany) and pure LB media was used 
as reference.  
 
5.4.2 S. albus culture 
 
The concentration of the spore suspension was calculated using colony 
forming units (cfu). Therefore, a dilution series was prepared (10-5, 10-6 and 
10-7) and from each dilution 500 µL was streaked out on MS agar plates. 
After three days incubation at 30°C, single colonie s were counted and the 
concentration of the spore suspension was calculated as follows:   
 
                                  
c =
number of colonies
dilution x 500 µL
 
5.5 Isolation of DNA 
 
5.5.1 Plasmid isolation from E.coli126 
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One mL of an overnight culture in LB medium was centrifuged for two 
minutes at 13,000 rpm and the supernatant was removed. The pellet was 
resuspended in 200 µL buffer P1 and 200 µL of buffer P2 was added and 
inverted four times. After adding 200 µL buffer P3 it was inverted four times 
and centrifuged for 5 minutes at 13,000 rpm. The supernatant was 
transferred into an Eppendorf-tube containing 500 µL chloroform and 
shaken vigorously. After 3 minutes centrfugation, the upper layer was 
transferred into a new tube containing 350 µL isopropanol and was shaken. 
The tube was then placed for 1 h at -20°C and centr ifuged at 4°C for 20 
minutes. The supernatant was removed and the pellet was washed with 
ice-cold 70% ethanol. The pellet was spun down shortly and the 
supernatant was removed. The pellet was then dried in a speed-vac 
(Speedvac 5301 Eppendorf, Hamburg, Germany) for 5 minutes and 
dissolved in 50 µL ddH2O. The DNA sample was stored at -20°C. 
 
The P1, P2 and P3 buffers126 were prepared as follows: 
 
P1 buffer (sterile-filtered): 
EDTA    0.74 g 
Tris-HCl   1.21 g 
ad 200 mL ddH2O 
pH 8.0 
 
 
P2 buffer (sterile-filtered): 
NaOH    4.0 g 
SDS    5.0 g 
ad 500 mL ddH2O 
 
P3 buffer (sterile-filtered): 
Potassium acetate   62.73 g 
ad 200mL ddH2O   200 ml 
pH 5.5 (with acetic acid)  
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5.5.2 Genomic DNA isolation from Streptomyces 
 
Bacterial colonies were dissolved in 20 ml LB and 500 µL 20% glycine that 
were then incubated for 24 hours at 30°C and at 200  rpm. 1.5 mL of the 
culture was harvested by centrifugation at 14,000 rpm for 2 minutes. The 
supernatant was removed and the pellet was resuspended in 500 µL STE 
with 5 mg/mL lysozyme and incubated for 3 h at 37°C . 500 µL 10% SDS 
and 100 µL 3 M NaOAc (pH 5.3) was added and then vortexed. Next, the 
mixture was shaken at 200 rpm for 45 minutes at 37°C. 250 µL of 
phenol/choloroform/isoamylalcohol (P/Chl/I) was added and vortexed for 30 
seconds. The tube was centrifuged for five minutes at 14,000 rpm. 
Subsequently, 800 µL from the upper layer was taken and mixed again with 
250 µl P/Chl/I and vortexed for 30 seconds. These steps were repeated two 
times. In the last step, 750 µL from the overlay was taken and mixed with 
750 µL isopropanol. After centrifuging for two minutes at 10,000 rpm, the 
supernatant was removed and the pellet was washed with 500 µl ice-cold 
70% EtOH. The pellet was dried for one hour under a clean bench and 
dissolved in 50 µL ddH2O overnight at 4°C. 
 
STE buffer 
EDTA (0.5 M, pH 8  400 µl 
Tris-HCl (1M), pH8  2 ml 
NaCl    1.17 g 
ad 200 mL ddH2O   
5.6 Photometric determination of DNA concentration 
 
The concentration of the isolated plasmid and genomic DNA was 
determined by a Biomate 3 spectrophotometer (Thermo Electron, 
Cambridge, UK). The DNA sample was diluted in a ratio to 1:20 using 
ddH2O. The measurement was carried out at wavelengths 260 nm and 280 
nm which correspond to the absorption maxima of DNA and protein, 
respectively.  
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5.7 Transfer methods for DNA 
5.7.1 Heat shock transformation 
 
First, chemically competent E. coli cells were prepared. A preparatory 
culture of E. coli XL1 blue was incubated in 5 mL LB at 37°C overnight  at 
200 rpm. 100 mL LB media was then inoculated with 1 mL of the 
preparatory culture at 37°C and 200 rpm, until the optical density
 
at 600 nm 
(OD600) reached 0.4. The culture was then transferred into two cold sterile 
50 mL Falcon tubes. The cells were harvested by centrifugation at 4°C for 
five minutes at 5000 rpm. The supernatants were removed and the pellets 
were dissolved in 12.5 mL TFB I. After five minutes of centrifugation at 
5000 rpm, the supernatants were removed, and the pellets were dissolved 
in 2 mL TFB II and added to one tube. The cells were aliquoted into 100 µL 
portions, flash-frozen in liquid nitrogen and stored at -80°C.  
 
To carry out the heat shock transformation, chemically competent E. coli 
XL1 blue cells were thawed for 5 minutes on ice. After adding up to 10 µL 
DNA from the ligation to the cells, the mixture was incubated for 30 minutes 
on ice. The heat shock was performed for exactly 60 seconds at 42°C and 
then the cells were immediately incubated for 2 minutes on ice. 900 µL 
liquid LB media was added and incubated for 1 hour at 37°C. The culture 
was then centrifuged at 10,000 rpm for 30 seconds. 700 µL was discarded 
and the pellet was resuspended in the remaining 300 µL and streaked out. 
The plates were incubated overnight at 37°C. 
5.7.2 Electroporation  
 
First, electrocompetent E. coli cells were prepared. A preparatory culture of 
E. coli XL1 blue was incubated in 5 mL LB at 37°C overnight  at 200 rpm. 
200 ml LB media was then inoculated with 5 mL of the preparatory culture 
at 37°C and 200 rpm until the optical density
 
at OD600 reached 0.4. The 
culture was then transferred into cold sterile 50 mL Falcon tubes. The cells 
were harvested by centrifugation at 4°C for five mi nutes at 5000 rpm. The 
supernatant was discarded and the pellet was carefully resuspended in 50 
mL of sterile 10% glycerol. After six to seven times of washing the cells, the 
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pellet was resuspended in 1 mL 10% ice-cold glycerol. Aliquots of 50 µL 
portions were prepared and the cells were flash-frozen with liquid nitrogen 
and stored at -80°C.  
 
Electroporation was carried out by using a Biorad electroporator with a 
shocking cuvette chamber (Munich, Germany) and by mixing 0.05-0.5 µg of 
plasmid with 50 µL electrocompetent E.coli XL1 blue cells and incubating 
that for 5-10 minutes on ice. The sample was transferred into a chilled 
electroporation cuvette (0.2 cm electrode cap) on ice and then electro-
pulsed with the parameters: 
 
Voltage   2500 V 
Resistance   200 Ω 
Condenser capacity 25 µF 
 
After the electro-pulse, 1 mL of LB was immediately added into the cuvette 
and the sample was transferred into a sterile 1.5 mL tube. Next, the cells 
were incubated for 1 h at 37°C shaking at 200 rpm a nd 75 µL of the mix 
was plated onto selective agar plates. 
5.7.3 Conjugation into S. albus after Flett et al.171 
 
The conjugation construct was transferred into the E. coli 
ET12567/pUZ8002 using electroporation (section 5.7.2). The plasmid 
pUZ8002 is a helper plasmid for oriT-containing plasmids, that is however 
not transferred due to a mutation in its oriT. Transformations were 
confirmed using colony PCR by picking single colonies from the plate. The 
positive clones were then incubated at 37°C overnig ht in 5 mL LB media 
containing Kan25, Cm25 and Apr50.  
 
The next day, 100 µL of the preparatory E. coli cultures were re-inoculated 
in 5 ml LB containing the corresponding antibiotics and grown until an 
OD600 of 0.4 was reached. Furthermore, approximately 2 x 108 of S. albus 
spores from the stock solution (5.3.2) were resuspended in 500 µL TES 
buffer (0.05 M TES, pH 8.0). The spores were then heat shocked at 50°C 
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for 10 minutes; subsequently 500 µL of the double strength germination 
media were added, and the spores were incubated for a further 1.5 h at 
37°C and at 200 rpm. 1 mL of the E. coli cells was then washed three times 
using LB media. Subsequently, the supernatant was discarded. For 
conjugation, the spore suspension was mixed with the E. coli cells and 
centrifuged for 30 seconds at 10,000 rpm. The supernatant was discarded, 
and the pellet was resuspended in the remaining media. The mixture was 
then streaked out on a 2CM agar plate until the plate surface was dry. After 
an incubation time of 16-18 h at 30°C, the plate wa s overlayed with an 
antibiotic solution of 1 mL nalidixic acid. Subsequently, the incubation was 
continued for 3-5 days at 30°C until potential exco njugants appeared.  
 
Potential exconjugants were re-inoculated on 2CM- and MS plates for 3-7 
days at 30°C. Afterwards, the spores were inoculate d in 20 mL LB liquid 
cultures for the isolation of genomic DNA (5.5.2). The DNA was then used 
as a template for the confirmation of DNA integration into the genome of S. 
albus using PCR (section 5.8.1). 
5.8 Polymerase chain reaction (PCR) 
 
PCR is a standard method used in molecular biology and it allows a rapid 
amplification of specific known DNA sequences for further analysis. There 
are three major steps in PCR: denaturation, annealing and elongation, 
which are repeated at varying temperatures and numbers of cycles 
depending on the experiment.  
 
5.8.1 Preparative PCR 
 
In the present study, a Biometra PCR Thermocycler T-Gradient (Göttingen, 
Germany) was used to amplify the grh minimal PKS (grhA, grhB and grhC), 
cyclases (grhE, grhQ and grhT) from the griseorhodin gene cluster. All PCR 
reactions were performed using a Expand High FidelityPLUS PCR System 
(Roche, Grenzach-Wyhlen, Germany). In case of control reactions, Taq 
polymerase (Jena Bioscience, Jena, Germany) was used.  
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Buffer (5 x for Taq and for Hifi 10x)            5.0 µL resp.10 µL buffer   
dNTP (10 mM)      1.00 µL 
DMSO (100%)     2.5 µL 
DNA (µg/mL)      1.00 µL 
Forward primer (50 µM)     0.50 µL 
Reverse primer (50 µM)     0.50 µL 
Expand Hifi polymerase/Taq polymerase  0.50 µL/0.25 µL  
ad 50 µL ddH2O      
 
The annealing temperature Tanneal in the PCR programme is calculated as 
follows:  
 
Tanneal = Tm – 5°C where the lower T m value (Table 10) of the applied 
primers is used. 
 
PCR programme: 
Lid temperature   105°C 
Initial denaturation   94°C  2 min 
Denaturation    94°C  1 min 
Annealing    x °C  1 min         34 cycles 
Extension (1 kb/min)  72°C  x min 
Final extension   72°C  10 min 
Cooling    4°C   
 
5.8.2 Colony PCR 
 
For colony PCR, a master mix was prepared as indicated. The master mix 
was then aliquoted into reaction mix tubes, colony material was taken 
directly from the plate and mixed with the reaction mix. The initial 
denaturation time was increased up to five minutes.  
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Master mix: 
 
Buffer (5x)    5 µL buffer   
dNTP (10 mM)    1.00 µL 
DMSO (100%)   1.25 µL 
DNA       small amount of colony material 
Forward primer (50 µM)   0.25 µL  
Reverse primer (50 µM)   0.25 µL  
Taq polymerase (5 U/µl))  0.125 µL 
ad 25 µL ddH2O    
 
PCR programme: 
Lid temperature   105°C 
Initial denaturation   94°C  5 min 
Denaturation    94°C  1 min 
Annealing    x °C  1 min         34 cycles 
Extension (1 kb/min)  72°C  x min 
Final extension   72°C  10 min 
Cooling    4°C   
5.9 Agarose gel electrophoresis 
 
The products from PCR, enzyme digests, gel extractions and plasmid 
isolations were analysed by gel electrophoresis (Biometra agarose gel 
electrophoresis system with a power source Standard Power Pack P25, 
Göttingen, Germany) in 1.0% agarose using 1x TAE buffer diluted from 50x 
TAE buffer (2 M Tris-acetate, pH 8.0, 0.1 M EDTA) with 0.1 µg/mL ethidium 
bromide. Prior to electrophoresis, the products were mixed with 1µL of 6 x 
loading buffer (0.25% (w/v) bromophenol blue, 0.25% (w/v) xylene cyanol, 
30% (w/w) glycerol). Electrophoresis was performed at 100 V for 10-35 
minutes. Gels were viewed and photographed by ultraviolet (UV) 
transillumination (Syngene Gene Genius gel documentation system, 
Cambridge, United Kingdom). 
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5.10  Isolation of DNA from agarose gel 
 
The gel extraction was performed with the QIAgen Gel Extraction Kit 
(Qiagen, Hilden, Germany). All buffers were supplied with the kit. The target 
DNA fragment was cut from the gel using a sharp scalpel and transferred to 
a 1.5 mL tube. To 1 volume of gel (100 mg ~ 100 µl) 3 volumes of QC 
buffer were added, and the sample was incubated for 10 minutes at 50°C to 
completely dissolve the fragment in buffer. The solution was then 
transferred into a Qiaquick column and centrifuged at 13,000 rpm for 1 
minute. After discarding the flow-through, 500 µl of QC buffer was added 
and the column was centrifuged at 13,000 rpm for 1 minute. The flow-
through was discarded and 750 µL PE buffer added and was centrifuged 
again for 1 minute at 13,000 rpm. After discarding the flow-through it was 
centrifuged for 1 minute at 13,000 rpm to remove the residual PE buffer. 
The Qiaquick column was transferred into a new 1.5 ml E-tube and after 
adding 30 µL sterile ddH2O the column was incubated for 1 minute at RT. 
To collect the DNA from the column it was centrifuged for 1 minute at 
13,000 rpm. The DNA sample was conserved at -20°C. 
5.11  TA cloning 
5.11.1 Construction via TA cloning126 
 
10 µl of the vector pKS+ was digested with 2.5 µl EcoRV and incubated for 
2 hours at 37°C. The restriction enzyme was heat-in activated at 80°C for 20 
minutes. 3´ T overhangs were added using 0.5 µl of Taq polymerase and 
10 µL of 10 mM dTTP. The reaction tube was then incubated at 70°C for 
two hours. 100 µL of chloroform was added and the E-tube was shaken 
vigorously. After centrifugation at 13,000 rpm for five minutes, the 
supernatant was transferred into a new E-tube filled with 70 µL isopropanol 
and was shaken vigorously. The reaction tube was precipitated at -20°C for 
one hour and centrifuged for 20 minutes at 13,000 rpm and 4°C. The 
supernatant was removed and 200 µL of ice-cold 70% ethanol was added. 
The tube was centrifuged shortly and the ethanol was removed. The pellet 
was dried in a speed vac at 45°C for five minutes a nd dissolved with 30 µL 
ddH2O. The vector portion was then stored at -20°C for further use. 
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5.11.2 Ligation into TA vector 
 
The following ligation reagents were used for TA cloning applying the NEB 
protocol using T4 ligase (NEB, Frankfurt am Main, Germany):  
 
T4 ligase buffer (10x)   1 µL 
Insert DNA (µg/mL)    7 µL 
Vector DNA (µg/mL)   1 µL 
T4 ligase (5 U/µl)    1 µL 
         
The ligation portion was incubated overnight at 4°C  and the next day, a 
heat-inactivation at 65°C was carried out prior to electroporation or heat 
shock transformation respectively. To screen for positive clones, a 
blue/white selection was used based on the disruption of the lacZ gene in 
the TA vector. The white clones were positive clones and were then 
inoculated overnight at 37°C with corresponding ant ibiotics for plasmid DNA 
isolation. 
 
5.11.3 Sequencing of TA vector 
 
Prior to further cloning, TA vectors containing the PCR inserts were 
sequenced at the sequencing company GATC (Constance, Germany). For 
this purpose, standard sequencing primers T7 and T3 (Table 5.3) were 
used. The obtained sequences were analysed using the software Vector 
NTI (Invitrogen, Karlsruhe).  
 
5.12  Enzymatic modification of DNA 
5.12.1 Enzyme digests  
 
For enzyme digest reactions, various endonucleases (NEB, Frankfurt am 
Main, Germany) were applied. The following reagents were mixed together:  
   
Restriction enzyme buffer (10x)  1.0 µL 
DNA (µg/mL)    0.75 µL 
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Restriction enzyme  (5 U/µl)  0.5 µL 
ad 10 µL ddH2O    
 
The digests were incubated at 37°C for 1-3 hours. F or control digests, a 10 
µl portion was used; for larger cloning batches, 50 µL portions were 
prepared.  A heat-inactivation step at 65°C for 20 min was required if the 
material was further used for desphosphorylation. 
 
5.12.2 Dephosphorylation of DNA 
 
Dephosphorylation was required to avoid religation of the digested vector. 
The following reagents were mixed together applying the Fermentas shrimp 
alkaline phosphatase (SAP) (Fermentas, Frankfurt am Main, Germany):  
   
Digestion enzyme buffer (10x)    5.0 µL 
DNA (µg/mL)      40.0 µL 
SAP (5 U/µl)             1.0 µL 
ad 50 µL ddH2O        
 
The dephosphorylation reaction was incubated at 37° C for 45 min. A heat 
inactivation step at 65°C for 20 min was required t o inactivate the enzyme. 
5.12.3 Ligation 
 
The ligation was performed by applying the NEB protocol using T4 ligase. 
The reagents were mixed together as follows. The ratio between insert and 
vector was 1:1 to 3:1 depending on the yield of the target DNA. 
  
T4 ligase buffer (10x) 1 µL 
Insert DNA (µg/µL)   x µL 
Vector DNA (µg/µL  x µL 
T4 ligase (5 U/µl)  1 µL 
ad 10 µL ddH2O   
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The ligation was incubated at 4°C overnight. A heat -inactivation step at 
65°C for 20 min was required to inactivate the enzy me. 
 
5.13  λ-Red-mediated homologous recombination131 
 
During this study, the λ-Red-mediated recombination technique was applied 
to create in-frame deletions in the griseorhodin biosynthetic gene cluster. 
Gene knock-out is performed in a one-step directed insertion of linear DNA 
fragments into the target DNA. The linear DNA fragment used in this study 
was a streptomycin resistance gene cassette aadA (Figure 61) amplified 
from the plasmid pIJ778 (Appendix 8.1). 
 
    
aadA
19 nt REV17 nt FOR
FRT
 
 
Fig. 61: The streptomycin resistance cassette used for generating gene knock-outs 
in the present study. 
 
The resistance cassette contains short homologous areas that control the 
double crossover after electroporation of the cassette. In the present study, 
the cyclase genes grhE, grhQ and grhT as well as the genes from grhH to 
grhP and from grhH to grhQ in the griseorhodin gene cluster were deleted. 
For each gene knock-out, two long primers were designed (section 5.3) 
containing the 5´ end matching 39 nucleotides (nt) to the target gene to be 
deleted and the 3´ end with 19 or 17 nt matching to the right or the left side 
of the resistance cassette. Furthermore, a SpeI restriction site ACTAGT 
was integrated into the sequences of the homologous areas of the cluster 
and the resistance cassette sequences for a later restriction of the cassette. 
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5.13.1 PCR amplification of the resistance cassette for the 
homologous recombination 
  
In the present study, this PCR was used to amplify the streptomycin 
resistance cassette aadA from the plasmid pIJ778. All PCR reactions were 
performed using a PCR Expand High FidelityPLUS PCR System and a 
Thermocycler. The following reagents were mixed together: 
 
Hifi buffer (10x)     10 µL   
dNTP (10 mM)      1.00 µL 
DMSO (100%)     2.5 µL 
DNA (µg/mL)      1.00 µL 
Forward primer (50 µM)     0.50 µL  
Reverse primer (50 µM)     0.50 µL  
Expand Hifi polymerase    0.50 µL   
Ad 50 µL ddH2O      
 
PCR programme: 
Lid temperature  105°C 
Initial denaturation  94°C  2 min 
Denaturation   94°C  1 min   10 cycles  
Annealing   50°C  1 min     
  
Extension (1 kb/min) 72°C  1 min 30 sec 
Denaturation   94°C  1 min   15 cycles 
Annealing   55°C  1 min    
Extension   72°C  1 min 30 sec 
Final extension  72°C  10 min 
Cooling   4°C   
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5.13.2 Electroporation of pMP31 into E. coli BW25113/pIJ790 
 
The cosmid pMP31 contains the complete griseorhodin A gene cluster. In 
order to perform gene knock-outs, it needs to be transformed into the E. coli 
strain BW25113/pIJ790 for subsequent homologous recombination. The 
vector pIJ790 contains the lambda phage genes exo, bet and gam which 
are controlled by the arabinose-induced promoter. Expression in E. coli 
BW25113/pIJ790 leads to dramatically enhanced recombination 
frequencies. Therefore, the E. coli strain BW25113/pIJ790 was grown 
overnight at 30°C in 5 mL LB with glucose containin g Cm25. 300 µL of the 
overnight culture were inoculated into 30 mL SOB and grown at 30°C 
shaking at 200 rpm until OD600 reached 0.4 The cells were then prepared 
for electroporation (section 5.6.2); the cosmid pMP31 was transformed and 
streaked out on selective LB agar plates with Cm25 and Apr50 and incubated 
overnight at 30°C.  
 
5.13.3 Electroporation of the streptomycin resistance 
cassette into E. coli BW25113/pIJ790/pMP31 
 
To perform gene knock-outs in the griseorhodin cluster, the E. coli strain 
BW25113/pIJ790/pMP31 was grown overnight at 30°C an d 200 µL of the 
preparatory culture were reinoculated into a 50 mL SOB culture. To induce 
the lambda phage genes exo, bet and gam on the vector pIJ790, 500 µL of 
1 M L-arabinose stock solution (final concentration 10 mM) were added. 
The culture was grown at 30°C and at 200 rpm to an OD600 of 0.4. The cells 
were then prepared for electroporation, and 2 µL of the amplified and 
purified streptomycin resistance cassette were transformed into the cells. 
These were then streaked out on LB agar plates with Apr50 and Str50 and 
incubated at 37°C.  
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5.13.4 Removal of the resistance cassette 
 
5.13.4.1 Digest of the streptomycin cassette 
 
To ensure a successful expression of the gene cluster after the gene 
inactivation, the streptomycin resistance cassette was removed using the 
digest enzyme SpeI. Therefore, the following reagents were mixed 
together: 
 
Restriction enzyme buffer (10x)  5.0 µL 
DNA (µg/mL)    5.0 µL 
BSA (10x)     5.0 µL 
Restriction enzyme SpeI (5 U/µl)            2.5 µL 
ad 50µL ddH2O               
 
The digest was incubated for 3 h at 37°C and heat-i nactivated for 20 
minutes at 65°C.  
 
5.13.4.2 Religation 
 
After the restriction the cluster was religated using the following reagents: 
 
Ligase buffer (10x)  1.0 µL 
DNA (µg/mL)  8.0 µL 
T4 ligase (5 U/µl)  1.0 µL 
 
The religation was incubated overnight at 4°C and h eat-inactivated at 65°C 
for 20 minutes. After successful religation, the cosmid was conjugated in 
the host organism S. albus for expression. 
 
5.14  Reverse transcriptase PCR (RT-PCR) 
5.14.1 RNA isolation 
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RNA was isolated using a Qiagen RNA isolation kit with some 
modifications. S. albus cultures were grown for 3 days at 30°C, 1.5 mL of 
the culture was harvested at 10,000 rpm for 2 minutes and the supernatant 
was carefully removed. The pellet was then suspended in 100 µL of 
lysozyme-containing TE buffer (for Gram-positive bacteria: 6 µl of 50 
mg/mL lysozyme stock solution were added per 100 µL TE buffer) by 
vortexing and incubating at RT for 10 minutes. 350 µL of the RLT buffer in 
ß-mercaptoethanol (ß-ME) (for the stock solution: 10 µL of ß-ME were 
added per 1 mL buffer RLT) were then added and mixed by vortexing. 250 
µL 100% ethanol were added to the lysate and mixed by inversion. The 
sample was applied to an RNeasy column that was placed in a 2 mL 
collection tube and centrifuged for 15 s at 10,000 rpm and the flow-through 
was discarded. 350 µL RW1 buffer were added into the RNeasy column, 
centrifuged for 15 s at 10,000 rpm and the flow-through was discarded. The 
DNase I stock solution was prepared by adding 10 µL DNase I stock 
solution to 70 µL RDD buffer and mixed gently by inverting the tube. The 
DNase I incubation mix (80 µL) was added directly onto the RNeasy silica-
gel membrane and incubated at RT for 35 minutes.  
 
350 µL RW1 buffer were added into the RNeasy column, centrifuged for 15 
s at 10,000 rpm and the flow-through was discarded. The column was then 
transferred into a new 2 mL collection tube. 500 µL of the RPE buffer were 
added onto the RNeasy column, centrifuged for 15 s at 10,000 rpm and the 
flow-through was discarded. Another 500 µL of the RPE buffer were added 
to the Rneasy column and centrifuged for 2 minutes at 10,000 rpm. The 
RNeasy column was transferred into a new 2 mL collection tube and 
centrifuged at 14,000 rpm for 1 minute. For elution, the RNeasy column 
was transferred into a new 1.5 mL collection tube, 30 µL of the RNase free 
water was pipetted onto the membrane and the tube was centrifuged at 
10,000 rpm for 1 minute. Next, the DNase I stock solution was prepared by 
adding 10 µL DNase I stock solution to 70 µL RDD buffer. This was added 
to 30 µL RNA solution and incubated at RT for 45 minutes.   
 
           5 Materials and methods       
                                                                                                                   122 
350 µL of the RLT buffer were added and mixed. 250 µL of the 100% 
ethanol were added to the diluted RNA and mixed by inverting the tube. 
The sample was applied to an RNeasy column, placed in a 2 mL collection 
tube and centrifuged for 15 s at 10,000 rpm and the flow-through was 
discarded. 350 µL of the RW1 buffer were pipetted into the RNeasy column 
and centrifuged for 15 s at 10,000 rpm. The flow-through was discarded. 
The DNase I stock solution was prepared by adding 10 µL DNase I stock 
solution to 70 µL RDD buffer and mixed gently by inverting the tube. The 
DNase I incubation mix (80 µL) was added directly onto the RNeasy silica-
gel membrane and incubated at RT for 35 minutes.  
 
350 µl of the RW1 buffer were pipetted into the RNeasy column and 
centrifuged for 15 s at 10,000 rpm. The flow-through was discarded. The 
RNeasy column was transferred into a new 2 mL collection tube. 500 µL of 
the RPE buffer were added onto the RNeasy column and centrifuged for 15 
s at 10,000 rpm. Another 500 µL of the RPE buffer were added to the 
RNeasy column and centrifuged for 15 s at 10,000 rpm. The RNeasy 
column was placed into a new 2 mL collection tube and centrifuged at 
14,000 rpm for 1 minute. For elution, the RNeasy column was placed into a 
new 1.5 mL collection tube and 30 µL of the RNase free water were added 
onto the membrane and was centrifuged at 10,000 rpm for 1 minute. 
5.14.2 RT-PCR 
 
In this study, RT-PCR was used to synthesise the cDNA of the minimal 
PKS from the isolated RNA. For all RT-PCR reactions, the Superscript One 
Step RT-PCR System (Invitrogen, Karlsruhe, Germany) was used. The 
following reagents were mixed together:  
 
 
Reaction mix (2x)     5 µL  
RNA (µg/mL)    0.3 µL 
Forward primer (10 µM)   0.5 µL  
Reverse primer (10 µM)   0.5 µL  
OneStep RT-PCR enzyme mix   0.25 µL  
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RNase-free ddH2O     3.25 µL  
 
 
PCR programme: 
Lid temperature   105°C 
cDNA synthesis   55°C  30 min 
Initial denaturation   94°C  2 min 
Denaturation    94°C  1 min 
Annealing    x °C  1 min         40 cycles 
Extension (1 kb/min)  68°C  x min 
Final extension   68°C  10 min 
Cooling    4°C   
 
 
5.15  Natural product analysis 
 
5.15.1 Extraction 
 
5.15.1.1  Extraction of cells and agar from agar plates 
 
Secondary metabolite production was performed using S. albus as a host 
organism. Initially, a preliminary analysis of the mutants was carried out 
using agar plates. Therefore, different media such as 2CM, MS and R5 
were tested. After appropriate incubation (5-7 days) at 30°C, the cell 
material was scraped off the plates using a spatula and dissolved in 2 mL of 
95:5:1 EtOAc/MeOH/AcOH in a reaction tube. To destroy the cells and to 
get access to the metabolites, the cell solution was ultra-sonicated 
(Bandelin Sonopuls HD2070, Berlin, Germany; 80-90% of maximum output; 
the sonication was carried out five times for 10 seconds each time). The 
reaction tube was then centrifuged for 5 min at 5,000 rpm and the 
supernatant taken and dried in a rotary evaporator (Heidolph VV2000, 
Keilheim, Germany). The dry extract was then dissolved in acetonitrile 
(ACN) with 0.05% trifluoric acid (TFA) and used directly used for HPLC or 
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HPLC-MS analysis. Otherwise the extract was further dried under high 
vacuum and stored at -20°C. 
 
The agar was mixed with 50 mL 95:5:1 EtOAc/MeOH/AcOH and stirred for 
several hours and then filtered. The solvent was removed using a rotary 
evaporator. The dry extract was then dissolved in acetonitrile (ACN) with 
0.05% trifluoric acid (TFA) and used directly used for HPLC or HPLC-MS 
analysis. 
5.15.1.2  Liquid cultures extraction 
 
5.15.1.2.1 EtOAc/MeOH/AcOH and EtOAc extraction 
 
The extraction of metabolites from the liquid cultures required a separation 
of the cells from the media. Therefore, the liquid culture was divided into 1 L 
plastic centrifuge tubes and centrifuged at 3600 rpm for 1 h. The media was 
poured into flasks and extracted three times with 95:5:1 
EtOAc/MeOH/AcOH or with 100% EtOAc. Subsequently, the organic phase 
was washed three times with ddH2O (if acidic conditions were used), dried 
with Na2SO4 and rotary-evaporated to dryness.  
 
The cells were freeze-dried prior to extraction using liquid nitrogen and a 
freeze-dryer (Thermo Heto PowerDry LL3000, Langenselbold, Germany). 
The next day, the cells were subjected to 100% MeOH and stirred for 
several hours and then filtered. MeOH was removed using a rotary 
evaporator and the cells were extracted three times using 100% EtOAc. 
Subsequently, the extract was rotary-evaporated to dryness. The 
concentrated crude extract was then subjected to a silica gel column 
(section 5.13.3.1). 
 
5.15.1.2.2 MeOH/celite extraction 
 
A portion of the freeze-dried cells were extracted using 100% MeOH and 
celite. Therefore, the cells were subjected to 100% MeOH and stirred for 
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several hours. Afterwards, the cells were filtered through celite under 
vacuum. The cells with the celite material were then scraped off the filter, 
subjected again to fresh 100% MeOH, stirred for several hours and filtered 
again through celite. This was repeated three times and subsequently 
MeOH was removed using a rotary evaporator. The concentrated crude 
extract was then subjected to a LH20 column (section 5.13.3.2) 
 
5.15.2 Thin layer chromatography (TLC) 
 
5.15.2.1  Normal phase (NP) 
 
NP TLC was used as a standard procedure in the analysis of metabolite 
production. For this, different TLC plates such as amine, cyano and silica 
plates were used (Macherey-Nagel, Düren, Germany). The mobile phase 
used here was a mix of petrolether/ethylacetate, whereas different ratios 
were applied as well as 9:1 CHCl3/MeOH.   
 
5.15.2.2  Reverse phase (RP) 
 
RP TLC was used for the analysis of the metabolites as well. For this, 
alugram RP-18 W/UV254 TLC plates (Macherey-Nagel, Düren, Germany) 
were used. The mobile phase used was ACN/H2O with 0.05% TFA in a 
ratio of 7:3 as well as CHCl3/MeOH which was used in a ratio of 9:1. 
Detection was carried out using UV light at 254 nm as well as 366 nm. 
5.15.3 Column chromatography 
 
5.15.3.1  Silica gel flash chromatography 
 
The concentrated crude extract from the cells and the media was subjected 
to silica gel flash chromatography. Prior to use, the column material was 
impregnated with 2 M NaH2PO4 by mixing 500 mg column material with 1 L 
2 M NaH2PO4, strirring for 2 h and eventually dried at 80°C. A n isocratic 
solvent system 9:1 CHCl3/MeOH was used for elution. The fractions were 
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dried in a rotary evaporator and a preliminary analysis of the fractions was 
performed using the Jasco HPLC system (section 5.13.4.1). 
5.15.3.2  LH20 chromatography (Jasco) 
 
The media extract was subjected to LH20 chromatography. An isocratic 
solvent system with 100% MeOH was used for elution of the fractions and 
to purify the column material, DMSO was eluted through the column. The 
fractions were dried in a rotary evaporator and a preliminary analysis of the 
fractions was performed using the Jasco HPLC system (section 5.13.4.1). 
 
5.15.3.3  LH20 chromatography (Dionex) 
 
The concentrated cell crude extracts originating from the ∆grhU and ∆grhV 
mutants were separated on a LH20 column. An isocratic solvent system 
with 100% MeOH was used for elution at a flow rate of 2 mL/min. The 
absorbance at 254 nm was monitored throughout the experiment using a 
UV detector and a chart recorder. Fractions were collected at 5 min 
intervals starting from the peak observed on the chart recorder until the 
absorbance stabilised at the baseline. The fractions were dried in a speed 
vac and analysed using the Dionex HPLC system (section 5.12.4.2). 
5.15.4 High pressure liquid chromatography (HPLC) 
 
For all HPLC runs, HPLC-grade ACN and ddH2O were used. Furthermore, 
the ddH2O was acidified with 0.05%TFA. 
 
5.15.4.1  Analytical HPLC (Jasco) 
 
Analytical HPLC was performed using a Jasco HPLC system with a MD-
2015 PDA detection system (Groß-Umstadt, Germany). The samples were 
run on a reverse phase column (PerfectChrom 100 C18, 5µm, 250 mm x 4 
mm) with a flow rate of 1.5 mL/min and monitored at 254 nm.    
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HPLC Method 1:  
1 min of 10% ACN/ddH2O, a linear gradient to 100% ACN for 30 min; 
isocratic at 100% ACN for 5 min and then returned to 10% ACN/ddH2O in 2 
min and re-equilibriated for 3 min. 
 
HPLC Method 2:  
5 min of 10% ACN/ddH2O, a linear gradient to 95% ACN/H2O for 20 min; 
isocratic at 95% ACN/ddH2O for another 5 min and then returned to 10% 
ACN/H2O in 2 min and re-equilibriated for 3 min. 
 
5.15.4.2  Analytical HPLC (Dionex) 
 
Analytical HPLC was performed as well with a Dionex HPLC equipped with 
a UVD 340U diode array detector (Göttingen, Germany). The LH20 
chromatography fractions were run by repetitive analytical RP HPLC 
(column: Phenomex Prodigy ODS3, 5 µm, 250 mm x 4 mm) at a flow rate of 
1 mL/min and monitored at 254 nm. 
 
HPLC Method 3:  
1 min of 10% ACN/ddH2O, a linear gradient to 100% ACN for 30 min; 
isocratic at 100% ACN for 5 min and then returned to 10% ACN/ddH2O in 2 
min and re-equilibriated for 3 min. 
5.15.4.3  Semi-preparative HPLC 
 
Semi-preparative HPLC was performed with a Knauer HPLC equipped with 
a UV detector S-2800 (Berlin, Germany). Fractions from the preparative 
HPLC were run by repetitive semi-preparative RP HPLC (column: 
Macherey Nagel Sphinx RP5 µm, 250 mm x 8 mm) at the flow rate of 3.4 
mL/min and monitored at 254 nm. 
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HPLC method 4: 
5 min of 60% ACN/ddH2O, a linear gradient to 65% ACN for 15 min; 
isocratic at 100% ACN for 5 min and then returned to 60% ACN/ddH2O in 5 
min and re-equilibriated for 5 min. 
 
5.15.4.4  Preparative HPLC 
 
Preparative HPLC was performed using a Shimadzu HPLC equipped with a 
UV detector SPD-20A (Duisburg, Germany). The fractions were run by 
repetitive preparative RP HPLC (column: Kromasil 100 C 18, 5 µ, 250 mm x 
20 mm) at flow rates of 6 mL and monitored at 254 nm. 
 
HPLC method 5: 
1 min of 10% ACN/H2O, a linear gradient to 100% ACN for 30 min; isocratic 
at 100% ACN for 5 min and then returned to 10% ACN/H2O in 2 min and 
re-equilibriated for 3 min. 
 
5.15.5 Mass spectrometry (MS) 
 
5.15.5.1  HPLC-High Resolution (HR) Electrospray Ionisation (ESI) MS 
(Bruker Daltonik) 
 
For all HPLC-HRESIMS runs, HPLC-grade ACN and ddH2O were used. 
Furthermore, ddH2O was acidified with 0.05%TFA. 
 
HPLC-MS analysis were carried out using an Agilent 1200 Series HPLC 
system with an autosampler, microOTOF-Q flight of time spectrometer and 
an Apollo-ESI source (Bruker Daltonik, Bremen, Germany). HPLC was 
performed using analytical RP columns (PerfectChrom 100 C18, 5µm, 250 
mm x 4 mm; Macherey Nagel Sphinx RP RP5 µm, 250 mm x 4 mm) at a 
flow rate of 1 mL/ml and monitored at 254 nm. For the determination of the 
exact masses an external calibration was carried out with sodium formate. 
The HPLC method 2 (section 5.15.4.1) was used for the HPLC. 
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HPLC Method 2:  
 5 min of 10% ACN/ddH2O, a linear gradient to 95% ACN/H2O for 20 min; 
isocratic at 95% ACN/ddH2O for another 5 min and then returned to 10% 
ACN/H2O in 5 min and re-equilibriated for 5 min. 
5.15.5.2  HRESIMS (Thermo Fisher Scientific)  
 
High Resolution ESI-MS and MS/MS spectra were recorded at the 
University of Naples on a Thermo LTQ Orbitrap mass spectrometer 
(Thermo Fisher Scientific, Pennsylvania, USA). Spectra were recorded by 
infusion into the ESI source using MeOH as the solvent. 
5.15.6 NMR 
 
5.15.6.1   Capillary NMR 
 
CapNMR data was recorded on a Varian INOVA 500 spectrometer (Palo 
Alto, USA) at 23°C, operating at 500 MHz. The INOVA  was equipped with a 
variable temperature and a Protasis capillary probe (Marlborough, USA).   
 
5.15.6.2   Cryogenic NMR 
 
1H and 13C NMR was recorded at the University of Naples on a Varian 
UnityInova spectrometer, operating at 700 and 175 MHz. The UnityInova 
was equipped with a Varian cryogenic probe. Chemical shifts were 
referenced to the residual solvent signal (MeOH: δH 3.31, δC 49.0). For an 
accurate measurement of the coupling constants, the one-dimensional 1H 
NMR spectra were transformed at 64K points (digital resolution: 0.09 Hz). 
Homonuclear 1H connectivities were determined by a COSY experiment. 
The HSQC spectra were optimized for 1JCH = 142 Hz, and the HMBC 
experiments for 2,3JCH = 8.3 Hz.  
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5.16  Synthesis of diazomethane148 
 
For the synthesis of diazomethane, 0.5 mg potassium hydroxide was 
dissolved in 1 ml water diluted with 95% ethanol in a flask. It was cooled in 
an ice bath and a solution of 0.5 mg Diazald in 7.5 ml diethyl ether was 
slowly added with a Pasteur pipette. When all the Diazald was added, the 
neck of the reaction flask was closed and heated in a warm water bath up 
to 65°C. The yellow diazomethane-ether mixture was distilled until all the 
yellow colour had disappeared from the reaction flask. The yellow distillate 
in the receiver contained diazomethane and it was immediately mixed with 
the sample to be derivatised. 
 
5.17  Chemicals used in this study 
 
Solvents in p.a. quality (acetone, acetonitrile, chloroform, isopropanol, ethyl 
acetate, acetic acid and methanol) were purchased from the companies 
Fluka / Riedel-de-Haën (Seelze, Germany), Merck (Darmstadt, Germany), 
Fisher Scientific (Schwerte, Germany). HPLC-grade solvents were 
purchased from the companies Merck and J. T. Baker / Mallinckrodt Baker 
(Deventer, Netherlands). 
 
Table 16: Chemicals used in this study. 
Chemical Company 
Agar Roth, Karlsruhe 
Agarose NEEO quality Roth, Karlsruhe 
L-Arabinose Fluka / Riedel-de-Haën, 
Seelze 
Ammonium heptamolybdate tetrahydrate Merck, Darmstadt 
Ammonium sulphate Applichem, Darmstadt, 
Germany 
Ampicillin sodium salt Roth, Karlsruhe 
Apramycin sulphate Sigma-Aldrich, Seelze, 
Germany 
Bovine serum albumine (BSA-solution 10 mg/mL) NEB, Frankfurt/Main 
 5-Bromo-4-chloro-3-indolyl-β-D- 
galactopyranoside (X-Gal) 
AppliChem, Darmstadt, 
Germany 
Bromo phenol blue sodium salt AppliChem, Darmstadt 
Calcium carbonate Roth, Karlsruhe 
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Calcium chloride KMF, Lohmar, Germany 
Carbenicillin disodium salt Roth, Karlsruhe 
Casamino acids Becton Dickinson, 
Heidelberg, Germany 
Chloramphenicol Fluka / Riedel-de-Haën, 
Seelze 
[D1] Chloroform (CDCl3) Euriso-Top, Gif sur Yvette, 
France 
Copper(II) chloride dihydrat Grüssing, Filsum, Germany 
Copper (II) sulphate AppliChem, Darmstadt 
Desoxythiamine-5’-triphosphate (dTTP) Invitrogen, Karlsruhe 
Desoxynucleotide (dNTPs) Invitrogen, Karlsruhe 
Dipotassiumhydrogenphosphate dehydrate Merck, Darmstadt 
N,N-Dimethylformamide (DMF) Fisher-Scientific, Schwerte, 
Germany 
Dimethylsulfoxide (DMSO) Roth, Karlsruhe 
[D6] Dimethyl sulfoxide (DMSO-d6) Euriso-Top, Gif sur Yvette 
Dinatriumhydrogenphosphate dehydrate Fluka / Riedel-de-Haën, 
Seelze 
1kb DNA ladder Roth, Karlsruhe 
Hydrochloric acid Fluka / Riedel-de-Haën, 
Seelze 
Iron(II)sulphate heptahydrate Merck, Darmstadt 
Iron(III)chloride hexahydrate Alfa Aesar, Karlsruhe, 
Germany 
Ethidium bromide Roth, Karlsruhe 
Ethylenediaminetetraacetic acid (EDTA) KMF, Lohmar 
D(+)-Glucose monohydrate Fluka / Riedel-de-Haën, 
Seelze 
Glycerol Merck, Darmstadt 
Glycine Fisher-Scientific, Schwerte 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) Roth, Karlsruhe 
Potassium acetate ABCR; Karlsruhe, Germany 
Potassium carbonate AppliChem, Darmstadt 
Potassium chloride Acros Organics, Geel 
(Belgium) 
Potassium dihydrogen phosphate Merck, Darmstadt 
Potassium sulphate Grüssing, Filsum 
Kanamycin sulphate Roth, Karlsruhe 
Potato starch, soluble Sigma-Aldrich, Seelze 
Lysozyme Roth, Karlsruhe 
Magnesium chloride hexahydrate Fluka / Riedel-de-Haën, 
Seelze 
Magnesium sulphate heptahydrate Roth, Karlsruhe 
Manganese chloride tetrahydrate Merck, Darmstadt 
Mannitol Roth, Karlsruhe 
3-(N-morpholino) propanesulfonic acid (MOPS) Sigma-Aldrich, Seelze 
Nalidixic acid Roth, Karlsruhe 
L-Prolin Acros Organics, Geel  
Ribonuclease A (RNase A) Roth, Karlsruhe 
Silica gel 60 (0,040- 0,063 mm) Merck, Darmstadt 
Sulfuric acid Fluka / Riedel-de-Haën, 
Seelze 
Sodium acetate Acros Organics, Geel 
Sodium tetraborat decahydrate Sigma-Aldrich, Seelze 
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Sodium carbonate KMF, Lohmar 
Sodium chloride Grüssing, Filsum 
Sodium dihydrogen phosphate dehydrate Roth, Karlsruhe 
Sodium dodecyl sulphate (SDS) Roth, Karlsruhe 
Sodium hydroxide KMF, Lohmar 
Tris(hydroxymethyl)aminomethane (Tris) Roth, Karlsruhe 
Tryptic Soy Broth (TSB) Becton Dickinson, 
Heidelberg 
Tryptone Becton Dickinson, 
Heidelberg 
Xylene cyanol Merck, Darmstadt 
Yeast extract Becton Dickinson, 
Heidelberg 
Zinc chloride Acros Organics, Geel 
Zinc sulphate Merck, Darmstadt 
 
5.18  Equipment used in this study 
 
Single-use reaction- and centrifuge tubes, serological pipettes, pipette tips, 
Petri dishes and tubes were purchased from the company Sarstedt 
(Nümbrecht, Germany). 
Table 17: Equipment used in this study. 
Equipment  Company 
Analytical balance CP225D Sartorius, Göttingen, Germany 
Autoclave V65 Systec, Wettenberg, Germany 
Balance 440-47N Kern, Balingen-Frommern, Germany 
Balance BP110 Sartorius, Göttingen, 
Micro cuvette (1,6 mL) Sarstedt, Nümbrecht 
Incubation shaker Certomat BS-1 Sartorius, Göttingen 
Incubator B12 Thermo, Langenselbold, Germany 
Membrane vacuum pump Vacuubrand, Wertheim, Germany 
Micro cuvette UltraVette (70-850 µL) Roth, Karlsruhe 
Microwave Lifetec Medion, Essen, Germany 
Micro centrifuge Mikro200 Hettich, Tuttlingen, Germany 
Micro centrifuge 5417R Eppendorf, Hamburg, Germany 
Micro centrifuge Mikro200R Hettich, Tuttlingen 
Multipette: Eppendorf Research 100  Eppendorf, Hamburg 
Pipetten Pipetman P2 - P10 mL Gilson, Middleton, USA 
HPLC vials with lid and septum for autosampler Bio-Rad, Munich 
Shaker Rotamax 120 Heidolph, Kelheim 
Sterile bench Biowizard Kojair, Vilppula, Finland 
5 Materials and methods 
133                                                                
Steril filter (0,2 µm, Celluloseacetat, FP 30/0,2) Whatman / Schleicher & 
Schuell, Dassel, Germany 
Table centrifuge Rotina 35R Hettich, Tittlingen 
Table centrifuge Z513K Hermle, Wehingen, Germany 
UV-Crosslinker CL1000 UVP, Cambridge, United Kingdom 
Vortex VTX-3000L LMS, Tokio, Japan 
Water bath GFL, Burgwedel, Germany 
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6 List of abbreviations 
 
A     Ampere 
AA     Amino acid  
ACN     Acetonitrile 
AcOH     Acetic acid 
ACP     Acyl carrier protein 
Act/act Proteins and genes of the actinorhodin 
gene cluster 
Amp100 Ampicillin in final concentration 100 µg/ml 
ARO Aromatase 
Apr50 Apramycin in final concentration 50µg/ml 
AT  Acyltransferase 
Aur/aur Proteins and genes of the aurachin gene 
cluster 
Ben/ben Proteins and genes of the benastation 
gene cluster 
BLAST Basic Local Alignment Search Tool 
BVMO Baeyer-Villiger monooxygenase 
bp     Base pair 
BSA     Bovine Serum Albumine 
°C     Degree Celsius 
CapNMR    Capillary probe NMR 
CD3Cl     Deuterated chloroform 
CE     Capillary electrophoresis 
CapLC    Capillary HPLC 
CLF  “chain length factor” = Ketosynthaseß  
cDNA     Complementary DNA 
Cm25 Chloramphenicol in final concentration 25 
µg/ml 
Cmm Proteins and genes of the chromomycin 
gene cluster 
COSY two-dimensional NMR correlation 
spectroscopy with 1H-1H correlation 
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CYC     Cyclase 
CYP-450    Cytochrome P450 
ddH2O    Double distilled water 
DEBS     6-deoxyerythronolid B synthase 
DH     Dehydrogenase 
DMAC    Dihydroxymethylanthrachinone 
DMF     Dimethylene formamide 
DMSO    Dimethylene sulfideoxide 
DNA     Deoxyribonucleic acid 
dNTP     Deoxynucleotide triphosphate 
et al.     et alii (and others) 
E. coli     Escherichia coli 
E-tube     Eppendorf tubes (1.5 or 2 ml plastic tubes) 
EDTA     Ethylene di-amine tetra-acetic acid 
Enc/enc Proteins and genes of the enterocin gene 
cluster 
ER Enoylreductase 
ESI Electrospray ionisation 
EtOAC    Ethyl acetate 
FA     Fatty acid 
FAD     Flavin adenine dinukleotide 
FAS     Fatty acid synthase 
Fig.     Figure 
Fdm/fdm Proteins and genes of the fredericamycin 
gene cluster 
Frn/frn Proteins and genes of the frenolicin gene 
cluster 
Grh/grh Proteins and genes of the griseorhodin A 
gene cluster 
GT Glycosyltransferase 
h     Hour 
Hed/hed Proteins and genes of the hedamycin 
gene cluster 
Hifi     High Fidelity Polymerase 
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HMBC Heteronuclear multiple bond coherence 
(long-range coupling between different 
nuclear species) 
HMQC Heteronuclear multiple quantum 
coherence (direct coupling between 
different nuclear species) 
HPLC     High pressure liquid chromatography 
HRMS    High resolution mass spectrometry 
g     Relative centrifugal force 
g     Gram 
IPTG      Isopropyl β-D-1-thiogalactopyranoside 
Jad/jad Proteins and genes of the jadomycin gene 
cluster 
K Kelvin 
Kb     Kilobase 
Kan25     Kanamycin in final concentration 25 µg/ml 
KR     Ketoreductase 
KS     Ketosynthase 
L     Litre 
LB     Luria Bertani 
LC     Liquid chromatography 
LC-MS    Liquid chromatography mass spectrometry 
Llp/llp Proteins and genes of the lysolipin gene 
cluster 
Lnd/lnd Proteins and genes of the landomycin 
gene cluster 
m     Milli- (1 x 10-3) 
M     Molar 
MCAT     Malonyl-CoA:APC transferase 
MCS     Multiple cloning site 
µ     Micro- (1 x 10-6) 
mM     Millimolar 
MeOH    Methanol 
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Minimal PKS The minimal set of PKS containing ACP 
and KSα-KSβ 
min     Minutes 
MOPS    3-(N-morpholino)propanesulfonic acid 
MS     Mass spectrometry/mass spectrometer  
MT     Methyltransferase 
Mtm/mtm Proteins and genes of the mithramycin 
gene cluster 
MW     Molecular weight 
NAD     Nicotiamide adenine dinucleotide 
NaOH     Sodium hydroxide 
NMR     Nuclear magnetic spectroscopy 
NP     Normal phase 
OD     Optical density 
ORF     Open reading frame 
Oxy/oxy Proteins and genes of the oxytetracycline 
gene cluster 
p     Pico- (1 x 10-12) 
P/Chl/I    Phenol/choloroform/isoamylalcohol 
PCR     Polymerase chain reaction 
PKS     Polyketide synthase 
RBS     Ribosomal binding site 
RNA      Ribonucleic acid 
RNase A     Ribonuclease A 
rpm      Rotation per minute 
resp.     Respectively 
RP     Reverse phase 
RT     Room temperature 
RT-PCR    Reverse transcriptase PCR 
s     Seconds 
SAM     S-adenosyl methionine 
SDS     Sodium dodecyl sulphate 
S. albus    Streptomyces albus 
s/n     Signal-to-noise ratio 
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sp.     Species 
Str50 Streptomycin in final concentration 50 
µg/ml 
TAE      Tris-acetate-EDTA buffer 
Taq polymerase   DNA Polymerase from Thermus aquaticus 
TFA     Trifluoric acid 
TLC     Thin layer chromatography 
Tcm/tcm Proteins and genes of the tetracenomycin 
gene cluster 
TE Thioesterase  
U      Unit (Unit of enzyme activity) 
µl     Microlitre 
UV     Ultraviolet 
     
w/v      Weight per volume 
wt     Wildtype 
X-Gal  5-Bromo-4-chloro-3-indolyl-β-D- 
galactopyranoside 
 
 
Nucleotide bases 
 
A  Purine base Adenine   G Purine base Guanine 
C  Pyrimidine base Cytosine  T  Pyrimidine base Thymine
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8 Appendix 
 
8.1 Vector maps 
 
The following cosmid and vectors were used in the present study. 
 
8.1.1 pMP31 
 
pMP31
cos
AprR
SV 40 ori
Int
attP
OriT
Complete grh cluster
 
 
 
Fig. 62: Vector map of the cosmid pMP31. 
 
The expression cosmid pMP31 containing the complete grh biosynthetic gene 
cluster (46.7kb). The cosmid enables the conjugation of the grh cluster into the 
expression host S. albus by intergrating into its genome.  
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8.1.2 pIJ790 
 
    
Fig. 63: Vector map of pIJ778. 
 
The plasmid pIJ778 containing a streptomycin resistance cassette aadA. This 
plasmid was used as DNA template for the amplification of the resistance cassette. 
 
8.1.3 pKJ55 
 
  
pKJ55
5894 bp
permE*
int
attP AprR
oriT
Eco RI (675)
 
 
Fig. 64: Vector map of pKJ55. 
 
The plasmid pKJ55 is an E. coli – Streptomyces shuttle vector. This vector enables 
conjugation into the expression host S. albus by integrating into its genome. 
 
 
 
 
 
pIJ778
4377 bp
aadA
amp
20bp priming site FOR
19 priming site REV
FRT
FRT
OriT
EcoRI (2115)
HindIII (690)
8 Appendix      
152 
8.2 NMR spectra 
 
8.2.1 13,13´-fused bis-tridecaketide dimer 78 
 
 
Fig. 65: 1H NMR spectra of 13,13´-fused bis-tridecaketide dimer 78. 
 
The acquisition was performed in CD3OD at 700 MHz. 
 
 
Fig. 66: 13C-NMR spectra of 13,13´-fused bis-tridecaketide dimer 78. 
 
The acquisition was performed in CD3OD at 700 MHz. 
  8 Appendix  
  153  
 
 
 
 
Fig. 67: 1H-1H-COSY NMR spectra of 13,13´-fused bis-tridecaketide 78. 
 
The acquisition was performed in CD3OD at 700 MHz. 
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Fig. 68: HSQC-NMR spectra of 13,13´-fused bis-tridecaketide 78. 
 
The acquisition was performed in CD3OD at 700 MHz. 
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Fig. 69: HMBC-NMR spectra of 13,13´-fused bis-tridecaketide dimer 78. 
 
The acquisition was performed in CD3OD at 700 MHz. 
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Fig. 70: HMBC-NMR spectra of 13,13´-fused bis-tridecaketide dimer 78. 
 
The acquisition was performed in CD3OD at 700 MHz. 
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8.2.2 HP1 
 
 
Fig. 71: 1H NMR spectra of HP1. 
 
The acquisition was performed in DMSO-d6 at 700 MHz. 
 
Fig. 72: 1H-1H COSY spectra of HP1.  
 
The acquisition was performed in DMSO-d6 at 700 MHz. 
 
 
8 Appendix      
158 
8.3 UV spectra 
 
8.3.1 ∆grhV mutant 
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Fig. 73: UV spectra of the compounds from the ∆grhV mutant. 
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Fig 73 continued: UV spectra of the compounds from the ∆grhV mutant. 
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Fig 73 continued: UV spectra of the compounds from the ∆grhV mutant. 
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Fig 73 continued: UV spectra of the compounds from the ∆grhV mutant. 
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8.3.2 ∆grhU mutant 
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Fig. 74: UV spectra of the compounds from the ∆grhU mutant. 
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Fig 74 continued: UV spectra of the compounds from the ∆grhU mutant. 
 
 
8.3.3 ∆grhH-P mutant 
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Fig. 75: UV spectra of the compounds from the ∆grhH-P mutant. 
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Fig 75 continued: UV spectra of the compounds from the ∆grhH-P mutant. 
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8.4 Mass spectra 
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Fig. 76: HRESIMS of the compounds from the ∆grhV mutant. 
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M2_4_1 
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Fig. 76 continued: HRESIMS of the compounds from the ∆grhV mutant. 
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103
 
 
Fig. 76 continued: HRESIMS of the compounds from ∆grhV mutant. 
 
     
HP1
 
 
Fig. 77: HRESIMS of the compounds from the ∆grhH-P mutant. 
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ME13_2_1
 
 
Fig 77 continued: HRESIMS of the compounds from the ∆grhH-P mutant. 
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Fig 77 continued: HRESIMS of the compounds from the ∆grH-Pmutant. 
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8.4.1 ∆grhE mutant 
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Fig. 78: HRESIMS of the compound from the ∆grhE mutant. 
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